Compositions and methods for treating severe pain

ABSTRACT

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

This application is a continuation that claims priority pursuant to 35U.S.C. § 120 to U.S. patent application Ser. No. 15/684,197, filed onAug. 25, 2017, a continuation that claims priority to U.S. Ser. No.15/295,933, filed Oct. 17, 2016, now U.S. Pat. No. 9,795,577, acontinuation that claims priority to U.S. Ser. No. 14/975,599, filedDec. 18, 2015, now U.S. Pat. No. 9,504,664, a continuation that claimspriority to U.S. Ser. No. 14/155,080, filed Jan. 14, 2014, now U.S. Pat.No. 9,265,742, a continuation-in-part application that a) claimspriority pursuant to 35 U.S.C. § 119(e) to U.S. Provisional PatentApplication 61/752,309, filed Feb. 4, 2013, and U.S. Provisional PatentApplication 61/752,356, filed Jan. 14, 2013, b) claims priority pursuantto 35 U.S.C. § 120 to U.S. Non-Provisional patent application Ser. No.13/365,824, filed Feb. 3, 2012, now U.S. Pat. No. 8,895,536, acontinuation-in-part application that claims priority to InternationalPatent Application PCT/GB2011/052115, filed Oct. 31, 2011, aninternational patent application that claims priority to GB 1018289.7,filed Oct. 29, 2010, GB 1113730.4, filed Aug. 10, 2011, GB 1113729.6,filed Aug. 10, 2011, GB 1113728.8, filed Aug. 10, 2011, and GB1101937.9, filed Feb. 4, 2011, and c) claims priority pursuant to 35U.S.C. § 120 to patent application U.S. Ser. No. 13/365,828, filed Feb.3, 2012, now U.S. Pat. No. 8,895,537, a continuation-in-part applicationthat claims priority to International Patent ApplicationPCT/GB2011/052115, filed Oct. 31, 2011, an international patentapplication that claims priority to GB 1018289.7, filed Oct. 29, 2010,GB 1113730.4, filed Aug. 10, 2011, GB 1113729.6, filed Aug. 10, 2011, GB1113728.8, filed Aug. 10, 2011, and GB 1101937.9, filed Feb. 4, 2011,each of which is hereby incorporated by reference in its entirety.

Pain is a subjective and very complex perception that signals to anindividual that tissue damage has occurred or may be occurring. Pain maybe transitory, lasting only until the noxious stimulus causing the painis removed or the underling damage or pathology has healed or may lastsbeyond the healing of an injury, continuing for a period of severalmonths or longer. A pain response has both physiological as well aspsychological components. A pain response evokes a wide range ofsensations that may be described as a dull, aching sensation, a sharpstabbing sensation, a hot, cold, or icy-hot sensation, a tingling oritchy sensation or a numbness. Pain can be felt in one area of the body,such as your back, abdomen or chest or throughout the body, such as whenall the muscles in a body ache from the flu.

Severe pain is the most common reason for an individual to consult ahealthcare provider in the United States. It is a major symptom in manymedical conditions, and can significantly interfere with a person'squality of life and general functioning. As such, severe pain is asignificant and costly healthcare problem.

Current therapies for treating severe pain are limited, often involvingthe administration of multiple medications with the understanding thatpain relief will not be complete and the quality of life may not berestored. These therapies may require frequent dosing, can be associatedwith undesirable systemic side effects, and typically provideunsatisfactory relief. Therefore, there remains a need for a therapeuticoption developed specifically for severe pain that provides sustainedrelief while minimizing the potential for systemic side effects anddrug-drug interactions.

The present specification discloses pharmaceutical compositions andmethods for treating an individual suffering from a severe paincondition. The pharmaceutical compositions disclosed herein areessentially a lipid delivery system that enables a therapeutic compoundhaving anti-pain activity to be delivered in a manner that moreeffectively inhibits a pain response. The end result is an improvedtreatment for a severe pain condition.

SUMMARY

Aspects of the present specification disclose a pharmaceuticalcomposition comprising a therapeutic compound and apharmaceutically-acceptable adjuvant. A therapeutic compound may have ananti-pain activity. Other aspects of the present specification disclosea pharmaceutical composition comprising a therapeutic compound disclosedherein, a pharmaceutically-acceptable solvent, and apharmaceutically-acceptable adjuvant. In other aspects, thepharmaceutical compositions disclosed herein further comprise apharmaceutically-acceptable stabilizing agent.

Other aspects of the present specification disclose a method ofpreparing a pharmaceutical composition, the method comprising the stepof contacting a therapeutic compound with a pharmaceutically-acceptableadjuvant under conditions which allow the formation of thepharmaceutical composition. Other aspects of the present specificationdisclose a method of preparing a pharmaceutical composition, the methodcomprising the steps: a) contacting a pharmaceutically-acceptablesolvent with a therapeutic compound under conditions which allow thetherapeutic compound to dissolve in the pharmaceutically-acceptablesolvent, thereby forming a solution, wherein the therapeutic compoundhas an anti-pain activity, and b) contacting the solution formed in step(a) with a pharmaceutically-acceptable adjuvant under conditions whichallow the formation of the pharmaceutical composition. In other aspects,the method of preparing disclosed herein further comprises c) removingthe pharmaceutically-acceptable solvent from the pharmaceuticalcomposition.

Other aspects of the present specification disclose a pharmaceuticalcomposition, the pharmaceutical composition made according to a methodcomprising the step of contacting a therapeutic compound with apharmaceutically-acceptable adjuvant under conditions which allow theformation of the pharmaceutical composition. Other aspects of thepresent specification disclose a pharmaceutical composition, thepharmaceutical composition made according to a method comprising thesteps: a) contacting a pharmaceutically-acceptable solvent with atherapeutic compound under conditions which allow the therapeuticcompound to dissolve in the pharmaceutically-acceptable solvent, therebyforming a solution, wherein the therapeutic compound has an anti-painactivity, and b) contacting the solution formed in step (a) with apharmaceutically-acceptable adjuvant under conditions which allow theformation of the pharmaceutical composition. In other aspects, themethod of making a pharmaceutical composition disclosed herein furthercomprises c) removing the pharmaceutically-acceptable solvent from thepharmaceutical composition.

Other aspects of the present specification disclose a method of treatingan individual with a severe pain condition, the method comprising thestep of administering to the individual in need thereof a pharmaceuticalcomposition disclosed herein, wherein administration results in areduction in a symptom associated with the severe pain condition,thereby treating the individual.

Other aspects of the present specification disclose a use of apharmaceutical composition disclosed herein in the manufacture of amedicament for the treatment of a severe pain condition.

Other aspects of the present specification disclose a use of apharmaceutical composition disclosed herein for the treatment of asevere pain condition.

DESCRIPTION

Aspects of the present specification disclose, in part, a composition. Acomposition disclosed herein is generally administered as apharmaceutical acceptable composition. As used herein, the term“pharmaceutically acceptable” refers any molecular entity or compositionthat does not produce an adverse, allergic or other untoward or unwantedreaction when administered to an individual. As used herein, the term“pharmaceutically acceptable composition” is synonymous with“pharmaceutical composition” and means a therapeutically effectiveconcentration of an active ingredient, such as, e.g., any of thetherapeutic compounds disclosed herein. A pharmaceutical compositiondisclosed herein is useful for medical and veterinary applications. Apharmaceutical composition may be administered to an individual alone,or in combination with other supplementary active ingredients, agents,drugs or hormones.

A pharmaceutical composition disclosed herein may optionally include apharmaceutically-acceptable carrier that facilitates processing of anactive ingredient into pharmaceutically-acceptable compositions. As usedherein, the term “pharmacologically-acceptable carrier” is synonymouswith “pharmacological carrier” and means any carrier that hassubstantially no long term or permanent detrimental effect whenadministered and encompasses terms such as “pharmacologically acceptablevehicle, stabilizer, diluent, additive, auxiliary or excipient.” Such acarrier generally is mixed with a therapeutic compound or permitted todilute or enclose the active compound and can be a solid, semi-solid, orliquid agent. It is understood that a therapeutic compound or otheractive ingredient can be soluble or can be delivered as a suspension inthe desired carrier or diluent. Any of a variety of pharmaceuticallyacceptable carriers can be used including, without limitation, aqueousmedia such as, e.g., water, saline, glycine, hyaluronic acid and thelike; solid carriers such as, e.g., mannitol, lactose, starch, magnesiumstearate, sodium saccharin, talcum, cellulose, glucose, sucrose,magnesium carbonate, and the like; solvents; dispersion media; coatings;antibacterial and antifungal agents; isotonic and absorption delayingagents; or any other inactive ingredient. Selection of apharmacologically acceptable carrier can depend on the mode ofadministration. Except insofar as any pharmacologically acceptablecarrier is incompatible with the active ingredient, its use inpharmaceutically acceptable compositions is contemplated. Non-limitingexamples of specific uses of such pharmaceutical carriers can be foundin Pharmaceutical Dosage Forms and Drug Delivery Systems (Howard C.Ansel et al., eds., Lippincott Williams & Wilkins Publishers, 7th ed.1999); REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (Alfonso R.Gennaro ed., Lippincott, Williams & Wilkins, 20th ed. 2000); Goodman &Gilman's The Pharmacological Basis of Therapeutics (Joel G. Hardman etal., eds., McGraw-Hill Professional, 10th ed. 2001); and Handbook ofPharmaceutical Excipients (Raymond C. Rowe et al., APhA Publications,4th edition 2003). These protocols are routine procedures and anymodifications are well within the scope of one skilled in the art andfrom the teaching herein.

A pharmaceutical composition disclosed herein can optionally include,without limitation, other pharmaceutically acceptable components (orpharmaceutical components), including, without limitation, buffers,preservatives, tonicity adjusters, salts, antioxidants, osmolalityadjusting agents, physiological substances, pharmacological substances,bulking agents, emulsifying agents, wetting agents, sweetening orflavoring agents, and the like. Various buffers and means for adjustingpH can be used to prepare a pharmaceutical composition disclosed herein,provided that the resulting preparation is pharmaceutically acceptable.Such buffers include, without limitation, acetate buffers, citratebuffers, phosphate buffers, neutral buffered saline, phosphate bufferedsaline and borate buffers. It is understood that acids or bases can beused to adjust the pH of a composition as needed. Pharmaceuticallyacceptable antioxidants include, without limitation, sodiummetabisulfite, sodium thiosulfate, acetylcysteine, butylatedhydroxyanisole and butylated hydroxytoluene. Useful preservativesinclude, without limitation, benzalkonium chloride, chlorobutanol,thimerosal, phenylmercuric acetate, phenylmercuric nitrate, a stabilizedoxy chloro composition and chelants, such as, e.g., DTPA orDTPA-bisamide, calcium DTPA, and CaNaDTPA-bisamide. Tonicity adjustorsuseful in a pharmaceutical composition include, without limitation,salts such as, e.g., sodium chloride, potassium chloride, mannitol orglycerin and other pharmaceutically acceptable tonicity adjustor. Thepharmaceutical composition may be provided as a salt and can be formedwith many acids, including but not limited to, hydrochloric, sulfuric,acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be moresoluble in aqueous or other protonic solvents than are the correspondingfree base forms. It is understood that these and other substances knownin the art of pharmacology can be included in a pharmaceuticalcomposition.

In one embodiment, a pharmaceutical composition disclosed hereincomprises a therapeutic compound having an anti-pain activity and apharmaceutically-acceptable adjuvant. An anti-pain activity encompassesa deadening or absence of the sense of pain or nociception without lossof consciousness and includes, without limitation, an analgesicactivity, and/or a nociceptive activity. In another embodiment, apharmaceutical composition disclosed herein comprises a therapeuticcompound having an anti-pain activity, a pharmaceutically-acceptablesolvent, and a pharmaceutically-acceptable adjuvant. In aspects of thisembodiment, a pharmaceutical composition disclosed herein may furthercomprise a pharmaceutically-acceptable stabilizing agent. In otheraspects of this embodiment, a pharmaceutical composition disclosedherein may further comprise a pharmaceutically-acceptable carrier, apharmaceutically-acceptable component, or bothpharmaceutically-acceptable carrier and pharmaceutically-acceptablecomponent.

Aspects of the present specification disclose, in part, a therapeuticcompound. A therapeutic compound is a compound that providespharmacological activity or other direct effect in the diagnosis, cure,mitigation, treatment, or prevention of disease, or to affect thestructure or any function of the body of man or animals. A therapeuticcompound disclosed herein may be used in the form of a pharmaceuticallyacceptable salt, solvate, or solvate of a salt, e.g. the hydrochloride.Additionally, therapeutic compound disclosed herein may be provided asracemates, or as individual enantiomers, including the R- orS-enantiomer. Thus, the therapeutic compound disclosed herein maycomprise a R-enantiomer only, a S-enantiomer only, or a combination ofboth a R-enantiomer and a S-enantiomer of a therapeutic compound. Atherapeutic compound disclosed herein may have an anti-pain activity.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a severe pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a severe pain response by,e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90% or at least 95%. In other aspects ofthis embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a severe pain response in a rangefrom, e.g., about 10% to about 100%, about 20% to about 100%, about 30%to about 100%, about 40% to about 100%, about 50% to about 100%, about60% to about 100%, about 70% to about 100%, about 80% to about 100%,about 10% to about 90%, about 20% to about 90%, about 30% to about 90%,about 40% to about 90%, about 50% to about 90%, about 60% to about 90%,about 70% to about 90%, about 10% to about 80%, about 20% to about 80%,about 30% to about 80%, about 40% to about 80%, about 50% to about 80%,or about 60% to about 80%, about 10% to about 70%, about 20% to about70%, about 30% to about 70%, about 40% to about 70%, or about 50% toabout 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a nociceptive pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a nociceptive pain responseby, e.g., at least 10%, at least 15%, at least 20%, at least 25%, atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90% or at least 95%. In other aspectsof this embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a nociceptive pain response in arange from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a pain response mediated by anociceptive receptor. In aspects of this embodiment, a therapeuticcompound disclosed herein has an anti-pain activity capable of reducinga pain response mediated by a nociceptive receptor by, e.g., at least10%, at least 15%, at least 20%, at least 25%, at least 30%, at least35%, at least 40%, at least 45%, at least 50%, at least 55%, at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least85%, at least 90% or at least 95%. In other aspects of this embodiment,a therapeutic compound disclosed herein has an anti-pain activitycapable of reducing a pain response mediated by a nociceptive receptorin a range from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a somatic pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a somatic pain response by,e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90% or at least 95%. In other aspects ofthis embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a somatic pain response in arange from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a visceral pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a visceral pain response by,e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90% or at least 95%. In other aspects ofthis embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a visceral pain response in arange from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a pathological pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a pathological pain responseby, e.g., at least 10%, at least 15%, at least 20%, at least 25%, atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90% or at least 95%. In other aspectsof this embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a pathological pain response in arange from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a neuropathic pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a neuropathic pain responseby, e.g., at least 10%, at least 15%, at least 20%, at least 25%, atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90% or at least 95%. In other aspectsof this embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a neuropathic pain response in arange from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a central neuropathic painresponse. In aspects of this embodiment, a therapeutic compounddisclosed herein has an anti-pain activity capable of reducing a centralneuropathic pain response by, e.g., at least 10%, at least 15%, at least20%, at least 25%, at least 30%, at least 35%, at least 40%, at least45%, at least 50%, at least 55%, at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90% or at least95%. In other aspects of this embodiment, a therapeutic compounddisclosed herein has an anti-pain activity capable of reducing a centralneuropathic pain response in a range from, e.g., about 10% to about100%, about 20% to about 100%, about 30% to about 100%, about 40% toabout 100%, about 50% to about 100%, about 60% to about 100%, about 70%to about 100%, about 80% to about 100%, about 10% to about 90%, about20% to about 90%, about 30% to about 90%, about 40% to about 90%, about50% to about 90%, about 60% to about 90%, about 70% to about 90%, about10% to about 80%, about 20% to about 80%, about 30% to about 80%, about40% to about 80%, about 50% to about 80%, or about 60% to about 80%,about 10% to about 70%, about 20% to about 70%, about 30% to about 70%,about 40% to about 70%, or about 50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a peripheral neuropathic painresponse. In aspects of this embodiment, a therapeutic compounddisclosed herein has an anti-pain activity capable of reducing aperipheral neuropathic pain response by, e.g., at least 10%, at least15%, at least 20%, at least 25%, at least 30%, at least 35%, at least40%, at least 45%, at least 50%, at least 55%, at least 60%, at least65%, at least 70%, at least 75%, at least 80%, at least 85%, at least90% or at least 95%. In other aspects of this embodiment, a therapeuticcompound disclosed herein has an anti-pain activity capable of reducinga peripheral neuropathic pain response in a range from, e.g., about 10%to about 100%, about 20% to about 100%, about 30% to about 100%, about40% to about 100%, about 50% to about 100%, about 60% to about 100%,about 70% to about 100%, about 80% to about 100%, about 10% to about90%, about 20% to about 90%, about 30% to about 90%, about 40% to about90%, about 50% to about 90%, about 60% to about 90%, about 70% to about90%, about 10% to about 80%, about 20% to about 80%, about 30% to about80%, about 40% to about 80%, about 50% to about 80%, or about 60% toabout 80%, about 10% to about 70%, about 20% to about 70%, about 30% toabout 70%, about 40% to about 70%, or about 50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a mononeuropathic pain response.In aspects of this embodiment, a therapeutic compound disclosed hereinhas an anti-pain activity capable of reducing a mononeuropathic painresponse by, e.g., at least 10%, at least 15%, at least 20%, at least25%, at least 30%, at least 35%, at least 40%, at least 45%, at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90% or at least 95%. In otheraspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a mononeuropathic painresponse in a range from, e.g., about 10% to about 100%, about 20% toabout 100%, about 30% to about 100%, about 40% to about 100%, about 50%to about 100%, about 60% to about 100%, about 70% to about 100%, about80% to about 100%, about 10% to about 90%, about 20% to about 90%, about30% to about 90%, about 40% to about 90%, about 50% to about 90%, about60% to about 90%, about 70% to about 90%, about 10% to about 80%, about20% to about 80%, about 30% to about 80%, about 40% to about 80%, about50% to about 80%, or about 60% to about 80%, about 10% to about 70%,about 20% to about 70%, about 30% to about 70%, about 40% to about 70%,or about 50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a mononeuropathic multiplex painresponse. In aspects of this embodiment, a therapeutic compounddisclosed herein has an anti-pain activity capable of reducing amononeuropathic multiplex pain response by, e.g., at least 10%, at least15%, at least 20%, at least 25%, at least 30%, at least 35%, at least40%, at least 45%, at least 50%, at least 55%, at least 60%, at least65%, at least 70%, at least 75%, at least 80%, at least 85%, at least90% or at least 95%. In other aspects of this embodiment, a therapeuticcompound disclosed herein has an anti-pain activity capable of reducinga mononeuropathic multiplex pain response in a range from, e.g., about10% to about 100%, about 20% to about 100%, about 30% to about 100%,about 40% to about 100%, about 50% to about 100%, about 60% to about100%, about 70% to about 100%, about 80% to about 100%, about 10% toabout 90%, about 20% to about 90%, about 30% to about 90%, about 40% toabout 90%, about 50% to about 90%, about 60% to about 90%, about 70% toabout 90%, about 10% to about 80%, about 20% to about 80%, about 30% toabout 80%, about 40% to about 80%, about 50% to about 80%, or about 60%to about 80%, about 10% to about 70%, about 20% to about 70%, about 30%to about 70%, about 40% to about 70%, or about 50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a polyneuropathic pain response.In aspects of this embodiment, a therapeutic compound disclosed hereinhas an anti-pain activity capable of reducing a polyneuropathic painresponse by, e.g., at least 10%, at least 15%, at least 20%, at least25%, at least 30%, at least 35%, at least 40%, at least 45%, at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90% or at least 95%. In otheraspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a polyneuropathic painresponse in a range from, e.g., about 10% to about 100%, about 20% toabout 100%, about 30% to about 100%, about 40% to about 100%, about 50%to about 100%, about 60% to about 100%, about 70% to about 100%, about80% to about 100%, about 10% to about 90%, about 20% to about 90%, about30% to about 90%, about 40% to about 90%, about 50% to about 90%, about60% to about 90%, about 70% to about 90%, about 10% to about 80%, about20% to about 80%, about 30% to about 80%, about 40% to about 80%, about50% to about 80%, or about 60% to about 80%, about 10% to about 70%,about 20% to about 70%, about 30% to about 70%, about 40% to about 70%,or about 50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing an autonomic neuropathic painresponse. In aspects of this embodiment, a therapeutic compounddisclosed herein has an anti-pain activity capable of reducing anautonomic neuropathic pain response by, e.g., at least 10%, at least15%, at least 20%, at least 25%, at least 30%, at least 35%, at least40%, at least 45%, at least 50%, at least 55%, at least 60%, at least65%, at least 70%, at least 75%, at least 80%, at least 85%, at least90% or at least 95%. In other aspects of this embodiment, a therapeuticcompound disclosed herein has an anti-pain activity capable of reducingan autonomic neuropathic pain response in a range from, e.g., about 10%to about 100%, about 20% to about 100%, about 30% to about 100%, about40% to about 100%, about 50% to about 100%, about 60% to about 100%,about 70% to about 100%, about 80% to about 100%, about 10% to about90%, about 20% to about 90%, about 30% to about 90%, about 40% to about90%, about 50% to about 90%, about 60% to about 90%, about 70% to about90%, about 10% to about 80%, about 20% to about 80%, about 30% to about80%, about 40% to about 80%, about 50% to about 80%, or about 60% toabout 80%, about 10% to about 70%, about 20% to about 70%, about 30% toabout 70%, about 40% to about 70%, or about 50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a neuralgia pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a neuralgia pain response by,e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90% or at least 95%. In other aspects ofthis embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a neuralgia pain response in arange from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a complex regional pain syndromepain response. In aspects of this embodiment, a therapeutic compounddisclosed herein has an anti-pain activity capable of reducing a complexregional pain syndrome pain response by, e.g., at least 10%, at least15%, at least 20%, at least 25%, at least 30%, at least 35%, at least40%, at least 45%, at least 50%, at least 55%, at least 60%, at least65%, at least 70%, at least 75%, at least 80%, at least 85%, at least90% or at least 95%. In other aspects of this embodiment, a therapeuticcompound disclosed herein has an anti-pain activity capable of reducinga complex regional pain syndrome pain response in a range from, e.g.,about 10% to about 100%, about 20% to about 100%, about 30% to about100%, about 40% to about 100%, about 50% to about 100%, about 60% toabout 100%, about 70% to about 100%, about 80% to about 100%, about 10%to about 90%, about 20% to about 90%, about 30% to about 90%, about 40%to about 90%, about 50% to about 90%, about 60% to about 90%, about 70%to about 90%, about 10% to about 80%, about 20% to about 80%, about 30%to about 80%, about 40% to about 80%, about 50% to about 80%, or about60% to about 80%, about 10% to about 70%, about 20% to about 70%, about30% to about 70%, about 40% to about 70%, or about 50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a referred pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a referred pain response by,e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90% or at least 95%. In other aspects ofthis embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a referred pain response in arange from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a deafferentation pain response.In aspects of this embodiment, a therapeutic compound disclosed hereinhas an anti-pain activity capable of reducing a deafferentation painresponse by, e.g., at least 10%, at least 15%, at least 20%, at least25%, at least 30%, at least 35%, at least 40%, at least 45%, at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90% or at least 95%. In otheraspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a deafferentation painresponse in a range from, e.g., about 10% to about 100%, about 20% toabout 100%, about 30% to about 100%, about 40% to about 100%, about 50%to about 100%, about 60% to about 100%, about 70% to about 100%, about80% to about 100%, about 10% to about 90%, about 20% to about 90%, about30% to about 90%, about 40% to about 90%, about 50% to about 90%, about60% to about 90%, about 70% to about 90%, about 10% to about 80%, about20% to about 80%, about 30% to about 80%, about 40% to about 80%, about50% to about 80%, or about 60% to about 80%, about 10% to about 70%,about 20% to about 70%, about 30% to about 70%, about 40% to about 70%,or about 50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a dysfunctional pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a dysfunctional pain responseby, e.g., at least 10%, at least 15%, at least 20%, at least 25%, atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90% or at least 95%. In other aspectsof this embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a dysfunctional pain response ina range from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a headache pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a headache pain response by,e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90% or at least 95%. In other aspects ofthis embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a headache pain response in arange from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

In an embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a migraine pain response. Inaspects of this embodiment, a therapeutic compound disclosed herein hasan anti-pain activity capable of reducing a migraine pain response by,e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90% or at least 95%. In other aspects ofthis embodiment, a therapeutic compound disclosed herein has ananti-pain activity capable of reducing a migraine pain response in arange from, e.g., about 10% to about 100%, about 20% to about 100%,about 30% to about 100%, about 40% to about 100%, about 50% to about100%, about 60% to about 100%, about 70% to about 100%, about 80% toabout 100%, about 10% to about 90%, about 20% to about 90%, about 30% toabout 90%, about 40% to about 90%, about 50% to about 90%, about 60% toabout 90%, about 70% to about 90%, about 10% to about 80%, about 20% toabout 80%, about 30% to about 80%, about 40% to about 80%, about 50% toabout 80%, or about 60% to about 80%, about 10% to about 70%, about 20%to about 70%, about 30% to about 70%, about 40% to about 70%, or about50% to about 70%.

A therapeutic compound disclosed herein may have a log P valueindicating that the compound is soluble in an organic solvent. As usedherein, the term “log P value” refers to the logarithm (base 10) of thepartition coefficient (P) for a compound and is a measure oflipophilicity. Typically, P is defined as the ratio of concentrations ofa unionized compound in the two phases of a mixture of two immisciblesolvents at equilibrium. Thus, log P=Log 10 (P), where P=[solute inimmiscible solvent 1]/[solute in immiscible solvent 2]. With regard toorganic and aqueous phases, the log P value of a compound is constantfor any given pair of aqueous and organic solvents, and its value can bedetermined empirically by one of several phase-partitioning methodsknown to one skilled in the art including, e.g., a shake flask assay, aHPLC assay, and an interface between two immiscible electrolytesolutions (ITIES) assay.

In aspects of this embodiment, a therapeutic compound disclosed hereinmay have a log P value indicating that the compound is substantiallysoluble in an organic solvent. In aspects of this embodiment, atherapeutic compound disclosed herein may have a log P value indicatingthat the compound is, e.g., at least 50% soluble in an organic solvent,at least 60% soluble in an organic solvent, at least 70% soluble in anorganic solvent, at least 80% soluble in an organic solvent, or at least90% soluble in an organic solvent. In aspects of this embodiment, atherapeutic compound disclosed herein may have a log P value indicatingthat the compound is between, e.g., about 50% to about 100% soluble inan organic solvent, about 60% to about 100% soluble in an organicsolvent, about 70% to about 100% soluble in an organic solvent, about80% to about 100% soluble in an organic solvent, or about 90% to about100% soluble in an organic solvent.

In aspects of this embodiment, a therapeutic compound disclosed hereinmay have a log P value of, e.g., more than 1.1, more than 1.2, more than1.4, more than 1.6, more than 1.8, more than 2.0, more than 2.2, morethan 2.4, more than 2.6, more than 2.8, more than 3.0, more than 3.2,more than 3.4, or more than 3.6. In other aspects of this embodiment, atherapeutic compound disclosed herein may have a log P value in therange of, e.g., between 1.8 and 4.0, between 2.0 and 4.0, between 2.1and 4.0, between 2.2 and 4.0, or between 2.3 and 4.0, between 2.4 and4.0, between 2.5 and 4.0, between 2.6 and 4.0, or between 2.8 and 4.0.In other aspects of this embodiment, a therapeutic compound disclosedherein may have a log P value in the range of, e.g., between 3.0 and4.0, or between 3.1 and 4.0, between 3.2 and 4.0, between 3.3 and 4.0,between 3.4 and 4.0, between 3.5 and 4.0, or between 3.6 and 4.0. Instill other aspects of this embodiment, a therapeutic compound disclosedherein may have a log P value in the range of, e.g., between 2.0 and2.5, between 2.0 and 2.7, between 2.0 and 3.0, or between 2.2 and 2.5.

A therapeutic compound disclosed herein may have a polar surface areathat is hydrophobic. As used herein, the term “polar surface area”refers to the surface sum over all of the polar atoms in the structureof a compound and is a measure of hydrophobicity. Typically, these polaratoms include, e.g., oxygen, nitrogen, and their attached hydrogens. Inaspects of this embodiment, a therapeutic compound disclosed herein mayhave a polar surface area of, e.g., less than 8.0 nm², less than 7.0nm², less than 6.0 nm², less than 5.0 nm², less than 4.0 nm², or lessthan 3.0 nm². In other aspects of this embodiment, a therapeuticcompound disclosed herein may have a polar surface area in the range of,e.g., between 3.0 nm² and 6.5 nm², between 3.0 nm² and 6.0 nm², between3.0 nm² and 5.5 nm², between 3.0 nm² and 5.0 nm², between 3.0 nm² and4.5 nm², between 3.5 nm² and 6.5 nm², between 3.5 nm² and 6.0 nm²,between 3.5 nm² and 5.5 nm², between 3.5 nm² and 5.0 nm², between 3.5nm² and 4.5 nm², between 4.0 nm² and 6.5 nm², between 4.0 nm² and 6.0nm², between 4.0 nm² and 5.5 nm², or between 4.0 nm² and 5.0 nm²,between 4.0 nm² and 4.5 nm², or between 4.5 nm² and 5.5 nm². In yetother aspects of this embodiment, a therapeutic compound disclosedherein may have a polar surface area in the range of, e.g., between 2.0nm² and 6.5 nm², between 2.0 nm² and 6.0 nm², between 2.0 nm² and 5.5nm², between 2.0 nm² and 5.0 nm², between 2.0 nm² and 4.5 nm², between2.5 nm² and 6.5 nm², between 2.5 nm² and 6.0 nm², between 2.5 nm² and5.5 nm², between 2.5 nm² and 5.0 nm², or between 2.5 nm² and 4.5 nm².

A therapeutic compound disclosed herein may be a non-steroidalanti-inflammatory drug (NSAID). NSAIDs are a large group of therapeuticcompounds with analgesic, anti-pain, and anti-pyretic properties. NSAIDsinclude, without limitation, Aceclofenac, Acemetacin, Actarit,Alcofenac, Alminoprofen, Amfenac, Aloxipirin, Aminophenazone,Antraphenine, Aspirin, Azapropazone, Benorilate, Benoxaprofen,Benzydamine, Butibufen, Celecoxib, Chlorthenoxacin, Choline Salicylate,Clometacin, Dexketoprofen, Diclofenac, Diflunisal, Emorfazone,Epirizole; Etodolac, Etoricoxib, Feclobuzone, Felbinac, Fenbufen,Fenclofenac, Flurbiprofen, Glafenine, Hydroxylethyl salicylate,Ibuprofen, Indometacin, Indoprofen, Ketoprofen, Ketorolac, Lactylphenetidin, Loxoprofen, Lumiracoxib, Mefenamic acid, Meloxicam,Metamizole, Metiazinic acid, Mofebutazone, Mofezolac, Nabumetone,Naproxen, Nifenazone, Niflumic acid, Oxametacin, Phenacetin, Pipebuzone,Pranoprofen, Propyphenazone, Proquazone, Protizinic acid, Rofecoxib,Salicylamide, Salsalate, Sulindac, Suprofen, Tiaramide, Tinoridine,Tolfenamic acid, Valdecoxib, and Zomepirac.

NSAIDs may be classified based on their chemical structure or mechanismof action. Non-limiting examples of NSAIDs include a salicylatederivative NSAID, a p-amino phenol derivative NSAID, a propionic acidderivative NSAID, an acetic acid derivative NSAID, an enolic acidderivative NSAID, a fenamic acid derivative NSAID, a non-selectivecyclo-oxygenase (COX) inhibitor, a selective cyclooxygenase 1 (COX 1)inhibitor, and a selective cyclooxygenase 2 (COX 2) inhibitor. A NSAIDmay be a profen. Examples of a suitable salicylate derivative NSAIDinclude, without limitation, Acetylsalicylic acid (asprin), Diflunisal,and Salsalate. Examples of a suitable p-amino phenol derivative NSAIDinclude, without limitation, Paracetamol and Phenacetin. Examples of asuitable propionic acid derivative NSAID include, without limitation,Alminoprofen, Benoxaprofen, Dexketoprofen, Fenoprofen, Flurbiprofen,Ibuprofen, Indoprofen, Ketoprofen, Loxoprofen, Naproxen, Oxaprozin,Pranoprofen, and Suprofen. Examples of a suitable acetic acid derivativeNSAID include, without limitation, Aceclofenac, Acemetacin, Actarit,Alcofenac, Amfenac, Clometacin, Diclofenac, Etodolac, Felbinac,Fenclofenac, Indometacin, Ketorolac, Metiazinic acid, Mofezolac,Nabumetone, Naproxen, Oxametacin, Sulindac, and Zomepirac. Examples of asuitable enolic acid (Oxicam) derivative NSAID include, withoutlimitation, Droxicam, Isoxicam, Lornoxicam, Meloxicam, Piroxicam, andTenoxicam. Examples of a suitable fenamic acid derivative NSAID include,without limitation, Flufenamic acid, Mefenamic acid, Meclofenamic acid,and Tolfenamic acid. Examples of a suitable selective COX-2 inhibitorsinclude, without limitation, Celecoxib, Etoricoxib, Firocoxib,Lumiracoxib, Meloxicam, Parecoxib, Rofecoxib, and Valdecoxib.

A therapeutic compound disclosed herein may be a PPARγ agonist. Examplesof a suitable PPARγ agonist include, without limitation, Benzbromarone,a cannabidiol, Cilostazol, Curcumin, Delta(9)-tetrahydrocannabinol,glycyrrhetinic acid, Indomethacin, Irbesartan, Monascin, mycophenolicacid, Resveratrol, 6-shogaol, Telmisartan, a thiazolidinedione likeRosiglitazone, Pioglitazone, and Troglitazone, a NSAID, and a fibrate.Other suitable PPARγ agonists are described in Masson andCaumont-Bertrand, PPAR Agonist Compounds, Preparation and Uses, US2011/0195993, which is hereby incorporated by reference in its entirety.

A therapeutic compound disclosed herein may be a nuclear receptorbinding agent. Examples of a suitable nuclear receptor binding agentinclude, without limitation, a Retinoic Acid Receptor (RAR) bindingagent, a Retinoid X Receptor (RXR) binding agent, a Liver X Receptor(LXR) binding agent and a Vitamin D binding agent.

A therapeutic compound disclosed herein may be an anti-hyperlipidemicagent. There are several classes of anti-hyperlipidemic agents (alsoknown as hypolipidemic agents). They may differ in both their impact onthe cholesterol profile and adverse effects. For example, some may lowerlow density lipoprotein (LDL), while others may preferentially increasehigh density lipoprotein (HDL). Clinically, the choice of an agent willdepend on the cholesterol profile of an individual, cardiovascular riskof an individual, and/or the liver and kidney functions of anindividual. Examples of a suitable anti-hyperlipidemic agent include,without limitation, a fibrate, a statin, a tocotrienol, a niacin, a bileacid sequestrants (resin), a cholesterol absorption inhibitor, apancreatic lipase inhibitor, and a sympathomimetic amine.

A therapeutic compound disclosed herein may be a fibrate. Fibrates are aclass of amphipathic carboxylic acids with lipid level modifyingproperties. These therapeutic compounds are used for a range ofmetabolic disorders. One non-limiting use is as an anti-hyperlipidemicagent where it may lower levels of, e.g., triglycerides and LDL as wellas increase levels of HDL. Examples of a suitable fibrate include,without limitation, Bezafibrate, Ciprofibrate, Clofibrate, Gemfibrozil,and Fenofibrate.

A therapeutic compound disclosed herein may be a statin. Statins (orHMG-CoA reductase inhibitors) are a class of therapeutic compounds usedto lower LDL and/or cholesterol levels by inhibiting the enzyme HMG-CoAreductase, which plays a central role in the production of cholesterolin the liver. To compensate for the decreased cholesterol availability,synthesis of hepatic LDL receptors is increased, resulting in anincreased clearance of LDL particles from the blood. Examples of asuitable statin include, without limitation, Atorvastatin, Fluvastatin,Lovastatin, Pitavastatin, Pravastatin, Rosuvastatin, and Simvastatin.

A therapeutic compound disclosed herein may be a tocotrienol.Tocotrienols are another class of HMG-CoA reductase inhibitors and maybe used to lower LDL and/or cholesterol levels by inducing hepatic LDLreceptor up-regulation and/or decreasing plasma LDL levels. Examples ofa suitable tocotrienol include, without limitation, a γ-tocotrienol anda δ-tocotrienol.

A therapeutic compound disclosed herein may be a niacin. Niacins are aclass of therapeutic compounds with lipid level modifying properties.For example, a niacin may lower LDL by selectively inhibiting hepaticdiacyglycerol acyltransferase 2, reduce triglyceride synthesis, and VLDLsecretion through a receptor HM74 and HM74A or GPR109A. Thesetherapeutic compounds are used for a range of metabolic disorders. Onenon-limiting use is as an anti-hyperlipidemic agent where it may inhibitthe breakdown of fats in adipose tissue. Because a niacin blocks thebreakdown of fats, it causes a decrease in free fatty acids in the bloodand, as a consequence, decreases the secretion of very-low-densitylipoproteins (VLDL) and cholesterol by the liver. By lowering VLDLlevels, a niacin may also increase the level of HDL in blood. Examplesof a suitable niacin include, without limitation, acipimox, niacin,nicotinamide, and vitamin B3.

A therapeutic compound disclosed herein may be a bile acid sequestrant.Bile acid sequestrants (also known as resins) are a class of therapeuticcompounds used to bind certain components of bile in thegastrointestinal tract. They disrupt the enterohepatic circulation ofbile acids by sequestering them and preventing their reabsorption fromthe gut. Bile acid sequestrants are particularly effective for loweringLDL and cholesterol by sequestering the cholesterol-containing bileacids released into the intestine and preventing their reabsorption fromthe intestine. In addition, a bile acid sequestrant may also raise HDLlevels. Examples of a suitable bile acid sequestrant include, withoutlimitation, Cholestyramine, Colesevelam, and Colestipol.

A therapeutic compound disclosed herein may be a cholesterol absorptioninhibitor. Cholesterol absorption inhibitors are a class of therapeuticcompounds that inhibits the absorption of cholesterol from theintestine. Decreased cholesterol absorption leads to an upregulation ofLDL-receptors on the surface of cells and an increased LDL-cholesteroluptake into these cells, thus decreasing levels of LDL in the bloodplasma. Examples of a suitable cholesterol absorption inhibitor include,without limitation, Ezetimibe, a phytosterol, a sterol and a stanol.

A therapeutic compound disclosed herein may be a fat absorptioninhibitor. Fat absorption inhibitors are a class of therapeuticcompounds that inhibits the absorption of fat from the intestine.Decreased fat absorption reduces caloric intake. In one aspect, a fatabsorption inhibitor inhibits pancreatic lipase, an enzyme that breaksdown triglycerides in the intestine. Examples of a suitable fatabsorption inhibitor include, without limitation, Orlistat.

A therapeutic compound disclosed herein may be a sympathomimetic amine.Sympathomimetic amines are a class of therapeutic compounds that mimicthe effects of transmitter substances of the sympathetic nervous systemsuch as catecholamines, epinephrine (adrenaline), norepinephrine(noradrenaline), and/or dopamine. A sympathomimetic amine may act as anα-adrenergic agonist, a β-adrenergic agonist, a dopaminergic agonist, amonoamine oxidase (MAO) inhibitor, and a COMT inhibitor. Suchtherapeutic compounds, among other things, are used to treat cardiacarrest, low blood pressure, or even delay premature labor. Examples of asuitable sympathomimetic amine include, without limitation, Clenbuterol,Salbutamol, ephedrine, pseudoephedrine, methamphetamine, amphetamine,phenylephrine, isoproterenol, dobutamine, methylphenidate,lisdexamfetamine, cathine, cathinone, methcathinone, cocaine,benzylpiperazine (BZP), methylenedioxypyrovalerone (MDPV),4-methylaminorex, pemoline, phenmetrazine, and propylhexedrine.

A therapeutic compound disclosed herein may be an ester of a therapeuticcompound. An ester of a therapeutic compound increases the log P valuerelative to the same therapeutic compound, but without the estermodification. An ester group may be attached to a therapeutic compoundby, e.g., a carboxylic acid or hydroxyl functional group present of thetherapeutic compound. An ester of a therapeutic compound may have anincreased hydrophobicity, and as such, may be dissolved in a reducedvolume of solvent disclosed herein. In some instances, an ester of atherapeutic compound may be combined directly with an adjuvant disclosedherein, thereby eliminating the need of a solvent. An ester of atherapeutic compound may enable the making of a pharmaceuticalcomposition disclosed herein, in situations where a non-esterified formof the same therapeutic compound is otherwise immiscible in a solventdisclosed herein. An ester of a therapeutic compound may still bedelivered in a manner that more effectively inhibits a pro-inflammatoryresponse as long as the compound is combined with an adjuvant disclosedherein. In one embodiment, a therapeutic compound may be reacted withethyl ester in order to form an ethyl ester of the therapeutic compound.

In another embodiment, a pharmaceutical composition disclosed hereindoes not comprise a pharmaceutically-acceptable solvent disclosedherein. In an aspect of this embodiment, a pharmaceutical compositioncomprises a therapeutic compound and a pharmaceutically-acceptableadjuvant, but does not comprise a pharmaceutically-acceptable solventdisclosed herein.

A pharmaceutical composition disclosed herein may comprise a therapeuticcompound in an amount sufficient to allow customary administration to anindividual. In aspects of this embodiment, a pharmaceutical compositiondisclosed herein may be, e.g., at least 5 mg, at least 10 mg, at least15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg,at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg,at least 85 mg, at least 90 mg, at least 95 mg, or at least 100 mg of atherapeutic compound. In other aspects of this embodiment, apharmaceutical composition disclosed herein may be, e.g., at least 5 mg,at least 10 mg, at least 20 mg, at least 25 mg, at least 50 mg, at least75 mg, at least 100 mg, at least 200 mg, at least 300 mg, at least 400mg, at least 500 mg, at least 600 mg, at least 700 mg, at least 800 mg,at least 900 mg, at least 1,000 mg, at least 1,100 mg, at least 1,200mg, at least 1,300 mg, at least 1,400 mg, or at least 1,500 mg of atherapeutic compound. In yet other aspects of this embodiment, apharmaceutical composition disclosed herein may be in the range of,e.g., about 5 mg to about 100 mg, about 10 mg to about 100 mg, about 50mg to about 150 mg, about 100 mg to about 250 mg, about 150 mg to about350 mg, about 250 mg to about 500 mg, about 350 mg to about 600 mg,about 500 mg to about 750 mg, about 600 mg to about 900 mg, about 750 mgto about 1,000 mg, about 850 mg to about 1,200 mg, or about 1,000 mg toabout 1,500 mg. In still other aspects of this embodiment, apharmaceutical composition disclosed herein may be in the range of,e.g., about 10 mg to about 250 mg, about 10 mg to about 500 mg, about 10mg to about 750 mg, about 10 mg to about 1,000 mg, about 10 mg to about1,500 mg, about 50 mg to about 250 mg, about 50 mg to about 500 mg,about 50 mg to about 750 mg, about 50 mg to about 1,000 mg, about 50 mgto about 1,500 mg, about 100 mg to about 250 mg, about 100 mg to about500 mg, about 100 mg to about 750 mg, about 100 mg to about 1,000 mg,about 100 mg to about 1,500 mg, about 200 mg to about 500 mg, about 200mg to about 750 mg, about 200 mg to about 1,000 mg, about 200 mg toabout 1,500 mg, about 5 mg to about 1,500 mg, about 5 mg to about 1,000mg, or about 5 mg to about 250 mg.

Aspects of the present specification disclose, in part, apharmaceutically-acceptable solvent. A solvent is a liquid, solid, orgas that dissolves another solid, liquid, or gaseous (the solute),resulting in a solution. Solvents useful in the pharmaceuticalcompositions disclosed herein include, without limitation, apharmaceutically-acceptable polar aprotic solvent, apharmaceutically-acceptable polar protic solvent and apharmaceutically-acceptable non-polar solvent. Apharmaceutically-acceptable polar aprotic solvent includes, withoutlimitation, dichloromethane (DCM), tetrahydrofuran (THF), ethyl acetate,acetone, dimethylformamide (DMF), acetonitrile (MeCN), dimethylsulfoxide (DMSO). A pharmaceutically-acceptable polar protic solventincludes, without limitation, acetic acid, formic acid, ethanol,n-butanol, 1-butanol, 2-butanol, isobutanol, sec-butanol, tert-butanol,n-propanol, isopropanol, 1,2 propan-diol, methanol, glycerol, and water.A pharmaceutically-acceptable non-polar solvent includes, withoutlimitation, pentane, cyclopentane, hexane, cyclohexane, benzene,toluene, 1,4-Dioxane, chloroform, n-methyl-pyrrolidone (NMP), anddiethyl ether.

A pharmaceutical composition disclosed herein may comprise a solvent inan amount sufficient to dissolve a therapeutic compound disclosedherein. In other aspects of this embodiment, a pharmaceuticalcomposition disclosed herein may comprise a solvent in an amount of,e.g., less than about 90% (v/v), less than about 80% (v/v), less thanabout 70% (v/v), less than about 65% (v/v), less than about 60% (v/v),less than about 55% (v/v), less than about 50% (v/v), less than about45% (v/v), less than about 40% (v/v), less than about 35% (v/v), lessthan about 30% (v/v), less than about 25% (v/v), less than about 20%(v/v), less than about 15% (v/v), less than about 10% (v/v), less thanabout 5% (v/v), or less than about 1% (v/v). In other aspects of thisembodiment, a pharmaceutical composition disclosed herein may comprise asolvent in an amount in a range of, e.g., about 1% (v/v) to 90% (v/v),about 1% (v/v) to 70% (v/v), about 1% (v/v) to 60% (v/v), about 1% (v/v)to 50% (v/v), about 1% (v/v) to 40% (v/v), about 1% (v/v) to 30% (v/v),about 1% (v/v) to 20% (v/v), about 1% (v/v) to 10% (v/v), about 2% (v/v)to 50% (v/v), about 2% (v/v) to 40% (v/v), about 2% (v/v) to 30% (v/v),about 2% (v/v) to 20% (v/v), about 2% (v/v) to 10% (v/v), about 4% (v/v)to 50% (v/v), about 4% (v/v) to 40% (v/v), about 4% (v/v) to 30% (v/v),about 4% (v/v) to 20% (v/v), about 4% (v/v) to 10% (v/v), about 6% (v/v)to 50% (v/v), about 6% (v/v) to 40% (v/v), about 6% (v/v) to 30% (v/v),about 6% (v/v) to 20% (v/v), about 6% (v/v) to 10% (v/v), about 8% (v/v)to 50% (v/v), about 8% (v/v) to 40% (v/v), about 8% (v/v) to 30% (v/v),about 8% (v/v) to 20% (v/v), about 8% (v/v) to 15% (v/v), or about 8%(v/v) to 12% (v/v).

In one embodiment, a solvent may comprise a pharmaceutically-acceptablealcohol. As used herein, the term “alcohol” refers to an organicmolecule comprising a hydroxyl functional group (—OH) bond to a carbonatom, where the carbon atom is saturated. In aspects of this embodiment,the alcohol may be, e.g., a C₂₋₄ alcohol, a C₁₋₄ alcohol, a C₁₋₅alcohol, a C₁₋₇ alcohol, a C₁₋₁₀ alcohol, a C₁₋₁₅ alcohol, or a C₁₋₂₀alcohol. In other aspects of this embodiment, an alcohol may be, e.g., aprimary alcohol, a secondary alcohol, or a tertiary alcohol. In otheraspects of this embodiment, an alcohol may be, e.g., an acyclic alcohol,a monohydric alcohol, a polyhydric alcohol (also known as a polyol orsugar alcohol), an unsaturated aliphatic alcohol, an alicyclic alcohol,or a combination thereof. Examples of a monohydric alcohol include,without limitation, methanol, ethanol, propanol, butanol, pentanol, and1-hexadecanol. Examples of a polyhydric alcohol include, withoutlimitation, glycol, glycerol, arabitol, erythritol, xylitol, maltitol,sorbitol (gluctiol), mannitol, inositol, lactitol, galactitol (iditol),and isomalt. Examples of an unsaturated aliphatic alcohol include,without limitation, prop-2-ene-1-ol, 3,7-dimethylocta-2,6-dien-1-ol, andprop-2-in-1-ol. Examples of an alicyclic alcohol include, withoutlimitation, cyclohexane-1,2,3,4,5,6-hexol and2-(2-propyl)-5-methyl-cyclohexane-1-ol.

In another embodiment, a solvent may comprise an ester ofpharmaceutically-acceptable alcohol and an acid. Suitablepharmaceutically-acceptable alcohols include the ones disclosed herein.Suitable acids include, without limitation, acetic acid, butaric acid,and formic acid. An ester of an alcohol and an acid include, withoutlimitation, methyl acetate, methyl buterate, methyl formate, ethylacetate, ethyl buterate, ethyl formate, propyl acetate, propyl buterate,propyl formate, butyl acetate, butyl buterate, butyl formate, isobutylacetate, isobutyl buterate, isobutyl formate, pentyl acetate, pentylbuterate, pentyl formate, and 1-hexadecyl acetate, 1-hexadecyl buterate,and 1-hexadecyl formate.

In another embodiment, a solvent may comprise apharmaceutically-acceptable glycol ether. Glycol ethers are a group ofsolvents based on alkyl ethers of ethylene glycol. Non-limiting examplesinclude diethylene glycol monomethyl ether (2-(2-methoxyethoxy)ethanol),diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol),diethylene glycol monopropyl ether (2-(2-propoxyethoxy)ethanol),diethylene glycol monoisopropyl ether (2-(2-isopropoxyethoxy)ethanol),and diethylene glycol mono-n-butyl ether (2-(2-butoxyethoxy)ethanol).Diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol) iscommercially available as TRANSCUTOL®.

In another embodiment, a solvent may comprise apharmaceutically-acceptable diol. A diol or double alcohol is a chemicalcompound containing two hydroxyl groups (—OH groups).

In another embodiment, a solvent may comprise apharmaceutically-acceptable propylene glycol.

Propylene glycol, also called 1,2-propanediol or propane-1,2-diol, is anorganic compound with formula C₃H₈O₂ or HO—CH₂—CHOH—CH₃.

In another embodiment, a solvent may comprise apharmaceutically-acceptable dipropylene glycol. Dipropylene glycol is amixture of three isomeric chemical compounds, 4-oxa-2,6-heptandiol,2-(2-Hydroxy-propoxy)-propan-1-ol, and2-(2-Hydroxy-1-methyl-ethoxy)-propan-1-ol.

In another embodiment, a solvent may comprise apharmaceutically-acceptable polypropylene glycol (PPG) polymer. PPGpolymers polymers, also known as polypropylene oxide (PPO) polymers orpolyoxypropylene (POP) polymers, are prepared by polymerization ofpropylene oxide and are commercially available over a wide range ofmolecular weights from 100 g/mol to 10,000,000 g/mol. PPG polymers witha low molecular mass are liquids or low-melting solids, whereas PPGpolymers of a higher molecular mass are solids. A PPG polymer include,without limitation, PPG 100, PPG 200, PPG 300, PPG 400, PPG 500, PPG600, PPG 700, PPG 800, PPG 900, PPG 1000, PPG 1100, PPG 1200, PPG 1300,PPG 1400, PPG 1500, PPG 1600, PPG 1700, PPG 1800, PPG 1900, PPG 2000,PPG 2100, PPG 2200, PPG 2300, PPG 2400, PPG 2500, PPG 2600, PPG 2700,PPG 2800, PPG 2900, PPG 3000, PPG 3250, PPG 3350, PPG 3500, PPG 3750,PPG 4000, PPG 4250, PPG 4500, PPG 4750, PPG 5000, PPG 5500, PPG 6000,PPG 6500, PPG 7000, PPG 7500, PPG 8000, PPG 8500, PPG 9000, PPG 9500,PPG 10,000, PPG 11,000, PPG 12,000, PPG 13,000, PPG 14,000, PPG 15,000,PPG 16,000, PPG 17,000, PPG 18,000, PPG 19,000, or PPG 20,000.

In another embodiment, a solvent may comprise apharmaceutically-acceptable polyethylene glycol (PEG) polymer. PEGpolymers, also known as polyethylene oxide (PEO) polymers orpolyoxyethylene (POE) polymers, are prepared by polymerization ofethylene oxide and are commercially available over a wide range ofmolecular weights from 100 g/mol to 10,000,000 g/mol. PEG polymers witha low molecular mass are liquids or low-melting solids, whereas PEGpolymers of a higher molecular mass are solids. A PEG polymer include,without limitation, PEG 100, PEG 200, PEG 300, PEG 400, PEG 500, PEG600, PEG 700, PEG 800, PEG 900, PEG 1000, PEG 1100, PEG 1200, PEG 1300,PEG 1400, PEG 1500, PEG 1600, PEG 1700, PEG 1800, PEG 1900, PEG 2000,PEG 2100, PEG 2200, PEG 2300, PEG 2400, PEG 2500, PEG 2600, PEG 2700,PEG 2800, PEG 2900, PEG 3000, PEG 3250, PEG 3350, PEG 3500, PEG 3750,PEG 4000, PEG 4250, PEG 4500, PEG 4750, PEG 5000, PEG 5500, PEG 6000,PEG 6500, PEG 7000, PEG 7500, PEG 8000, PEG 8500, PEG 9000, PEG 9500,PEG 10,000, PEG 11,000, PEG 12,000, PEG 13,000, PEG 14,000, PEG 15,000,PEG 16,000, PEG 17,000, PEG 18,000, PEG 19,000, or PEG 20,000.

In another embodiment, a solvent may comprise apharmaceutically-acceptable glyceride. Glycerides comprise a substitutedglycerol, where one, two, or all three hydroxyl groups of the glycerolare each esterified using a fatty acid to produce monoglycerides,diglycerides, and triglycerides, respectively. In these compounds, eachhydroxyl groups of glycerol may be esterified by different fatty acids.Additionally, glycerides may be acetylated to produce acetylatedmonoglycerides, acetylated diglycerides, and acetylated triglycerides.

In one embodiment, a solvent may comprise a pharmaceutically-acceptablesolid solvent. Solid solvents may be useful in the manufacture of asolid dose formulation of a pharmaceutical composition disclosed herein.Typically, a solid solvent is melted in order to dissolve a therapeuticcompound. A pharmaceutically-acceptable solid solvent includes, withoutlimitation, menthol and PEG polymers above about 20,000 g/mol.

Aspects of the present specification disclose, in part, apharmaceutically-acceptable adjuvant. An adjuvant is a pharmacologicalagent that modifies the effect of other agents, such as, e.g., atherapeutic compound disclosed herein. In addition, an adjuvantdisclosed herein may be used as a solvent that dissolves a therapeuticcompound disclosed herein, forming a adjuvant solution. An adjuvantdisclosed herein facilitates delivery of a therapeutic compound in amanner that more effectively inhibits a pro-inflammatory response. Inone embodiment, an adjuvant disclosed herein facilitates the delivery ofa therapeutic compound disclosed herein into macrophages.

A pharmaceutical composition disclosed herein may comprise apharmaceutically-acceptable adjuvant in an amount sufficient to mix witha solution disclosed herein or an emulsion disclosed herein. In otheraspects of this embodiment, a pharmaceutical composition disclosedherein may comprise an adjuvant in an amount of, e.g., at least 10%(v/v), at least 20% (v/v), at least 30% (v/v), at least 35% (v/v), atleast 40% (v/v), at least 45% (v/v), at least 50% (v/v), at least 55%(v/v), at least 60% (v/v), at least 65% (v/v), at least 70% (v/v), atleast 75% (v/v), at least 80% (v/v), at least 85% (v/v), at least 90%(v/v), at least 95% (v/v), or at least 99% (v/v). In other aspects ofthis embodiment, a pharmaceutical composition disclosed herein maycomprise an adjuvant in an amount in a range of, e.g., about 30% (v/v)to about 99% (v/v), about 35% (v/v) to about 99% (v/v), about 40% (v/v)to about 99% (v/v), about 45% (v/v) to about 99% (v/v), about 50% (v/v)to about 99% (v/v), about 30% (v/v) to about 98% (v/v), about 35% (v/v)to about 98% (v/v), about 40% (v/v) to about 98% (v/v), about 45% (v/v)to about 98% (v/v), about 50% (v/v) to about 98% (v/v), about 30% (v/v)to about 95% (v/v), about 35% (v/v) to about 95% (v/v), about 40% (v/v)to about 95% (v/v), about 45% (v/v) to about 95% (v/v), or about 50%(v/v) to about 95% (v/v). In yet other aspects of this embodiment, apharmaceutical composition disclosed herein may comprise an adjuvant inan amount in a range of, e.g., about 70% (v/v) to about 97% (v/v), about75% (v/v) to about 97% (v/v), about 80% (v/v) to about 97% (v/v), about85% (v/v) to about 97% (v/v), about 88% (v/v) to about 97% (v/v), about89% (v/v) to about 97% (v/v), about 90% (v/v) to about 97% (v/v), about75% (v/v) to about 96% (v/v), about 80% (v/v) to about 96% (v/v), about85% (v/v) to about 96% (v/v), about 88% (v/v) to about 96% (v/v), about89% (v/v) to about 96% (v/v), about 90% (v/v) to about 96% (v/v), about75% (v/v) to about 93% (v/v), about 80% (v/v) to about 93% (v/v), about85% (v/v) to about 93% (v/v), about 88% (v/v) to about 93% (v/v), about89% (v/v) to about 93% (v/v), or about 90% (v/v) to about 93% (v/v).

In one embodiment, an adjuvant may be a pharmaceutically-acceptablelipid. A lipid may be broadly defined as a hydrophobic or amphiphilicsmall molecule. The amphiphilic nature of some lipids allows them toform structures such as vesicles, liposomes, or membranes in an aqueousenvironment. Non-limiting examples, of lipids include fatty acids,glycerolipids (like monoglycerides, diglycerides, and triglycerides),phospholipids, sphingolipids, sterol lipids, prenol lipids,saccharolipids, and polyketides. A pharmaceutical composition disclosedherein may comprise a lipid such as, e.g. an oil, an oil-based liquid, afat, a fatty acid, a wax, a fatty acid ester, a fatty acid salt, a fattyalcohol, a glyceride (mono-, di- or triglyceride), a partiallyhydrolyzed glycerolipid, a phospholipids, a glycol ester, a sucroseester, a glycerol oleate derivative, a medium chain triglyceride, or amixture thereof. Other examples of pharmaceutically-acceptable lipidsuseful as adjuvants are described in, e.g., U.S. Pat. Nos. 6,923,988,6,451,339, 6,383,471, 6,294,192, and 6,267,985, each of which is herebyincorporated by reference in its entirety.

A lipid useful in the pharmaceutical compositions disclosed herein maybe a pharmaceutically-acceptable fatty acid. A fatty acid comprises acarboxylic acid with a long unbranched hydrocarbon chain which may beeither saturated or unsaturated. Thus arrangement confers a fatty acidwith a polar, hydrophilic end, and a nonpolar, hydrophobic end that isinsoluble in water. Most naturally occurring fatty acids have ahydrocarbon chain of an even number of carbon atoms, typically between 4and 24 carbons, and may be attached to functional groups containingoxygen, halogens, nitrogen, and sulfur. Synthetic or non-natural fattyacids may have a hydrocarbon chain of any number of carbon atoms frombetween 3 and 40 carbons. Where a double bond exists, there is thepossibility of either a cis or a trans geometric isomerism, whichsignificantly affects the molecule's molecular configuration. Cis-doublebonds cause the fatty acid chain to bend, an effect that is morepronounced the more double bonds there are in a chain. Most naturallyoccurring fatty acids are of the cis configuration, although the transform does exist in some natural and partially hydrogenated fats andoils. Examples of fatty acids include, without limitation, Capryllicacid (8:0), pelargonic acid (9:0), Capric acid (10:0), Undecylic acid(11:0), Lauric acid (12:0), Tridecylic acid (13:0), Myristic acid(14:0), Myristoleic acid (14:1), Pentadecyclic acid (15:0), Palmiticacid (16:0), Palmitoleic acid (16:1), Sapienic acid (16:1), Margaricacid (17:0), Stearic acid (18:0), Oleic acid (18:1), Elaidic acid(18:1), Vaccenic acid (18:1), Linoleic acid (18:2), Linoelaidic acid(18:2), α-Linolenic acid (18:3), γ-Linolenic acid (18:3), Stearidonicacid (18:4), Nonadecylic acid (19:0), Arachidic acid (20:0), Eicosenoicacid (20:1), Dihomo-γ-linolenic acid (20:3), Mead acid (20:3),Arachidonic acid (20:4), Eicosapentaenoic acid (20:5), Heneicosylic acid(21:0), Behenic acid (22:0), Erucic acid (22:1), Docosahexaenoic acid(22:6), Tricosylic acid (23:0), Lignoceric acid (24:0), Nervonic acid(24:1), Pentacosylic acid (25:0), Cerotic acid (26:0), Heptacosylic acid(27:0), Montanic acid (28:0), Nonacosylic acid (29:0), Melissic acid(30:0), Henatriacontylic acid (31:0), Lacceroic acid (32:0), Psyllicacid (33:0), Geddic acid (34:0), Ceroplastic acid (35:0), andHexatriacontylic acid (36:0).

A lipid useful in the pharmaceutical compositions disclosed herein maybe a pharmaceutically-acceptable partially hydrogenated lipid. Theprocess of hydrogenation adds hydrogen atoms to unsaturated lipid,eliminating double bonds and making them into partially or completelysaturated lipid. Partial hydrogenation is a chemical rather thanenzymatic, that converts a part of cis-isomers into trans-unsaturatedlipids instead of hydrogenating them completely. In the first reactionstep, one hydrogen is added, with the other, coordinatively unsaturated,carbon being attached to the catalyst. The second step is the additionof hydrogen to the remaining carbon, producing a saturated fatty acid.The first step is reversible, such that the hydrogen is reabsorbed onthe catalyst and the double bond is re-formed. The intermediate withonly one hydrogen added contains no double bond and can freely rotate.Thus, the double bond can re-form as either cis or trans, of which transis favored, regardless the starting material.

In an embodiment, an adjuvant may be a pharmaceutically-acceptablesaturated or unsaturated fatty acid. In aspects of this embodiment, asaturated or unsaturated fatty acid comprises, e.g., at least 8, atleast 10, at least 12, at least 14, at least 16, at least 18, at least20, at least 22, at least 24, at least 26, at least 28, or at least 30carbon atoms. In other aspects of this embodiment, a saturated orunsaturated fatty acid comprises, e.g., between 4 and 24 carbon atoms,between 6 and 24 carbon atoms, between 8 and 24 carbon atoms, between 10and 24 carbon atoms, between 12 and 24 carbon atoms, between 14 and 24carbon atoms, or between 16 and 24 carbon atoms, between 4 and 22 carbonatoms, between 6 and 22 carbon atoms, between 8 and 22 carbon atoms,between 10 and 22 carbon atoms, between 12 and 22 carbon atoms, between14 and 22 carbon atoms, or between 16 and 22 carbon atoms, between 4 and20 carbon atoms, between 6 and 20 carbon atoms, between 8 and 20 carbonatoms, between 10 and 20 carbon atoms, between 12 and 20 carbon atoms,between 14 and 20 carbon atoms, or between 16 and 20 carbon atoms. Ifunsaturated, the fatty acid may have, e.g., 1 or more, 2 or more, 3 ormore, 4 or more, 5 or more, or 6 or more double bonds.

In aspects of this embodiment, a pharmaceutically-acceptable saturatedor unsaturated fatty acid is liquid at room temperature. The meltingpoint of a fatty acid is largely determined by the degree ofsaturation/unsaturation of the hydrocarbon chain. In aspects of thisembodiment, a saturated or unsaturated fatty acid has a melting pointtemperature of, e.g., 20° C. or below, 15° C. or below, 10° C. or below,5° C. or below, 0° C. or below, −5° C. or below, −10° C. or below, −15°C. or below, or −20° C. or below. In other aspects of this embodiment, asaturated or unsaturated fatty acid has a melting point temperature inthe range of, e.g., about −20° C. to about 20° C., about −20° C. toabout 18° C., about −20° C. to about 16° C., about −20° C. to about 12°C., about −20° C. to about 8° C., about −20° C. to about 4° C., about−20° C. to about 0° C., about −15° C. to about 20° C., about −15° C. toabout 18° C., about −15° C. to about 16° C., about −15° C. to about 12°C., about −15° C. to about 8° C., about −15° C. to about 4° C., about−15° C. to about 0° C.

In another embodiment, an adjuvant may comprise one kind ofpharmaceutically-acceptable fatty acid. In aspects of this embodiment,an adjuvant may comprise only palmitic acid, only stearic acid, onlyoleic acid, only linoleic acid, or only linolenic acid.

In another embodiment, an adjuvant may comprise a plurality of differentpharmaceutically-acceptable fatty acids. In aspects of this embodiment,an adjuvant may comprise, e.g., two or more different fatty acids, threeor more different fatty acids, four or more different fatty acids, fiveor more different fatty acids, or six or more different fatty acids.

In other aspects of this embodiment, an adjuvant may comprise two ormore different pharmaceutically-acceptable fatty acids including atleast palmitic acid, stearic acid, oleic acid, linoleic acid and/orlinolenic acid, and any combination thereof. In other aspects of thisembodiment, an adjuvant may comprise a ratio of palmitic acid and/orstearic acid and/or oleic acid:linolenic acid and/or linoleic acid of,e.g., at least 2:1, at least 3:1, at least 4:1, at least 5:1, at least6:1, at least 7:1, at least 8:1, at least 9:1, at least 10:1, at least15:1, or at least 20:1. In yet other aspects of this embodiment, anadjuvant may comprise a ratio of palmitic acid and/or stearic acidand/or oleic acid:linolenic acid and/or linoleic acid in a range of,e.g., about 1:1 to about 20:1, about 2:1 to about 15:1, about 4:1 toabout 12:1, or about 6:1 to about 10:1.

In other aspects of this embodiment, an adjuvant may comprise four ormore different pharmaceutically-acceptable fatty acids including atleast palmitic acid, stearic acid, oleic acid, linoleic acid and/orlinolenic acid, and any combination thereof. In other aspects of thisembodiment, an adjuvant may comprise a ratio of palmitic acid; stearicacid:linolenic acid:linoleic acid of, e.g., 10:10:1:1, 9:9:1:1, 8:8:1:1,7:7:1:1, 6:6:1:1, 5:5:1:1, 4:4:1:1, 3:3:1:1, 2:2:1:1, or 1:1:1:1. Inother aspects of this embodiment, an adjuvant may comprise a ratio ofpalmitic acid; stearic acid:linolenic acid:linoleic acid in a range of,e.g., about 10:10:1:1 to about 6:6:1:1, about 8:8:1:1 to about 4:4:1:1,or about 5:5:1:1 to about 1:1:1:1.

A lipid useful in the pharmaceutical compositions disclosed herein maybe a pharmaceutically-acceptable omega fatty acid. Non-limiting examplesof an omega fatty acid include omega-3, omega-6, omega-7, and omega-9.Omega-3 fatty acids (also known as n-3 fatty acids or ω-3 fatty acids)are a family of essential unsaturated fatty acids that have in common afinal carbon-carbon double bond in the n-3 position, that is, the thirdbond, counting from the methyl end of the fatty acid. The omega-3 fattyacids are “essential” fatty acids because they are vital for normalmetabolism and cannot be synthesized by the human body. An omega-3 fattyacid includes, without limitation, Hexadecatrienoic acid (16:3),α-Linolenic acid (18:3), Stearidonic acid (18:4), Eicosatrienoic acid(20:3), Eicosatetraenoic acid (20:4), Eicosapentaenoic acid (20:5),Heneicosapentaenoic acid (21:5), Docosapentaenoic acid (Clupanodonicacid) (22:5), Docosahexaenoic acid (22:6), Tetracosapentaenoic acid(24:5), Tetracosahexaenoic acid (Nisinic acid) (24:6).

Omega-6 fatty acids (also known as n-6 fatty acids or ω-6 fatty acids)are a family of unsaturated fatty acids that have in common a finalcarbon-carbon double bond in the n-6 position, that is, the sixth bond,counting from the methyl end of the fatty acid. An omega-6 fatty acidincludes, without limitation, Linoleic acid (18:2), γ-linolenic acid(18:3), Calendic acid (18:3), Eicosadienoic acid (20:2),Dihomo-γ-linolenic acid (20:3), Arachidonic acid (20:4), Docosadienoicacid (22:2), Adrenic acid (22:4), Docosapentaenoic acid (22:5),Tetracosatetraenoic acid (24:4), and Tetracosapentaenoic acid (24:5).

Omega-7 fatty acids (also known as n-7 fatty acids or ω-7 fatty acids)are a family of unsaturated fatty acids that have in common a finalcarbon-carbon double bond in the n-7 position, that is, the seventhbond, counting from the methyl end of the fatty acid. An omega-7 fattyacid includes, without limitation, 5-Dodecenoic acid (12:1),7-Tetradecenoic acid (14:1), 9-Hexadecenoic acid (Palmitoleic acid)(16:1), 11-Decenoic acid (Vaccenic acid) (18:1), 9Z,11E conjugatedLinoleic acid (Rumenic acid)(18:2), 13-Eicosenoic acid (Paullinic acid)(20:1), 15-Docosenoic acid (22:1), and 17-Tetracosenoic acid (24:1).

Omega-9 fatty acids (also known as n-9 fatty acids or ω-9 fatty acids)are a family of unsaturated fatty acids that have in common a finalcarbon-carbon double bond in the n-9 position, that is, the ninth bond,counting from the methyl end of the fatty acid. An omega-9 fatty acidincludes, without limitation, Oleic acid (18:1), Elaidic acid (18:1),Eicosenoic acid (20:1), Mead acid (20:3), Erucic acid (22:1), Nervonicacid (24:1), and Ricinoleic acid.

A lipid useful in the pharmaceutical compositions disclosed herein maybe a pharmaceutically-acceptable fat. Also known as a hard fat or solidfat, a fat includes any fatty acid that is solid at normal roomtemperature, such as, e.g. about 20° C. Fats consist of a wide group ofcompounds that are generally soluble in organic solvents and generallyinsoluble in water. A fat suitable as a lipid useful in thepharmaceutical compositions disclosed herein, may be a triglyceride, atriester of glycerol or any of several fatty acids.

A lipid useful in the pharmaceutical compositions disclosed herein maybe a pharmaceutically-acceptable oil. An oil, also known as a liquidfat, includes any fatty acid that is liquid at normal room temperature,such as, e.g. about 20° C. An oil suitable as a lipid useful in thepharmaceutical compositions disclosed herein, may be a natural oil, avegetable oil or any substance that does not mix with water and has agreasy feel. Examples of suitable natural oils include, withoutlimitation, mineral oil, triacetin, ethyl oleate, a hydrogenated naturaloil, or a mixture thereof. Examples of suitable vegetable oils include,without limitation, almond oil, arachis oil, avocado oil, canola oil,castor oil, coconut oil, corn oil, cottonseed oil, grape seed oil,hazelnut oil, hemp oil, linseed oil (flax seed oil), olive oil, palmoil, peanut oil, rapeseed oil, rice bran oil, safflower oil, sesame oil,soybean oil, soya oil, sunflower oil, theobroma oil (cocoa butter),walnut oil, wheat germ oil, or a mixture thereof. Each of these oils iscommercially available from a number of sources well recognized by thoseskilled in the art.

An oil is typically a mixture of various fatty acids. For example,Rapeseed oil, obtained from the seeds of Brassica napus, includes bothomega-6 and omega-3 fatty acids in a ratio of about 2:1. As anotherexample, linseed oil, obtained from the seeds of Linum usitatissimum,includes abut 7% palmitic acid, about 3.4-4.6% stearic acid, about18.5-22.6% oleic acid, about 14.2-17% linoleic acid, and about51.9-55.2% α-linolenic acid. As another example, theobroma oil, obtainedfrom the seeds of Theobroma cacao, includes glycerides derived frompalmitic acid, stearic acid, oleic acid, linoleic acid, and arichidicacid, with melting point of 34-38° C. In aspects of this embodiment, apharmaceutical composition comprises an oil including at least twodifferent fatty acids, at least three different fatty acids, at leastfour different fatty acids, at least five different fatty acids, or atleast six different fatty acids.

A lipid useful in the pharmaceutical compositions disclosed herein maybe a pharmaceutically-acceptable glycerolipid. Glycerolipids arecomposed mainly of mono-, di-, and tri-substituted glycerols. One groupof glycerolipids is the glycerides, where one, two, or all threehydroxyl groups of glycerol are each esterified using a fatty aciddisclosed herein to produce monoglycerides, diglycerides, andtriglycerides, respectively. In these compounds, each hydroxyl groups ofglycerol may be esterified by different fatty acids. Additionally,glycerides may be acetylated to produce acetylated monoglycerides,acetylated diglycerides, and acetylated triglycerides. One group ofglycerolipids is the glycerides, where one, two, or all three hydroxylgroups of glycerol have sugar residues attached via a glycosidiclinkage.

A lipid useful in the pharmaceutical compositions disclosed herein maybe a pharmaceutically-acceptable partially hydrolyzed glycerolipid. Inan aspect of this embodiment, a pharmaceutically-acceptable partiallyhydrolyzed glycerolipid is a triglyceride partially hydrolyzed into amixture of mono-, di-, and triglycerides.

A lipid useful in the pharmaceutical compositions disclosed herein maybe a pharmaceutically-acceptable glycol fatty acid ester. Apharmaceutically-acceptable glycol fatty acid ester can be a monoesterof a glycol, a diester of a glycol, or a triester of a glycol. A glycolfatty acid ester include, without limitation, a ethylene glycol fattyacid ester, a diethylene glycol fatty acid ester, a propylene glycolfatty acid ester, and a dipropylene fatty acid ester. Non-limitingexamples of glycol fatty acid esters include, e.g., ethelene glycolcaprylate, ethelene glycol pelargonate, ethelene glycol caprate,ethelene glycol undecylate, ethelene glycol laurate, ethelene glycoltridecylate, ethelene glycol myristate, ethelene glycol myristolate,ethelene glycol pentadecyclate, ethelene glycol palmitate, etheleneglycol palmitoleate, ethelene glycol sapienate, ethelene glycolmargarate, ethelene glycol stearate, ethelene glycol palmitostearate,ethelene glycol oleate, ethelene glycol elaidate, ethelene glycolvaccinate, ethelene glycol linoleate, ethelene glycol linoelaidate,ethelene glycol α-linolenate, ethelene glycol γ-linolenate, etheleneglycol stearidonate, ethelene glycol capprylocaprate, ethelene glycoldicapprylocaprate, diethelene glycol caprylate, diethelene glycolpelargonate, diethelene glycol caprate, diethelene glycol undecylate,diethelene glycol laurate, diethelene glycol tridecylate, dietheleneglycol myristate, diethelene glycol myristolate, diethelene glycolpentadecyclate, diethelene glycol palmitate, diethelene glycolpalmitoleate, diethelene glycol sapienate, diethelene glycol margarate,diethelene glycol stearate, diethelene glycol palmitostearate,diethelene glycol oleate, diethelene glycol elaidate, diethelene glycolvaccinate, diethelene glycol linoleate, diethelene glycol linoelaidate,diethelene glycol α-linolenate, diethelene glycol γ-linolenate,diethelene glycol stearidonate, diethelene glycol capprylocaprate,diethelene glycol dicapprylocaprate, propylene glycol caprylate,propylene glycol pelargonate, propylene glycol caprate, propylene glycolundecylate, propylene glycol laurate, propylene glycol tridecylate,propylene glycol myristate, propylene glycol myristolate, propyleneglycol pentadecyclate, propylene glycol palmitate, propylene glycolpalmitoleate, propylene glycol sapienate, propylene glycol margarate,propylene glycol stearate, propylene glycol palmitostearate, propyleneglycol oleate, propylene glycol elaidate, propylene glycol vaccinate,propylene glycol linoleate, propylene glycol linoelaidate, propyleneglycol α-linolenate, propylene glycol γ-linolenate, propylene glycolstearidonate, propylene glycol capprylocaprate, propylene glycoldicapprylocaprate, dipropylene glycol caprylate, dipropylene glycolpelargonate, dipropylene glycol caprate, dipropylene glycol undecylate,dipropylene glycol laurate, dipropylene glycol tridecylate, dipropyleneglycol myristate, dipropylene glycol myristolate, dipropylene glycolpentadecyclate, dipropylene glycol palmitate, dipropylene glycolpalmitoleate, dipropylene glycol sapienate, dipropylene glycolmargarate, dipropylene glycol stearate, dipropylene glycolpalmitostearate, dipropylene glycol oleate, dipropylene glycol elaidate,dipropylene glycol vaccinate, dipropylene glycol linoleate, dipropyleneglycol linoelaidate, dipropylene glycol α-linolenate, dipropylene glycolγ-linolenate, dipropylene glycol stearidonate, dipropylene glycolcapprylocaprate, dipropylene glycol dicapprylocaprate, or anycombination thereof.

A lipid useful in the pharmaceutical compositions disclosed herein maybe a pharmaceutically-acceptable polyether fatty acid ester. Apharmaceutically-acceptable polyether fatty acid ester can be amono-fatty acid ester of a polyether, a di-fatty acid ester of apolyether, or a tri-fatty acid ester of a polyether. A polyether fattyacid ester includes, without limitation, a PEG fatty acid ester, a PEGglyceryl fatty acid, a PEG fatty acid ester glyceride, a PPG fatty acidester, a PPG glyceryl fatty acid, and a PPG fatty acid ester glyceride.A PEG or PPG may be a molecular mass of, e.g., 5-20,000. Non-limitingexamples of polyether fatty acid esters include, e.g., a PEG caprylate,a PEG pelargonate, a PEG caprate, a PEG undecylate, a PEG laurate, a PEGtridecylate, a PEG myristate, a PEG myristolate, a PEG pentadecyclate, aPEG palmitate, a PEG palmitoleate, a PEG sapienate, a PEG margarate, aPEG stearate, a PEG palmitostearate, PEG oleate, PEG elaidate, PEGvaccinate, PEG linoleate, PEG linoelaidate, PEG α-linolenate, PEGγ-linolenate, PEG stearidonate, PEG capprylocaprate, PEGdicapprylocaprate, a PEG glyceryl caprylate, a PEG glyceryl pelargonate,a PEG glyceryl caprate, a PEG glyceryl undecylate, a PEG glyceryllaurate, a PEG glyceryl tridecylate, a PEG glyceryl myristate, a PEGglyceryl myristolate, a PEG glyceryl pentadecyclate, a PEG glycerylpalmitate, a PEG glyceryl palmitoleate, a PEG glyceryl sapienate, a PEGglyceryl margarate, a PEG glyceryl stearate, a PEG glycerylpalmitostearate, PEG glyceryl oleate, PEG glyceryl elaidate, PEGglyceryl vaccinate, PEG glyceryl linoleate, PEG glyceryl linoelaidate,PEG glyceryl α-linolenate, PEG glyceryl γ-linolenate, PEG glycerylstearidonate, PEG glyceryl capprylocaprate, PEG glyceryldicapprylocaprate, a capryloyl PEG glyceride, a pelargonoyl PEGglyceride, a caproyl PEG glyceride, an undecyloyl PEG glyceride, alauroyl PEG glyceride, a tridecyloyl PEG glyceride, a myristoyl PEGglyceride, a myristoloyl PEG glyceride, a pentadecycloyl PEG glyceride,a palmitoyl PEG glyceride, a palmitoleoyl PEG glyceride, a sapienoyl PEGglyceride, a margaroyl PEG glyceride, a stearoyl PEG glyceride, apalmitostearoyl PEG glyceride, an oleoyl PEG glyceride, an elaidoyl PEGglyceride, a vaccinoyl PEG glyceride, a linoleoyl PEG glyceride, alinoelaidoyl PEG glyceride, an α-linolenoyl PEG glyceride, aγ-linolenoyl PEG glyceride, a stearidonoyl PEG glyceride, acapprylocaproyl PEG glyceride, a dicapprylocaproyl PEG glyceride, a PPGcaprylate, a PPG pelargonate, a PPG caprate, a PPG undecylate, a PPGlaurate, a PPG tridecylate, a PPG myristate, a PPG myristolate, a PPGpentadecyclate, a PPG palmitate, a PPG palmitoleate, a PPG sapienate, aPPG margarate, a PPG stearate, a PPG palmitostearate, a PPG oleate, aPPG elaidate, a PPG vaccinate, a PPG linoleate, a PPG linoelaidate, aPPG α-linolenate, a PPG γ-linolenate, a PPG stearidonate, a PPGcapprylocaprate, a PPG dicapprylocaprate, a PPG glyceryl caprylate, aPPG glyceryl pelargonate, a PPG glyceryl caprate, a PPG glycerylundecylate, a PPG glyceryl laurate, a PPG glyceryl tridecylate, a PPGglyceryl myristate, a PPG glyceryl myristolate, a PPG glycerylpentadecyclate, a PPG glyceryl palmitate, a PPG glyceryl palmitoleate, aPPG glyceryl sapienate, a PPG glyceryl margarate, a PPG glycerylstearate, a PPG glyceryl palmitostearate, a PPG glyceryl oleate, a PPGglyceryl elaidate, a PPG glyceryl vaccinate, a PPG glyceryl linoleate, aPPG glyceryl linoelaidate, a PPG glyceryl α-linolenate, a PPG glycerylγ-linolenate, a PPG glyceryl stearidonate, a PPG glycerylcapprylocaprate, a PPG glyceryl dicapprylocaprate, a capryloyl PPGglyceride, a pelargonoyl PPG glyceride, a caproyl PPG glyceride, anundecyloyl PPG glyceride, a lauroyl PPG glyceride, a tridecyloyl PPGglyceride, a myristoyl PPG glyceride, a myristoloyl PPG glyceride, apentadecycloyl PPG glyceride, a palmitoyl PPG glyceride, a palmitoleoylPPG glyceride, a sapienoyl PPG glyceride, a margaroyl PPG glyceride, astearoyl PPG glyceride, a palmitostearoyl PPG glyceride, an oleoyl PPGglyceride, an elaidoyl PPG glyceride, a vaccinoyl PPG glyceride, alinoleoyl PPG glyceride, a linoelaidoyl PPG glyceride, an α-linolenoylPPG glyceride, a γ-linolenoyl PPG glyceride, a stearidonoyl PPGglyceride, a capprylocaproyl PPG glyceride, a dicapprylocaproyl PPGglyceride, or any combination thereof.

Comercially available pharmaceutically-acceptable polyether fatty acidesters include, without limitation, caprylocaproyl macrogol-8 glycerides(LABRASOL®), propylene glycol monopalmitostearate (MONOSTEOL®), glyceryldibehenate (COMPRITOL® 888), glycerol behenate (COMPRITOL® E ATO),behenoyl pollyoxyl-8 glycerides (COMPRITOL® HD5 ATO), triglyceroldiisostearate (PLUROL® Diisostearique), PEG-8 beeswax (APIFIL®), lauroylmacrogol-32 glycerides (GELUCIRE 44/14), stearoyl macrogol-32 glycerides(GELUCIRE 50.13), propylene glycol dicaprylocaprate (LABRAFAC® PG),polyglycerol-3 dioleate (PLUROL® Oleique CC 497), propylene glycolmonolaurate (type I) (LAUROGLYCOL® FCC), propylene glycol monolaurate(type II) (LAUROGLYCOL® 90), propylene glycol monocaprylate (type I)(CAPRYOL® PGMC), propylene glycol monocaprylate (type II) (CAPRYOL® 90),linoleoyl macrogol-6 glycerides (LABRAFIL® M2125CS), oleoyl macrogol-6glycerides (LABRAFIL® M1944CS), lauroyl macrogol-6 glycerides (LABRAFIL®M2130CS), glycerol dipalmitostearate (Biogapress Vegetal BM297ATO),glycerol distearate (type I) (PRECIROL® ATO 5), and glycerolmonolinoleate (MAISINE™ 35-1).

A lipid useful in the pharmaceutical compositions disclosed herein maybe a mixture of pharmaceutically-acceptable lipids. Examples of mixturesof pharmaceutically-acceptable lipids include, without limitation, amixture of one or more glycerolipids disclosed herein, a mixture of oneor more glycol fatty acid esters disclosed herein, a mixture of morepolyether fatty acid esters disclosed herein, a mixture of moreglycerides disclosed herein.

In aspects of this embodiment, a mixture of pharmaceutically-acceptablelipids includes a mixture of mono-, di-, and/or triglycerides having amelting point of, e.g., about 33° C., about 34° C., about 35° C., about36° C., about 37° C., about 38° C., about 39° C., about 40° C., about41° C., about 43° C., about 43° C., about 44° C., about 45° C., about45° C., about 47° C., about 48° C., about 49° C., about 50° C. Inaspects of this embodiment, a mixture of pharmaceutically-acceptablelipids includes a mixture of mono-, di-, and/or triglycerides having amelting point of, e.g., about 30° C. to about 44° C., about 30° C. toabout 45° C., about 30° C. to about 46° C., about 30° C. to about 47°C., about 30° C. to about 48° C., about 30° C. to about 49° C., about30° C. to about 50° C., about 32° C. to about 44° C., about 32° C. toabout 45° C., about 32° C. to about 46° C., about 32° C. to about 47°C., about 32° C. to about 48° C., about 32° C. to about 49° C., about32° C. to about 50° C., about 34° C. to about 44° C., about 34° C. toabout 45° C., about 34° C. to about 46° C., about 34° C. to about 47°C., about 34° C. to about 48° C., about 34° C. to about 49° C., about34° C. to about 50° C., about 36° C. to about 44° C., about 36° C. toabout 45° C., about 36° C. to about 46° C., about 36° C. to about 47°C., about 36° C. to about 48° C., about 36° C. to about 49° C., about36° C. to about 50° C., about 38° C. to about 44° C., about 38° C. toabout 45° C., about 38° C. to about 46° C., about 38° C. to about 47°C., about 38° C. to about 48° C., about 38° C. to about 49° C., about38° C. to about 50° C., about 40° C. to about 44° C., about 40° C. toabout 45° C., about 40° C. to about 46° C., about 40° C. to about 47°C., about 40° C. to about 48° C., about 40° C. to about 49° C., about40° C. to about 50° C., about 42° C. to about 44° C., about 42° C. toabout 45° C., about 42° C. to about 46° C., about 42° C. to about 47°C., about 42° C. to about 48° C., about 42° C. to about 49° C., or about42° C. to about 50° C.

In other aspects of this embodiment, a mixture ofpharmaceutically-acceptable lipids includes a mixture PEG fatty acidesters having a melting point of, e.g., about 33° C., about 34° C.,about 35° C., about 36° C., about 37° C., about 38° C., about 39° C.,about 40° C., about 41° C., about 43° C., about 43° C., about 44° C.,about 45° C., about 45° C., about 47° C., about 48° C., about 49° C.,about 50° C. In aspects of this embodiment, a mixture ofpharmaceutically-acceptable lipids includes a mixture PEG fatty acidesters having a melting point of, e.g., about 30° C. to about 44° C.,about 30° C. to about 45° C., about 30° C. to about 46° C., about 30° C.to about 47° C., about 30° C. to about 48° C., about 30° C. to about 49°C., about 30° C. to about 50° C., about 32° C. to about 44° C., about32° C. to about 45° C., about 32° C. to about 46° C., about 32° C. toabout 47° C., about 32° C. to about 48° C., about 32° C. to about 49°C., about 32° C. to about 50° C., about 34° C. to about 44° C., about34° C. to about 45° C., about 34° C. to about 46° C., about 34° C. toabout 47° C., about 34° C. to about 48° C., about 34° C. to about 49°C., about 34° C. to about 50° C., about 36° C. to about 44° C., about36° C. to about 45° C., about 36° C. to about 46° C., about 36° C. toabout 47° C., about 36° C. to about 48° C., about 36° C. to about 49°C., about 36° C. to about 50° C., about 38° C. to about 44° C., about38° C. to about 45° C., about 38° C. to about 46° C., about 38° C. toabout 47° C., about 38° C. to about 48° C., about 38° C. to about 49°C., about 38° C. to about 50° C., about 40° C. to about 44° C., about40° C. to about 45° C., about 40° C. to about 46° C., about 40° C. toabout 47° C., about 40° C. to about 48° C., about 40° C. to about 49°C., about 40° C. to about 50° C., about 42° C. to about 44° C., about42° C. to about 45° C., about 42° C. to about 46° C., about 42° C. toabout 47° C., about 42° C. to about 48° C., about 42° C. to about 49°C., or about 42° C. to about 50° C.

In other aspects of this embodiment, a mixture ofpharmaceutically-acceptable lipids includes a mixture of mono-, di-,and/or triglycerides and PEG fatty acid esters having a melting pointof, e.g., about 33° C., about 34° C., about 35° C., about 36° C., about37° C., about 38° C., about 39° C., about 40° C., about 41° C., about43° C., about 43° C., about 44° C., about 45° C., about 45° C., about47° C., about 48° C., about 49° C., about 50° C. In aspects of thisembodiment, a mixture of pharmaceutically-acceptable lipids includes amixture of mono-, di-, and/or triglycerides and PEG fatty acid estershaving a melting point of, e.g., about 30° C. to about 44° C., about 30°C. to about 45° C., about 30° C. to about 46° C., about 30° C. to about47° C., about 30° C. to about 48° C., about 30° C. to about 49° C.,about 30° C. to about 50° C., about 32° C. to about 44° C., about 32° C.to about 45° C., about 32° C. to about 46° C., about 32° C. to about 47°C., about 32° C. to about 48° C., about 32° C. to about 49° C., about32° C. to about 50° C., about 34° C. to about 44° C., about 34° C. toabout 45° C., about 34° C. to about 46° C., about 34° C. to about 47°C., about 34° C. to about 48° C., about 34° C. to about 49° C., about34° C. to about 50° C., about 36° C. to about 44° C., about 36° C. toabout 45° C., about 36° C. to about 46° C., about 36° C. to about 47°C., about 36° C. to about 48° C., about 36° C. to about 49° C., about36° C. to about 50° C., about 38° C. to about 44° C., about 38° C. toabout 45° C., about 38° C. to about 46° C., about 38° C. to about 47°C., about 38° C. to about 48° C., about 38° C. to about 49° C., about38° C. to about 50° C., about 40° C. to about 44° C., about 40° C. toabout 45° C., about 40° C. to about 46° C., about 40° C. to about 47°C., about 40° C. to about 48° C., about 40° C. to about 49° C., about40° C. to about 50° C., about 42° C. to about 44° C., about 42° C. toabout 45° C., about 42° C. to about 46° C., about 42° C. to about 47°C., about 42° C. to about 48° C., about 42° C. to about 49° C., or about42° C. to about 50° C.

Commercially available mixtures of pharmaceutically-acceptable lipidsinclude, without limitation, mixtures of PEG-6 sterate and ethyleneglycol palmitostearate and PEG-32 stearate (TEFOSE® 1500; TEFOSE® 63),mixtures of triceteareth-4 phosphate and ethylene glycol palmitostearateand diethylene glycol palmitostearate (SEDEFOS® 75), mixtures ofglycerol monostearate and PEG-75 stearate (GELOT®), mixtures of cetylalcohol and ethoxylated fatty alcohols (seteth-2-, steareth-20)(EMULCIRE®), mixtures of saturated C₁₀-Cis triglycerides having amelting point around 33° C. (GELUCIRE® 33/01), mixtures of saturatedC₁₀-C₁₈ triglycerides having a melting point around 39° C. (GELUCIRE®39/01), mixtures of saturated C₁₀-C₁₈ triglycerides having a meltingpoint around 43° C. (GELUCIRE® 43/01), mixtures of glycerol monostearate40-55 (type I) and diglycerides (GELEOL® Mono and Diglycerides), andmixtures of medium-chain triglycerides (LABRAFAC® Lipophile WL 1349).

Aspects of the present specification disclose, in part, apharmaceutically-acceptable stabilizing agent. A stabilizing agentreduces or eliminates formation of esters of a therapeutic compound thatmay result as a unwanted reaction with the particular solvent used. Astabilizing agent include, without limitation, water, a sacrificial acidcomprising a fatty acid component and acetic acid, ethyl acetate, asodium acetate/acetic acid (E262), a monoglyceride, an acetylatedmonoglyceride, a diglyceride, an acetylated monoglyceride, an acetylateddiglyceride, a fatty acid, and a fatty acid salt.

In one embodiment, a pharmaceutically-acceptable stabilizing agent maycomprise a pharmaceutically-acceptable emulsifying agent. An emulsifyingagent (also known as an emulgent) is a substance that stabilizes anemulsion comprising a liquid dispersed phase and a liquid continuousphase by increasing its kinetic stability. Thus, in situations where thesolvent and adjuvant used to make a pharmaceutical composition disclosedherein are normally immiscible, an emulsifying agent disclosed herein isused to create a homogenous and stable emulsion. An emulsifying agentincludes, without limitation, a surfactant, a polysaccharide, a lectin,and a phospholipid.

In an aspect of this embodiment, an emulsifying agent may comprise asurfactant. As used hereon, the term “surfactant” refers to a natural orsynthetic amphiphilic compound. A surfactant can be non-ionic,zwitterionic, or ionic. Non-limiting examples of surfactants includepolysorbates like polysorbate 20 (TWEEN® 20), polysorbate 40 (TWEEN®40), polysorbate 60 (TWEEN® 60), polysorbate 61 (TWEEN® 61), polysorbate65 (TWEEN® 65), polysorbate 80 (TWEEN® 80), and polysorbate 81 (TWEEN®81); poloxamers (polyethylene-polypropylene copolymers), like Poloxamer124 (PLURONIC® L44), Poloxamer 181 (PLURONIC® L61), Poloxamer 182(PLURONIC® L62), Poloxamer 184 (PLURONIC® L64), Poloxamer 188 (PLURONIC®F68), Poloxamer 237 (PLURONIC® F87), Poloxamer 338 (PLURONIC® L108),Poloxamer 407 (PLURONIC® F127), polyoxyethyleneglycol dodecyl ethers,like BRIJ® 30, and BRIJ® 35; 2-dodecoxyethanol (LUBROL®-PX);polyoxyethylene octyl phenyl ether (TRITON® X-100); sodium dodecylsulfate (SDS); 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate(CHAPS);3-[(3-Cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate(CHAPSO); sucrose monolaurate; and sodium cholate. Other non-limitingexamples of surfactant excipients can be found in, e.g., Ansel, supra,(1999); Gennaro, supra, (2000); Hardman, supra, (2001); and Rowe, supra,(2003), each of which is hereby incorporated by reference in itsentirety.

In an aspect of this embodiment, an emulsifying agent may comprise apolysaccharide. Non-limiting examples of polysaccharides include guargum, agar, alginate, calgene, a dextran (like dextran 1K, dextran 4K,dextran 40K, dextran 60K, and dextran 70K), dextrin, glycogen, inulin,starch, a starch derivative (like hydroxymethyl starch, hydroxyethylstarch, hydroxypropyl starch, hydroxybutyl starch, and hydroxypentylstarch), hetastarch, cellulose, FICOLL, methyl cellulose (MC),carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC),hydroxypropyl cellulose (HPC), hydroxyethyl methyl cellulose (NEMC),hydroxypropyl methyl cellulose (HPMC); polyvinyl acetates (PVA);polyvinyl pyrrolidones (PVP), also known as povidones, having a K-valueof less than or equal to 18, a K-value greater than 18 or less than orequal to 95, or a K-value greater than 95, like PVP 12 (KOLLIDON® 12),PVP 17 (KOLLIDON® 17), PVP 25 (KOLLIDON® 25), PVP 30 (KOLLIDON® 30), PVP90 (KOLLIDON® 90); and polyethylene imines (PEI).

In an aspect of this embodiment, an emulsifying agent may comprise alectin. Lectins are sugar-binding proteins that are highly specific fortheir sugar moieties. Lectins may be classified according to the sugarmoiety that they bind to, and include, without limitation,mannose-binding lectins, galactose/N-acetylgalactosamine-bindinglectins, N-acetylgluxosamine-binding lectins, N-acetylneuramine-bindinglectins, N-acetylneuraminic acid-binding lectins, and fucose-bindinglectins. Non-limiting examples of surfactants include concanavain A,lentil lectin, snowdrop lectin, Roin, peanut agglutinin, jacain, hairyvetch lectin, wheat germ agglutinin, elderberry lectin, Maackiaanurensis leukoagglutinin, Maackia anurensis hemoagglutinin, Ulexeuropaeus agglutinin, and Aleuria aurantia lectin.

In an aspect of this embodiment, an emulsifying agent may comprise aphospholipid. The structure of the phospholipid generally comprises ahydrophobic tail and a hydrophilic head and is amphipathic in nature.Most phospholipids contain a diglyceride, a phosphate group, and asimple organic molecule such as choline; one exception to this rule issphingomyelin, which is derived from sphingosine instead of glycerol.Phospholipids include, without limitation, diacylglycerides andphosphosphingolipids. Non-limiting examples of diacylglycerides includea phosphatidic acid (phosphatidate) (PA), a phosphatidylethanolamine(cephalin) (PE), a phosphatidylcholine (lecithin) (PC), aphosphatidylserine (PS), and a phosphoinositide includingphosphatidylinositol (PI), phosphatidylinositol phosphate (PIP),phosphatidylinositol bisphosphate (PIP2), and phosphatidylinositoltriphosphate (PIP3). Non-limiting examples of phosphosphingolipidsinclude a ceramide phosphorylcholine (sphingomyelin) (SPH), ceramidephosphorylethanolamine (sphingomyelin) (Cer-PE), and ceramidephosphorylglycerol.

In one embodiment, a pharmaceutically-acceptable stabilizing agent doesnot comprise a pharmaceutically-acceptable emulsifying agent.

In another embodiment, a pharmaceutical composition does not comprise apharmaceutically-acceptable emulsifying agent.

The pharmaceutical compositions disclosed herein act as a deliverysystem that enable a therapeutic compound disclosed herein to be moreeffectively delivered or targeted to a cell type, tissue, organ, orregion of the body in a manner that more effectively inhibits a painresponse. This inhibition results in an improved treatment of a severepain. For example, a pharmaceutical composition disclosed herein mayfacilitate the delivery of a therapeutic compound disclosed herein intomacrophages. One possible mechanism that achieves this selectivebiodistribution is that the pharmaceutical compositions disclosed hereinmay be designed to take advantage of the activity of chylomicrons.Chylomicrons are relatively large lipoprotein particles having adiameter of 75 nm to 1,200 nm. Comprising triglycerides (85-92%),phospholipids (6-12%), cholesterol (1-3%) and apolipoproteins (1-2%),chylomicrons transport dietary lipids from the intestines to otherlocations in the body. Chylomicrons are one of the five major groups oflipoproteins, the others being VLDL, IDL, low-density lipoproteins(LDL), high-density lipoproteins (HDL), that enable fats and cholesterolto move within the water-based solution of the bloodstream.

During digestion, fatty acids and cholesterol undergo processing in thegastrointestinal tract by the action of pancreatic juices includinglipases and emulsification with bile salts to generate micelles. Thesemicelles allow the absorption of lipid as free fatty acids by theabsorptive cells of the small intestine, known as enterocytes. Once inthe enterocytes, triglycerides and cholesterol are assembled intonascent chylomicrons. Nascent chylomicrons are primarily composed oftriglycerides (85%) and contain some cholesterol and cholesteryl esters.The main apolipoprotein component is apolipoprotein B-48 (APOB48). Thesenascent chylomicrons are released by exocytosis from enterocytes intolacteals, lymphatic vessels originating in the villi of the smallintestine, and are then secreted into the bloodstream at the thoracicduct's connection with the left subclavian vein.

While circulating in lymph and blood, chylomicrons exchange componentswith HDL. The HDL donates apolipoprotein C-II (APOC2) and apolipoproteinE (APOE) to the nascent chylomicron and thus converts it to a maturechylomicron (often referred to simply as “chylomicron”). APOC2 is thecofactor for lipoprotein lipase (LPL) activity. Once triglyceride storesare distributed, the chylomicron returns APOC2 to the HDL (but keepsAPOE), and, thus, becomes a chylomicron remnant, now only 30-50 nm.APOB48 and APOE are important to identify the chylomicron remnant in theliver for endocytosis and breakdown into lipoproteins (VLDL, LDL andHDL). These lipoproteins are processed and stored by competent cells,including, e.g., hepatocytes, adipocytes and macrophages. Thus, withoutwishing to be limited by any theory, upon oral administration, apharmaceutical composition disclosed herein can be processed intomicelles while in the gastrointestinal tract, absorbed by enterocytesand assembled into nascent chylomicrons, remain associated withchylomicron remnants taken up by the liver, and ultimately loaded intomacrophages which are present in tissues experiencing pain.

As another example, a pharmaceutical composition disclosed herein mayfacilitate the delivery of a therapeutic compound disclosed herein intodentritic cells. One possible mechanism to achieve selectivebiodistribution of the pharmaceutical compositions disclosed herein maybe to take advantage of the endocytotic/phagocytotic activity ofdentritic cells. Dendritic cells are immune cells forming part of themammalian immune system. The main function of dendritic cells is toprocess antigen material and present it on the surface to other cells ofthe immune system. Thus, dendritic cells function as antigen-presentingcells that act as messengers between innate and adaptive immunity.Dendritic cells are present in tissues in contact with the externalenvironment, such as, e.g., the skin (where there is a specializeddendritic cell type called Langerhans cells) and the inner lining of thenose, lungs, stomach and intestines. These cells can also be found in animmature state in the blood. Once activated, they migrate to the lymphnodes where they interact with T cells and B cells to initiate and shapethe adaptive immune response. Dendritic cells are known to endocytoseand phagocytose lipid particles as part of their environmentalmonitoring and antigen presentation processes. Without wishing to belimited by any theory, upon topical or inhalatory administration, apharmaceutical composition disclosed herein can penetrate into the skinor inner lining of the nose, lungs, stomach and intestines, beendocytosed/phagocytosed by dentritic cells, and ultimately loaded intoT cells and/or B cells which are present in tissues experiencing pain.

Aspects of the present specification disclose, in part, a method ofpreparing a pharmaceutical composition disclosed herein. A methoddisclosed herein comprises the step of contacting apharmaceutically-acceptable adjuvant disclosed herein with a therapeuticcompound disclosed herein under conditions which allow the therapeuticcompound to dissolve in the pharmaceutically-acceptable adjuvant,thereby forming a pharmaceutical composition disclosed herein.

Aspects of the present specification disclose, in part, a method ofpreparing a pharmaceutical composition disclosed herein. A methoddisclosed herein comprises the steps of a) contacting apharmaceutically-acceptable solvent disclosed herein with a therapeuticcompound disclosed herein under conditions which allow the therapeuticcompound to dissolve in the pharmaceutically-acceptable solvent, therebyforming a solution; and b) contacting the solution formed in step (a)with a pharmaceutically-acceptable adjuvant disclosed herein underconditions which allow the formation of a pharmaceutical composition.The methods of preparing disclosed herein may further comprise a step(c) of removing the pharmaceutically-acceptable solvent from thepharmaceutical composition.

The amount of a therapeutic compound that is contacted with thepharmaceutically-acceptable solvent in step (a) of the method may be inany amount desired. Factors used to determine the amount of atherapeutic compound used include, without limitation, the final amountthe therapeutic compound desired in the pharmaceutical composition, thedesired concentration of a therapeutic compound in the solution, thehydrophobicity of the therapeutic compound, the lipophobicity of thetherapeutic compound, the temperature under which the contacting step(a) is performed, and the time under which the contacting step (a) isperformed, the particular formulation desired, and the particular routeof delivery of the pharmaceutical compound.

The volume of a pharmaceutically-acceptable solvent used in step (a) ofthe method may be any volume desired. Factors used to determine thevolume of a pharmaceutically-acceptable solvent used include, withoutlimitation, the final amount of a pharmaceutical composition desired,the desired concentration of a therapeutic compound in the solution, thehydrophobicity of the therapeutic compound, and the lipophobicity of thetherapeutic compound, the particular formulation desired, and theparticular route of delivery of the pharmaceutical compound.

In aspects of this embodiment, the amount of a therapeutic compound thatis contacted with the solvent in step (a) may be, e.g., at least 10 mg,at least 20 mg, at least 30 mg, at least 40 mg, at least 50 mg, at least60 mg, at least 70 mg, at least 80 mg, at least 90 mg, at least 100 mg,at least 200 mg, at least 300 mg, at least 400 mg, at least 500 mg, atleast 600 mg, at least 700 mg, at least 800 mg, at least 900 mg, atleast 1,000 mg, at least 1,100 mg, at least 1,200 mg, at least 1,300 mg,at least 1,400 mg, or at least 1,500 mg. In other aspects of thisembodiment, the amount of a therapeutic compound that is contacted withthe solvent in step (a) may be in the range of, e.g., about 10 mg toabout 100 mg, about 50 mg to about 150 mg, about 100 mg to about 250 mg,about 150 mg to about 350 mg, about 250 mg to about 500 mg, about 350 mgto about 600 mg, about 500 mg to about 750 mg, about 600 mg to about 900mg, about 750 mg to about 1,000 mg, about 850 mg to about 1,200 mg, orabout 1,000 mg to about 1,500 mg. In other aspects of this embodiment,the amount of a therapeutic compound that is dissolved in the solvent instep (a) may be in the range of, e.g., about 10 mg to about 250 mg,about 10 mg to about 500 mg, about 10 mg to about 750 mg, about 10 mg toabout 1,000 mg, about 10 mg to about 1,500 mg, about 50 mg to about 250mg, about 50 mg to about 500 mg, about 50 mg to about 750 mg, about 50mg to about 1,000 mg, about 50 mg to about 1,500 mg, about 100 mg toabout 250 mg, about 100 mg to about 500 mg, about 100 mg to about 750mg, about 100 mg to about 1,000 mg, about 100 mg to about 1,500 mg,about 200 mg to about 500 mg, about 200 mg to about 750 mg, about 200 mgto about 1,000 mg, or about 200 mg to about 1,500 mg.

Step (a) may be carried out at room temperature, in order to allow atherapeutic compound to dissolve fully in thepharmaceutically-acceptable solvent. However, in other embodiments ofthe method, Step (a) may be carried out at a temperature that is greaterthan room temperature. In aspects of this embodiment, Step (a) may becarried out at a temperature that is, e.g., greater than 21° C., greaterthan 25° C., greater than 30° C., greater than 35° C. or greater than37° C., greater than 40° C., greater than 42° C., greater than 45° C.,greater than 50° C., greater than 55° C., or greater than 60° C. Inaspects of this embodiment, Step (a) may be carried out at a temperaturethat is between, e.g., about 20° C. to about 30° C., about 25° C. toabout 35° C., about 30° C. to about 40° C., about 35° C. to about 45°C., about 40° C. to about 50° C., about 45° C. to about 55° C., or about50° C. to about 60° C. In certain cases, Step (a) may be carried out attemperatures below room temperature, in order to allow a therapeuticcompound to dissolve fully in solvent. However, in other embodiments ofthe method, step (a) may be carried out at a temperature that is lessthan room temperature, e.g., less than 10° C., greater than 5° C.,greater than 0° C., greater than −10° C. or greater than −20° C. Thecontacting in Step (a) may comprise mixing the therapeutic compound andthe pharmaceutically-acceptable solvent, e.g., by stirring, inversion,sonication, or vortexing. The mixing may be carried out for, e.g., atleast 1 second, at least 5 seconds, at least 10 seconds, at least 20seconds, at least 30 seconds, at least 45 seconds, at least 60 seconds,or more, until the therapeutic compound is fully dissolved in thesolvent.

After contacting, the concentration of a therapeutic compound disclosedherein in the solution may be in any concentration desired. In aspectsof this embodiment, the concentration of a therapeutic compounddisclosed herein in the solution may be, e.g., at least 0.00001 mg/mL,at least 0.0001 mg/mL, at least 0.001 mg/mL, at least 0.01 mg/mL, atleast 0.1 mg/mL, at least 1 mg/mL, at least 10 mg/mL, at least 25 mg/mL,at least 50 mg/mL, at least 100 mg/mL, at least 200 mg/mL, at least 500mg/mL, at least 700 mg/mL, at least 1,000 mg/mL, or at least 1,200mg/mL. In other aspects of this embodiment, the concentration of atherapeutic compound disclosed herein in the solution may be, e.g., atmost 1,000 mg/mL, at most 1,100 mg/mL, at most 1,200 mg/mL, at most1,300 mg/mL, at most 1,400 mg/mL, at most 1,500 mg/mL, at most 2,000mg/mL, at most 2,000 mg/mL, or at most 3,000 mg/mL. In other aspects ofthis embodiment, the concentration of a therapeutic compound disclosedherein in the solution may be in a range of, e.g., about 0.00001 mg/mLto about 3,000 mg/mL, about 0.0001 mg/mL to about 3,000 mg/mL, about0.01 mg/mL to about 3,000 mg/mL, about 0.1 mg/mL to about 3,000 mg/mL,about 1 mg/mL to about 3,000 mg/mL, about 250 mg/mL to about 3,000mg/mL, about 500 mg/mL to about 3,000 mg/mL, about 750 mg/mL to about3,000 mg/mL, about 1,000 mg/mL to about 3,000 mg/mL, about 100 mg/mL toabout 2,000 mg/mL, about 250 mg/mL to about 2,000 mg/mL, about 500 mg/mLto about 2,000 mg/mL, about 750 mg/mL to about 2,000 mg/mL, about 1,000mg/mL to about 2,000 mg/mL, about 100 mg/mL to about 1,500 mg/mL, about250 mg/mL to about 1,500 mg/mL, about 500 mg/mL to about 1,500 mg/mL,about 750 mg/mL to about 1,500 mg/mL, about 1,000 mg/mL to about 1,500mg/mL, about 100 mg/mL to about 1,200 mg/mL, about 250 mg/mL to about1,200 mg/mL, about 500 mg/mL to about 1,200 mg/mL, about 750 mg/mL toabout 1,200 mg/mL, about 1,000 mg/mL to about 1,200 mg/mL, about 100mg/mL to about 1,000 mg/mL, about 250 mg/mL to about 1,000 mg/mL, about500 mg/mL to about 1,000 mg/mL, about 750 mg/mL to about 1,000 mg/mL,about 100 mg/mL to about 750 mg/mL, about 250 mg/mL to about 750 mg/mL,about 500 mg/mL to about 750 mg/mL, about 100 mg/mL to about 500 mg/mL,about 250 mg/mL to about 500 mg/mL, about 0.00001 mg/mL to about 0.0001mg/mL, about 0.00001 mg/mL to about 0.001 mg/mL, about 0.00001 mg/mL toabout 0.01 mg/mL, about 0.00001 mg/mL to about 0.1 mg/mL, about 0.00001mg/mL to about 1 mg/mL, about 0.001 mg/mL to about 0.01 mg/mL, about0.001 mg/mL to about 0.1 mg/mL, about 0.001 mg/mL to about 1 mg/mL,about 0.001 mg/mL to about 10 mg/mL, or about 0.001 mg/mL to about 100mg/mL.

The volume of a pharmaceutically-acceptable adjuvant used in step (b) ofthe method may be any volume desired. Factors used to determine thevolume of a pharmaceutically-acceptable adjuvant used include, withoutlimitation, the final amount of a pharmaceutical composition desired,the desired concentration of a therapeutic compound in thepharmaceutical composition, the ratio of solvent:adjuvant used, and themiscibility of solvent and adjuvant, the particular formulation desired,and the particular route of delivery of the pharmaceutical compound.

In aspects of this embodiment, the ratio of solution:adjuvant may be,e.g., at least 5:1, at least 4:1, at least 3:1, at least 2:1, at least0:1, at least 1:1, at least 1:2, at least 1:3, at least 1:4, at least1:5, at least 1:6, at least 1:7, at least 1:8, at least 1:9, at least1:10, at least 1:15, at least 1:20, or at least 1:25. In other aspectsof this embodiment, the ratio of solution:adjuvant may be in a range of,e.g., about 5:1 to about 1:25, about 4:1 to about 1:25, about 3:1 toabout 1:25, about 2:1 to about 1:25, about 0:1 to about 1:25, about 1:1to about 1:25, about 1:2 to about 1:25, about 1:3 to about 1:25, about1:4 to about 1:25, about 1:5 to about 1:25, about 5:1 to about 1:20,about 4:1 to about 1:20, about 3:1 to about 1:20, about 2:1 to about1:20, about 0:1 to about 1:20, about 1:1 to about 1:20, about 1:2 toabout 1:20, about 1:3 to about 1:20, about 1:4 to about 1:20, about 1:5to about 1:20, about 5:1 to about 1:15, about 4:1 to about 1:15, about3:1 to about 1:15, about 0:1 to about 1:15, about 2:1 to about 1:15,about 1:1 to about 1:15, about 1:2 to about 1:15, about 1:3 to about1:15, about 1:4 to about 1:15, about 1:5 to about 1:15, about 5:1 toabout 1:12, about 4:1 to about 1:12, about 3:1 to about 1:12, about 2:1to about 1:12, about 0:1 to about 1:12, about 1:1 to about 1:12, about1:2 to about 1:12, about 1:3 to about 1:12, about 1:4 to about 1:12,about 1:5 to about 1:12, about 1:6 to about 1:12, about 1:7 to about1:12, about 1:8 to about 1:12, about 5:1 to about 1:10, about 4:1 toabout 1:10, about 3:1 to about 1:10, about 2:1 to about 1:10, about 0:1to about 1:10, about 1:1 to about 1:10, about 1:2 to about 1:10, about1:3 to about 1:10, about 1:4 to about 1:10, about 1:5 to about 1:10,about 1:6 to about 1:10, about 1:7 to about 1:10, or about 1:8 to about1:10.

Step (b) may be carried out at room temperature, in order to allow thesolution comprising the therapeutic compound to form the pharmaceuticalcomposition. However, in other embodiments of the method, Step (b) maybe carried out at a temperature that is greater than room temperature.In aspects of this embodiment, Step (b) may be carried out at atemperature that is, e.g., greater than 21° C., greater than 25° C.,greater than 30° C., greater than 35° C. or greater than 37° C., greaterthan 40° C., greater than 42° C., greater than 45° C., greater than 50°C., greater than 55° C., or greater than 60° C. In aspects of thisembodiment, Step (a) may be carried out at a temperature that isbetween, e.g., about 20° C. to about 30° C., about 25° C. to about 35°C., about 30° C. to about 40° C., about 35° C. to about 45° C., about40° C. to about 50° C., about 45° C. to about 55° C., or about 50° C. toabout 60° C. In certain cases, Step (b) may be carried out attemperatures below room temperature, in order to allow a therapeuticcompound to dissolve fully in a pharmaceutically-acceptable solvent.However, in other embodiments of the method, step (b) may be carried outat a temperature that is less than room temperature, e.g., less than 10°C., greater than 5° C., greater than 0° C., greater than −10° C. orgreater than −20° C. The contacting in Step (b) may comprise mixing thesolution and the pharmaceutically-acceptable adjuvant, e.g., bystirring, inversion, sonication, or vortexing. The mixing may be carriedout for, e.g., at least 1 second, at least 5 seconds, at least 10seconds, at least 20 seconds, at least 30 seconds, at least 45 seconds,at least 60 seconds, or more, until the pharmaceutical composition isformed.

In certain embodiments, a rapid cooling step may be used to reduce thetemperature of a pharmaceutical composition disclosed herein after itsformation. For example, a rapid cooling step may be used in procedureswere temperatures greater than room temperature are used to allow atherapeutic compound to dissolve fully in thepharmaceutically-acceptable solvent and/or to allow the solutioncomprising the therapeutic compound to form the pharmaceuticalcomposition. In aspects of this embodiment, a rapid cooling step resultsin a temperature decrease of, e.g., about 30° C. in 20 minutes, about25° C. in 20 minutes, about 20° C. in 20 minutes, about 15° C. in 20minutes, about 30° C. in 15 minutes, about 25° C. in 15 minutes, about20° C. in 15 minutes, about 15° C. in 15 minutes, about 30° C. in 10minutes, about 25° C. in 10 minutes, about 20° C. in 10 minutes, about15° C. in 10 minutes, about 30° C. in 5 minutes, about 25° C. in 5minutes, about 20° C. in 5 minutes, about 15° C. in 5 minutes. In otheraspects of this embodiment, a rapid cooling step results in atemperature decrease of, e.g., about 20° C. to about 30° C. in 20minutes, about 20° C. to about 30° C. in 15 minutes, about 20° C. toabout 30° C. in 10 minutes, about 20° C. to about 30° C. in 5 minutes,about 15° C. to about 25° C. in 20 minutes, about 15° C. to about 25° C.in 15 minutes, about 15° C. to about 25° C. in 10 minutes, about 15° C.to about 25° C. in 5 minutes, about 10° C. to about 20° C. in 20minutes, about 10° C. to about 20° C. in 15 minutes, about 10° C. toabout 20° C. in 10 minutes, or about 10° C. to about 20° C. in 5minutes.

In yet aspects of this embodiment, a rapid cooling step results in atemperature decrease of, e.g., about 2.0° C./minute, about 1.9°C./minute, about 1.8° C./minute, about 1.7° C./minute, about 1.6°C./minute, about 1.5° C./minute, about 1.4° C./minute, about 1.3°C./minute, about 1.2° C./minute, about 1.1° C./minute, about 1.0°C./minute, about 0.9° C./minute, about 0.8° C./minute, about 0.7°C./minute, about 0.6° C./minute, about 0.5° C./minute, about 0.4°C./minute, about 0.3° C./minute, about 0.2° C./minute, or about 0.1°C./minute. In still aspects of this embodiment, a rapid cooling stepresults in a temperature decrease of, e.g., about 0.1° C. to about 0.4°C./minute, about 0.2° C. to about 0.6° C./minute, about 0.4° C. to about0.8° C./minute, about 0.6° C. to about 1.0° C./minute, about 0.8° C. toabout 1.2° C./minute, about 1.0° C. to about 1.4° C./minute, about 1.2°C. to about 1.6° C./minute, about 1.4° C. to about 1.8° C./minute, about1.6° C. to about 2.0° C./minute, about 0.1° C. to about 0.5° C./minute,about 0.5° C. to about 1.0° C./minute, about 1.0° C. to about 1.5°C./minute, about 1.5° C. to about 2.0° C./minute, about 0.5° C. to about1.5° C./minute, or about 1.0° C. to about 2.0° C./minute.

In some embodiments, temperatures greater than room temperature employedin either Step (a) or Step (b) or both may be used to remove the solventfrom a pharmaceutical composition. In other embodiment, removal ofsolvent from a pharmaceutical composition requires a separate Step (c).In Step (c), the solvent removal from a pharmaceutical composition maybe accomplished using one of a variety of procedures known in the art,including, without limitation, evaporation, dialyzation, distillation,lypholization, and filtration. These removal procedures may be doneunder conditions of ambient atmosphere, under low pressure, or under avacuum and either at ambient temperature or at temperatures requiringheating.

In one embodiment, Step (c) may result in the complete removal of apharmaceutically-acceptable solvent from the pharmaceutical compositiondisclosed herein. In aspects of this embodiment, Step (c) may result in,e.g., at least 5%, at least 10%, at least 15%, at least 20%, at least25%, at least 30%, at least 35%, at least 40%, at least 45%, at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 93%, at least95%, at least 97%, or at least 99% removal of apharmaceutically-acceptable solvent from the pharmaceutical compositiondisclosed herein.

Step (c) is conducted at a temperature that allows for the evaporationof a pharmaceutically-acceptable solvent disclosed herein, and as such,an evaporation temperature is solvent dependant. Factors which influencean evaporation temperature of a solvent disclosed herein include,without limitation, the particular solvent used, the amount of solventpresent, the particular therapeutic compound present, the particularadjuvant present, the stability of the therapeutic compound present, thereactivity of the therapeutic compound present, the particularatmospheric pressure used, the time desired for complete evaporation.Generally, a pharmaceutical composition will require heating if theevaporation step is conducted at ambient pressure, e.g., 1 atm. However,under high vacuum conditions, the evaporation step may be conducted attemperatures below ambient temperature, e.g., less than 22° C.

In one embodiment, removal of solvent from the pharmaceuticalcomposition disclosed herein may be carried out at ambient atmosphericpressure and at a temperature above ambient temperature. In aspects ofthis embodiment, removal of solvent from the pharmaceutical compositiondisclosed herein may be carried out at ambient atmospheric pressure andat a temperature of, e.g., more than 25° C., more than 30° C., more than35° C., more than 40° C., more than 45° C., more than 50° C., more than55° C., more than 60° C., more than 65° C., more than 70° C., more than80° C., or more than 25° C. In other aspects of this embodiment, removalof solvent from the pharmaceutical composition disclosed herein may becarried out at ambient atmospheric pressure and at a temperature in arange of, e.g., about 25° C. to about 100° C., about 25° C. to about 95°C., about 25° C. to about 90° C., about 25° C. to about 85° C., about25° C. to about 80° C., about 25° C. to about 75° C., about 25° C. toabout 70° C., about 25° C. to about 65° C., or about 25° C. to about 60°C.

In another embodiment, removal of solvent from the pharmaceuticalcomposition disclosed herein may be carried out under vacuum and at atemperature below ambient temperature. In aspects of this embodiment,removal of solvent from the pharmaceutical composition disclosed hereinmay be carried out under vacuum and at a temperature of, e.g., less than20° C., less than 18° C., less than 16° C., less than 14° C., less than12° C., less than 10° C., less than 8° C., less than 6° C., less than 4°C., less than 2° C., or less than 0° C. In other aspects of thisembodiment, removal of solvent from the pharmaceutical compositiondisclosed herein may be carried out under vacuum and at a temperature ina range of, e.g., about −20° C. to about 20° C., about −20° C. to about18° C., about −20° C. to about 16° C., about −20° C. to about 14° C.,about −20° C. to about 12° C., about −20° C. to about 10° C., about −20°C. to about 8° C., about −20° C. to about 6° C., about −20° C. to about4° C., about −20° C. to about 2° C., about −20° C. to about 0° C., about−15° C. to about 20° C., about −10° C. to about 20° C., about −5° C. toabout 20° C., about 0° C. to about 20° C., about −10° C. to about 20°C., about −10° C. to about 18° C., about −10° C. to about 16° C., about−10° C. to about 14° C., about −10° C. to about 12° C., about −10° C. toabout 10° C., about −10° C. to about 8° C., about −10° C. to about 6°C., about −10° C. to about 4° C., about −10° C. to about 2° C., or about−10° C. to about 0° C.

The final concentration of a therapeutic compound disclosed herein in apharmaceutical composition disclosed herein may be of any concentrationdesired. In an aspect of this embodiment, the final concentration of atherapeutic compound in a pharmaceutical composition may be atherapeutically effective amount. In other aspects of this embodiment,the final concentration of a therapeutic compound in a pharmaceuticalcomposition may be, e.g., at least 0.00001 mg/mL, at least 0.0001 mg/mL,at least 0.001 mg/mL, at least 0.01 mg/mL, at least 0.1 mg/mL, at least1 mg/mL, at least 10 mg/mL, at least 25 mg/mL, at least 50 mg/mL, atleast 100 mg/mL, at least 200 mg/mL, at least 500 mg/mL, at least 700mg/mL, at least 1,000 mg/mL, or at least 1,200 mg/mL. In other aspectsof this embodiment, the concentration of a therapeutic compounddisclosed herein in the solution may be, e.g., at most 1,000 mg/mL, atmost 1,100 mg/mL, at most 1,200 mg/mL, at most 1,300 mg/mL, at most1,400 mg/mL, at most 1,500 mg/mL, at most 2,000 mg/mL, at most 2,000mg/mL, or at most 3,000 mg/mL. In other aspects of this embodiment, thefinal concentration of a therapeutic compound in a pharmaceuticalcomposition may be in a range of, e.g., about 0.00001 mg/mL to about3,000 mg/mL, about 0.0001 mg/mL to about 3,000 mg/mL, about 0.01 mg/mLto about 3,000 mg/mL, about 0.1 mg/mL to about 3,000 mg/mL, about 1mg/mL to about 3,000 mg/mL, about 250 mg/mL to about 3,000 mg/mL, about500 mg/mL to about 3,000 mg/mL, about 750 mg/mL to about 3,000 mg/mL,about 1,000 mg/mL to about 3,000 mg/mL, about 100 mg/mL to about 2,000mg/mL, about 250 mg/mL to about 2,000 mg/mL, about 500 mg/mL to about2,000 mg/mL, about 750 mg/mL to about 2,000 mg/mL, about 1,000 mg/mL toabout 2,000 mg/mL, about 100 mg/mL to about 1,500 mg/mL, about 250 mg/mLto about 1,500 mg/mL, about 500 mg/mL to about 1,500 mg/mL, about 750mg/mL to about 1,500 mg/mL, about 1,000 mg/mL to about 1,500 mg/mL,about 100 mg/mL to about 1,200 mg/mL, about 250 mg/mL to about 1,200mg/mL, about 500 mg/mL to about 1,200 mg/mL, about 750 mg/mL to about1,200 mg/mL, about 1,000 mg/mL to about 1,200 mg/mL, about 100 mg/mL toabout 1,000 mg/mL, about 250 mg/mL to about 1,000 mg/mL, about 500 mg/mLto about 1,000 mg/mL, about 750 mg/mL to about 1,000 mg/mL, about 100mg/mL to about 750 mg/mL, about 250 mg/mL to about 750 mg/mL, about 500mg/mL to about 750 mg/mL, about 100 mg/mL to about 500 mg/mL, about 250mg/mL to about 500 mg/mL, about 0.00001 mg/mL to about 0.0001 mg/mL,about 0.00001 mg/mL to about 0.001 mg/mL, about 0.00001 mg/mL to about0.01 mg/mL, about 0.00001 mg/mL to about 0.1 mg/mL, about 0.00001 mg/mLto about 1 mg/mL, about 0.001 mg/mL to about 0.01 mg/mL, about 0.001mg/mL to about 0.1 mg/mL, about 0.001 mg/mL to about 1 mg/mL, about0.001 mg/mL to about 10 mg/mL, or about 0.001 mg/mL to about 100 mg/mL.

A pharmaceutical composition produced using the methods disclosed hereinmay be formulated for either local or systemic delivery using topical,enteral or parenteral routes of administration. Additionally, atherapeutic compound disclosed herein may be formulated by itself in apharmaceutical composition, or may be formulated together with one ormore other therapeutic compounds disclosed herein in a singlepharmaceutical composition.

A pharmaceutical composition produced using the methods disclosed hereinmay be a liquid formulation, semi-solid formulation, or a solidformulation. A formulation disclosed herein can be produced in a mannerto form one phase, such as, e.g., an oil or a solid. Alternatively, aformulation disclosed herein can be produced in a manner to form twophase, such as, e.g., an emulsion. A pharmaceutical compositiondisclosed herein intended for such administration may be preparedaccording to any method known to the art for the manufacture ofpharmaceutical compositions. Semi-solid formulations suitable fortopical administration include, without limitation, ointments, creams,salves, and gels.

A liquid formulation can be formed by using various lipids like oils ofother fatty acids that remain as liquids in the temperature rangedesired. In an embodiment, a pharmaceutical composition disclosed hereinis liquid at room temperature. In aspects of this embodiment, apharmaceutical composition disclosed herein may be formulated to be aliquid at a temperature of, e.g., about 25° C. or higher, about 23° C.or higher, about 21° C. or higher, about 19° C. or higher, about 17° C.or higher, about 15° C. or higher, about 12° C. or higher, about 10° C.or higher, about 8° C. or higher, about 6° C. or higher, about 4° C. orhigher, or about 0° C. or higher.

In liquid and semi-solid formulations, a concentration of a therapeuticcompound disclosed herein typically may be between about 50 mg/mL toabout 1,000 mg/mL. In aspects of this embodiment, a therapeuticallyeffective amount of a therapeutic compound disclosed herein may be from,e.g., about 50 mg/mL to about 100 mg/mL, about 50 mg/mL to about 200mg/mL, about 50 mg/mL to about 300 mg/mL, about 50 mg/mL to about 400mg/mL, about 50 mg/mL to about 500 mg/mL, about 50 mg/mL to about 600mg/mL, about 50 mg/mL to about 700 mg/mL, about 50 mg/mL to about 800mg/mL, about 50 mg/mL to about 900 mg/mL, about 50 mg/mL to about 1,000mg/mL, about 100 mg/mL to about 200 mg/mL, about 100 mg/mL to about 300mg/mL, about 100 mg/mL to about 400 mg/mL, about 100 mg/mL to about 500mg/mL, about 100 mg/mL to about 600 mg/mL, about 100 mg/mL to about 700mg/mL, about 100 mg/mL to about 800 mg/mL, about 100 mg/mL to about 900mg/mL, about 100 mg/mL to about 1,000 mg/mL, about 200 mg/mL to about300 mg/mL, about 200 mg/mL to about 400 mg/mL, about 200 mg/mL to about500 mg/mL, about 200 mg/mL to about 600 mg/mL, about 200 mg/mL to about700 mg/mL, about 200 mg/mL to about 800 mg/mL, about 200 mg/mL to about900 mg/mL, about 200 mg/mL to about 1,000 mg/mL, about 300 mg/mL toabout 400 mg/mL, about 300 mg/mL to about 500 mg/mL, about 300 mg/mL toabout 600 mg/mL, about 300 mg/mL to about 700 mg/mL, about 300 mg/mL toabout 800 mg/mL, about 300 mg/mL to about 900 mg/mL, about 300 mg/mL toabout 1,000 mg/mL, about 400 mg/mL to about 500 mg/mL, about 400 mg/mLto about 600 mg/mL, about 400 mg/mL to about 700 mg/mL, about 400 mg/mLto about 800 mg/mL, about 400 mg/mL to about 900 mg/mL, about 400 mg/mLto about 1,000 mg/mL, about 500 mg/mL to about 600 mg/mL, about 500mg/mL to about 700 mg/mL, about 500 mg/mL to about 800 mg/mL, about 500mg/mL to about 900 mg/mL, about 500 mg/mL to about 1,000 mg/mL, about600 mg/mL to about 700 mg/mL, about 600 mg/mL to about 800 mg/mL, about600 mg/mL to about 900 mg/mL, or about 600 mg/mL to about 1,000 mg/mL.

In semi-solid and solid formulations, an amount of a therapeuticcompound disclosed herein typically may be between about 0.01% to about45% by weight. In aspects of this embodiment, an amount of a therapeuticcompound disclosed herein may be from, e.g., about 0.1% to about 45% byweight, about 0.1% to about 40% by weight, about 0.1% to about 35% byweight, about 0.1% to about 30% by weight, about 0.1% to about 25% byweight, about 0.1% to about 20% by weight, about 0.1% to about 15% byweight, about 0.1% to about 10% by weight, about 0.1% to about 5% byweight, about 1% to about 45% by weight, about 1% to about 40% byweight, about 1% to about 35% by weight, about 1% to about 30% byweight, about 1% to about 25% by weight, about 1% to about 20% byweight, about 1% to about 15% by weight, about 1% to about 10% byweight, about 1% to about 5% by weight, about 5% to about 45% by weight,about 5% to about 40% by weight, about 5% to about 35% by weight, about5% to about 30% by weight, about 5% to about 25% by weight, about 5% toabout 20% by weight, about 5% to about 15% by weight, about 5% to about10% by weight, about 10% to about 45% by weight, about 10% to about 40%by weight, about 10% to about 35% by weight, about 10% to about 30% byweight, about 10% to about 25% by weight, about 10% to about 20% byweight, about 10% to about 15% by weight, about 15% to about 45% byweight, about 15% to about 40% by weight, about 15% to about 35% byweight, about 15% to about 30% by weight, about 15% to about 25% byweight, about 15% to about 20% by weight, about 20% to about 45% byweight, about 20% to about 40% by weight, about 20% to about 35% byweight, about 20% to about 30% by weight, about 20% to about 25% byweight, about 25% to about 45% by weight, about 25% to about 40% byweight, about 25% to about 35% by weight, or about 25% to about 30% byweight.

In one embodiment, a liquid formulation comprises a therapeuticcompound, a glycol ether, a partially-hydrogenated fat, an oil, and analcohol. In an aspect of this embodiment, a liquid formulation comprisesabout 15% to about 35% by weight of therapeutic compound, about 5% toabout 25% by weight of glycol ether, about 15% to about 40% by weight ofpartially-hydrogenated fat, about 15% to about 40% of an oil, and about1% to about 15% of an alcohol. In another aspect of this embodiment, aliquid formulation comprises about 20% to about 30% by weight oftherapeutic compound, about 10% to about 20% by weight of glycol ether,about 20% to about 35% by weight of partially-hydrogenated fat, about20% to about 35% of an oil, and about 2% to about 10% of an alcohol. Inyet another aspect of this embodiment, a liquid formulation comprisesabout 23% to about 27% by weight of therapeutic compound, about 13% toabout 17% by weight of glycol ether, about 25% to about 30% by weight ofpartially-hydrogenated fat, about 25% to about 30% of an oil, and about4% to about 8% of an alcohol. In still another aspect of thisembodiment, a liquid formulation comprises about 24% to about 26% byweight of therapeutic compound, about 14% to about 16% by weight ofglycol ether, about 26% to about 28% by weight of partially-hydrogenatedfat, about 26% to about 28% of an oil, and about 5% to about 7% of analcohol. In other aspects of this embodiment, an oil is rapeseed oil ortheobroma oil.

In another embodiment, a liquid formulation comprises a therapeuticcompound, a glycol ether, a glyceryl monolinoleate, an oil, and analcohol. In an aspect of this embodiment, a liquid formulation comprisesabout 15% to about 35% by weight of therapeutic compound, about 5% toabout 25% by weight of glycol ether, about 15% to about 40% by weight ofglyceryl monolinoleate, about 15% to about 40% of an oil, and about 1%to about 15% of an alcohol. In another aspect of this embodiment, aliquid formulation comprises about 20% to about 30% by weight oftherapeutic compound, about 10% to about 20% by weight of glycol ether,about 20% to about 35% by weight of glyceryl monolinoleate, about 20% toabout 35% of an oil, and about 2% to about 10% of an alcohol. In yetanother aspect of this embodiment, a liquid formulation comprises about23% to about 27% by weight of therapeutic compound, about 13% to about17% by weight of glycol ether, about 25% to about 30% by weight ofglyceryl monolinoleate, about 25% to about 30% of an oil, and about 4%to about 8% of an alcohol. In still another aspect of this embodiment, aliquid formulation comprises about 24% to about 26% by weight oftherapeutic compound, about 14% to about 16% by weight of glycol ether,about 26% to about 28% by weight of glyceryl monolinoleate, about 26% toabout 28% of an oil, and about 5% to about 7% of an alcohol. In otheraspects of this embodiment, an oil is rapeseed oil or theobroma oil.

In another embodiment, a liquid formulation comprises an ibuprofen, adiethylene glycol monoethyl ether, a glyceryl monolinoleate, an oil, andan alcohol. In an aspect of this embodiment, a liquid formulationcomprises about 15% to about 35% by weight of an ibuprofen, about 5% toabout 25% by weight of diethylene glycol monoethyl ether, about 15% toabout 40% by weight of glyceryl monolinoleate, about 15% to about 40% ofan oil, and about 1% to about 15% of an alcohol. In another aspect ofthis embodiment, a liquid formulation comprises about 20% to about 30%by weight of an ibuprofen, about 10% to about 20% by weight ofdiethylene glycol monoethyl ether, about 20% to about 35% by weight ofglyceryl monolinoleate, about 20% to about 35% of an oil, and about 2%to about 10% of an alcohol. In yet another aspect of this embodiment, aliquid formulation comprises about 23% to about 27% by weight of anibuprofen, about 13% to about 17% by weight of diethylene glycolmonoethyl ether, about 25% to about 30% by weight of glycerylmonolinoleate, about 25% to about 30% of an oil, and about 4% to about8% of an alcohol. In still another aspect of this embodiment, a liquidformulation comprises about 24% to about 26% by weight of an ibuprofen,about 14% to about 16% by weight of diethylene glycol monoethyl ether,about 26% to about 28% by weight of glyceryl monolinoleate, about 26% toabout 28% of an oil, and about 5% to about 7% of an alcohol. In otheraspects of this embodiment, an ibuprofen may be a free acid of a salt ofibuprofen. In other aspects of this embodiment, an oil is rapeseed oilor theobroma oil.

In one embodiment, a liquid formulation comprises a therapeuticcompound, an ester of an alcohol, and an oil. In an aspect of thisembodiment, a liquid formulation comprises about 1% to about 10% byweight of therapeutic compound, about 1% to about 10% by weight of anester of an alcohol, and about 80% to about 98% of an oil. In anotheraspect of this embodiment, a liquid formulation comprises about 2% toabout 8% by weight of therapeutic compound, about 1% to about 7% byweight of an ester of an alcohol, and about 85% to about 97% of an oil.In yet another aspect of this embodiment, a liquid formulation comprisesabout 3% to about 7% by weight of therapeutic compound, about 2% toabout 6% by weight of an ester of an alcohol, and about 87% to about 95%of an oil. In still another aspect of this embodiment, a liquidformulation comprises about 4% to about 6% by weight of therapeuticcompound, about 3% to about 5% by weight of an ester of an alcohol, andabout 90% to about 92% of an oil. In other aspects of this embodiment,an oil is rapeseed oil or theobroma oil.

In another embodiment, a liquid formulation comprises a therapeuticcompound, an ethyl acetate, and an oil. In an aspect of this embodiment,a liquid formulation comprises about 1% to about 10% by weight oftherapeutic compound, about 1% to about 10% by weight of an ethylacetate, and about 80% to about 98% of an oil. In another aspect of thisembodiment, a liquid formulation comprises about 2% to about 8% byweight of therapeutic compound, about 1% to about 7% by weight of anethyl acetate, and about 85% to about 97% of an oil. In yet anotheraspect of this embodiment, a liquid formulation comprises about 3% toabout 7% by weight of therapeutic compound, about 2% to about 6% byweight of an ethyl acetate, and about 87% to about 95% of an oil. Instill another aspect of this embodiment, a liquid formulation comprisesabout 4% to about 6% by weight of therapeutic compound, about 3% toabout 5% by weight of an ethyl acetate, and about 90% to about 92% of anoil. In other aspects of this embodiment, an oil is rapeseed oil ortheobroma oil.

In another embodiment, a liquid formulation comprises an ibuprofen, anethyl acetate, and an oil. In an aspect of this embodiment, a liquidformulation comprises about 1% to about 10% by weight of an ibuprofen,about 1% to about 10% by weight of an ethyl acetate, and about 80% toabout 98% of an oil. In another aspect of this embodiment, a liquidformulation comprises about 2% to about 8% by weight of an ibuprofen,about 1% to about 7% by weight of an ethyl acetate, and about 85% toabout 97% of an oil. In yet another aspect of this embodiment, a liquidformulation comprises about 3% to about 7% by weight of an ibuprofen,about 2% to about 6% by weight of an ethyl acetate, and about 87% toabout 95% of an oil. In still another aspect of this embodiment, aliquid formulation comprises about 4% to about 6% by weight of anibuprofen, about 3% to about 5% by weight of an ethyl acetate, and about90% to about 92% of an oil. In other aspects of this embodiment, anibuprofen may be a free acid of a salt of ibuprofen. In other aspects ofthis embodiment, an oil is rapeseed oil or theobroma oil.

In one embodiment, a solid or semi-solid formulation disclosed herein isformulated without a hydrophilic solvent like water. Such formulationsresult in the formation of co-crystals of the lipids and therapeuticcompound. Stated another way, such formulations do not form liposomalemulsions and/or micellular particles, which require hydrophilicsolvent.

In one embodiment, a solid formulation comprises a therapeutic compound,a hard fat, a partially-hydrogenated fat, and a polyethylene glycol. Inan aspect of this embodiment, a solid formulation comprises about 1% toabout 30% by weight of therapeutic compound, about 8% to about 70% byweight of hard fat, about 2% to about 65% by weight ofpartially-hydrogenated fat, and about 1% to about 15% of polyethyleneglycol. In another aspect of this embodiment, a solid formulationcomprises about 10% to about 30% by weight of therapeutic compound,about 20% to about 50% by weight of hard fat, about 10% to about 30% byweight of partially-hydrogenated fat, and about 5% to about 15% ofpolyethylene glycol. In yet another aspect of this embodiment, a solidformulation comprises about 20% to about 30% by weight of therapeuticcompound, about 30% to about 50% by weight of hard fat, about 10% toabout 30% by weight of partially-hydrogenated fat, and about 7% to about13% of polyethylene glycol. In still another aspect of this embodiment,a solid formulation comprises about 20% to about 30% by weight oftherapeutic compound, about 35% to about 50% by weight of hard fat,about 15% to about 25% by weight of partially-hydrogenated fat, andabout 7% to about 13% of polyethylene glycol. In a further aspect ofthis embodiment, a solid formulation comprises about 23% to about 27% byweight of therapeutic compound, about 41% to about 47% by weight of hardfat, about 18% to about 22% by weight of partially-hydrogenated fat, andabout 9% to about 11% of polyethylene glycol. In other aspects of thisembodiment, a polyethylene glycol is, e.g., a PEG 100, a PEG 200, a PEG300, a PEG 400, a PEG 500, a PEG 600, or a PEG 700.

In another embodiment, a solid formulation comprises a therapeuticcompound, a mixture of mono-, di-, and triglycerides and PEG fatty acidesters, a glyceryl monolinoleate, and a polyethylene glycol. In anaspect of this embodiment, a solid formulation comprises about 1% toabout 30% by weight of therapeutic compound, about 8% to about 70% byweight of a mixture of mono-, di-, and triglycerides and PEG fatty acidesters, about 2% to about 65% by weight of a glyceryl monolinoleate, andabout 1% to about 15% of polyethylene glycol. In another aspect of thisembodiment, a solid formulation comprises about 10% to about 30% byweight of therapeutic compound, about 20% to about 50% by weight of amixture of mono-, di-, and triglycerides and PEG fatty acid esters,about 10% to about 30% by weight of a glyceryl monolinoleate, and about5% to about 15% of polyethylene glycol. In yet another aspect of thisembodiment, a solid formulation comprises about 20% to about 30% byweight of therapeutic compound, about 30% to about 50% by weight of amixture of mono-, di-, and triglycerides and PEG fatty acid esters,about 10% to about 30% by weight of a glyceryl monolinoleate, and about7% to about 13% of polyethylene glycol. In still another aspect of thisembodiment, a solid formulation comprises about 20% to about 30% byweight of therapeutic compound, about 35% to about 50% by weight of amixture of mono-, di-, and triglycerides and PEG fatty acid esters,about 15% to about 25% by weight of a glyceryl monolinoleate, and about7% to about 13% of polyethylene glycol. In a further aspect of thisembodiment, a solid formulation comprises about 23% to about 27% byweight of therapeutic compound, about 41% to about 47% by weight of amixture of mono-, di-, and triglycerides and PEG fatty acid esters,about 18% to about 22% by weight of a glyceryl monolinoleate, and about9% to about 11% of polyethylene glycol. In other aspects of thisembodiment, a polyethylene glycol is, e.g., a PEG 100, a PEG 200, a PEG300, a PEG 400, a PEG 500, a PEG 600, or a PEG 700.

In another embodiment, a solid formulation comprises an ibuprofen, amixture of mono-, di-, and triglycerides and PEG fatty acid esters, aglyceryl monolinoleate, and a polyethylene glycol. In an aspect of thisembodiment, a solid formulation comprises about 1% to about 30% byweight of an ibuprofen, about 8% to about 70% by weight of a mixture ofmono-, di-, and triglycerides and PEG fatty acid esters, about 2% toabout 65% by weight of a glyceryl monolinoleate, and about 1% to about15% of polyethylene glycol. In another aspect of this embodiment, asolid formulation comprises about 10% to about 30% by weight of anibuprofen, about 20% to about 50% by weight of a mixture of mono-, di-,and triglycerides and PEG fatty acid esters, about 10% to about 30% byweight of a glyceryl monolinoleate, and about 5% to about 15% ofpolyethylene glycol. In yet another aspect of this embodiment, a solidformulation comprises about 20% to about 30% by weight of an ibuprofen,about 30% to about 50% by weight of a mixture of mono-, di-, andtriglycerides and PEG fatty acid esters, about 10% to about 30% byweight of a glyceryl monolinoleate, and about 7% to about 13% ofpolyethylene glycol. In still another aspect of this embodiment, a solidformulation comprises about 20% to about 30% by weight of an ibuprofen,about 35% to about 50% by weight of a mixture of mono-, di-, andtriglycerides and PEG fatty acid esters, about 15% to about 25% byweight of a glyceryl monolinoleate, and about 7% to about 13% ofpolyethylene glycol. In a further aspect of this embodiment, a solidformulation comprises about 23% to about 27% by weight of an ibuprofen,about 41% to about 47% by weight of a mixture of mono-, di-, andtriglycerides and PEG fatty acid esters, about 18% to about 22% byweight of a glyceryl monolinoleate, and about 9% to about 11% ofpolyethylene glycol. In other aspects of this embodiment, a polyethyleneglycol is, e.g., a PEG 100, a PEG 200, a PEG 300, a PEG 400, a PEG 500,a PEG 600, or a PEG 700.

In another embodiment, a solid formulation comprises a therapeuticcompound, a hard fat, a partially-hydrogenated fat, a polyethyleneglycol, and a propylene glycol. In an aspect of this embodiment, a solidformulation comprises about 1% to about 30% by weight of therapeuticcompound, about 8% to about 70% by weight of hard fat, about 2% to about65% by weight of partially-hydrogenated fat, about 1% to about 15% ofpolyethylene glycol, and about 1% to about 15% of propylene glycol. Inanother aspect of this embodiment, a solid formulation comprises about10% to about 30% by weight of therapeutic compound, about 20% to about50% by weight of hard fat, about 10% to about 30% by weight ofpartially-hydrogenated fat, about 5% to about 15% of polyethyleneglycol, and about 5% to about 15% of propylene glycol. In yet anotheraspect of this embodiment, a solid formulation comprises about 20% toabout 30% by weight of therapeutic compound, about 30% to about 50% byweight of hard fat, about 10% to about 30% by weight ofpartially-hydrogenated fat, about 7% to about 13% of polyethyleneglycol, and about 7% to about 13% of propylene glycol. In still anotheraspect of this embodiment, a solid formulation comprises about 20% toabout 30% by weight of therapeutic compound, about 35% to about 50% byweight of hard fat, about 15% to about 25% by weight ofpartially-hydrogenated fat, about 7% to about 13% of polyethyleneglycol, and about 7% to about 13% of propylene glycol. In a furtheraspect of this embodiment, a solid formulation comprises about 23% toabout 27% by weight of therapeutic compound, about 41% to about 47% byweight of hard fat, about 18% to about 22% by weight ofpartially-hydrogenated fat, about 9% to about 11% of polyethyleneglycol, and about 9% to about 11% of propylene glycol. In other aspectsof this embodiment, a polyethylene glycol is, e.g., a PEG 100, a PEG200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, or a PEG 700.

In another embodiment, a solid formulation comprises a therapeuticcompound, a mixture of mono-, di-, and triglycerides and PEG fatty acidesters, a glyceryl monolinoleate, a polyethylene glycol, and a propyleneglycol. In an aspect of this embodiment, a solid formulation comprisesabout 1% to about 30% by weight of therapeutic compound, about 8% toabout 70% by weight of a mixture of mono-, di-, and triglycerides andPEG fatty acid esters, about 2% to about 65% by weight of a glycerylmonolinoleate, about 1% to about 15% of polyethylene glycol, and about1% to about 15% of propylene glycol. In another aspect of thisembodiment, a solid formulation comprises about 10% to about 30% byweight of therapeutic compound, about 20% to about 50% by weight of amixture of mono-, di-, and triglycerides and PEG fatty acid esters,about 10% to about 30% by weight of a glyceryl monolinoleate, about 5%to about 15% of polyethylene glycol, and about 5% to about 15% ofpropylene glycol. In yet another aspect of this embodiment, a solidformulation comprises about 20% to about 30% by weight of therapeuticcompound, about 30% to about 50% by weight of a mixture of mono-, di-,and triglycerides and PEG fatty acid esters, about 10% to about 30% byweight of a glyceryl monolinoleate, and about 7% to about 13% ofpolyethylene glycol, and about 7% to about 13% of propylene glycol. Instill another aspect of this embodiment, a solid formulation comprisesabout 20% to about 30% by weight of therapeutic compound, about 35% toabout 50% by weight of a mixture of mono-, di-, and triglycerides andPEG fatty acid esters, about 15% to about 25% by weight of a glycerylmonolinoleate, about 7% to about 13% of polyethylene glycol, and about7% to about 13% of propylene glycol. In a further aspect of thisembodiment, a solid formulation comprises about 23% to about 27% byweight of therapeutic compound, about 41% to about 47% by weight of amixture of mono-, di-, and triglycerides and PEG fatty acid esters,about 18% to about 22% by weight of a glyceryl monolinoleate, about 9%to about 11% of polyethylene glycol, and about 9% to about 11% ofpropylene glycol. In other aspects of this embodiment, a polyethyleneglycol is, e.g., a PEG 100, a PEG 200, a PEG 300, a PEG 400, a PEG 500,a PEG 600, or a PEG 700.

In another embodiment, a solid formulation comprises an ibuprofen, amixture of mono-, di-, and triglycerides and PEG fatty acid esters, aglyceryl monolinoleate, a polyethylene glycol, and a propylene glycol.In an aspect of this embodiment, a solid formulation comprises about 1%to about 30% by weight of an ibuprofen, about 8% to about 70% by weightof a mixture of mono-, di-, and triglycerides and PEG fatty acid esters,about 2% to about 65% by weight of a glyceryl monolinoleate, about 1% toabout 15% of polyethylene glycol, and about 1% to about 15% of propyleneglycol. In another aspect of this embodiment, a solid formulationcomprises about 10% to about 30% by weight of an ibuprofen, about 20% toabout 50% by weight of a mixture of mono-, di-, and triglycerides andPEG fatty acid esters, about 10% to about 30% by weight of a glycerylmonolinoleate, about 5% to about 15% of polyethylene glycol, and about5% to about 15% of propylene glycol. In yet another aspect of thisembodiment, a solid formulation comprises about 20% to about 30% byweight of an ibuprofen, about 30% to about 50% by weight of a mixture ofmono-, di-, and triglycerides and PEG fatty acid esters, about 10% toabout 30% by weight of a glyceryl monolinoleate, and about 7% to about13% of polyethylene glycol, and about 7% to about 13% of propyleneglycol. In still another aspect of this embodiment, a solid formulationcomprises about 20% to about 30% by weight of an ibuprofen, about 35% toabout 50% by weight of a mixture of mono-, di-, and triglycerides andPEG fatty acid esters, about 15% to about 25% by weight of a glycerylmonolinoleate, about 7% to about 13% of polyethylene glycol, and about7% to about 13% of propylene glycol. In a further aspect of thisembodiment, a solid formulation comprises about 23% to about 27% byweight of an ibuprofen, about 41% to about 47% by weight of a mixture ofmono-, di-, and triglycerides and PEG fatty acid esters, about 18% toabout 22% by weight of a glyceryl monolinoleate, about 9% to about 11%of polyethylene glycol, and about 9% to about 11% of propylene glycol.In other aspects of this embodiment, a polyethylene glycol is, e.g., aPEG 100, a PEG 200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, or a PEG700.

In another embodiment, a semi-solid formulation comprises a therapeuticcompound, a hard fat, a partially-hydrogenated fat, a polyethyleneglycol, and a propylene glycol. In an aspect of this embodiment, asemi-solid formulation comprises about 15% to about 55% by weight oftherapeutic compound, about 7% to about 20% by weight of hard fat, about20% to about 50% by weight of partially-hydrogenated fat, about 7% toabout 20% of polyethylene glycol, and about 1% to about 8% of propyleneglycol. In another aspect of this embodiment, a semi-solid formulationcomprises about 20% to about 50% by weight of therapeutic compound,about 8% to about 18% by weight of hard fat, about 25% to about 45% byweight of partially-hydrogenated fat, about 8% to about 18% ofpolyethylene glycol, and about 2% to about 6% of propylene glycol. Inanother aspect of this embodiment, a semi-solid formulation comprisesabout 20% to about 50% by weight of therapeutic compound, about 10% toabout 16% by weight of hard fat, about 25% to about 45% by weight ofpartially-hydrogenated fat, about 10% to about 16% of polyethyleneglycol, and about 2% to about 6% of propylene glycol. In yet anotheraspect of this embodiment, a semi-solid formulation comprises about 20%to about 50% by weight of therapeutic compound, about 11% to about 15%by weight of hard fat, about 30% to about 40% by weight ofpartially-hydrogenated fat, about 11% to about 15% of polyethyleneglycol, and about 3% to about 5% of propylene glycol. In still anotheraspect of this embodiment, a semi-solid formulation comprises about 25%to about 44% by weight of therapeutic compound, about 12% to about 14%by weight of hard fat, about 32% to about 39% by weight ofpartially-hydrogenated fat, about 12% to about 14% of polyethyleneglycol, and about 4% of propylene glycol. In other aspects of thisembodiment, a polyethylene glycol is, e.g., a PEG 100, a PEG 200, a PEG300, a PEG 400, a PEG 500, a PEG 600, or a PEG 700.

In another embodiment, a semi-solid formulation comprises a therapeuticcompound, a mixture of mono-, di-, and triglycerides and PEG fatty acidesters, a glyceryl monolinoleate, a polyethylene glycol, and a propyleneglycol. In an aspect of this embodiment, a semi-solid formulationcomprises about 15% to about 55% by weight of therapeutic compound,about 7% to about 20% by weight of a mixture of mono-, di-, andtriglycerides and PEG fatty acid esters, about 20% to about 50% byweight of a glyceryl monolinoleate, about 7% to about 20% ofpolyethylene glycol, and about 1% to about 8% of propylene glycol. Inanother aspect of this embodiment, a semi-solid formulation comprisesabout 20% to about 50% by weight of therapeutic compound, about 8% toabout 18% by weight of a mixture of mono-, di-, and triglycerides andPEG fatty acid esters, about 25% to about 45% by weight of a glycerylmonolinoleate, about 8% to about 18% of polyethylene glycol, and about2% to about 6% of propylene glycol. In another aspect of thisembodiment, a semi-solid formulation comprises about 20% to about 50% byweight of therapeutic compound, about 10% to about 16% by weight of amixture of mono-, di-, and triglycerides and PEG fatty acid esters,about 25% to about 45% by weight of a glyceryl monolinoleate, about 10%to about 16% of polyethylene glycol, and about 2% to about 6% ofpropylene glycol. In yet another aspect of this embodiment, a semi-solidformulation comprises about 20% to about 50% by weight of therapeuticcompound, about 11% to about 15% by weight of a mixture of mono-, di-,and triglycerides and PEG fatty acid esters, about 30% to about 40% byweight of a glyceryl monolinoleate, and about 11% to about 15% ofpolyethylene glycol, and about 3% to about 5% of propylene glycol. Instill another aspect of this embodiment, a semi-solid formulationcomprises about 25% to about 44% by weight of therapeutic compound,about 12% to about 14% by weight of a mixture of mono-, di-, andtriglycerides and PEG fatty acid esters, about 32% to about 39% byweight of a glyceryl monolinoleate, about 12% to about 14% ofpolyethylene glycol, and about 4% of propylene glycol. In other aspectsof this embodiment, a polyethylene glycol is, e.g., a PEG 100, a PEG200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, or a PEG 700.

In another embodiment, a semi-solid formulation comprises an ibuprofen,a mixture of mono-, di-, and triglycerides and PEG fatty acid esters, aglyceryl monolinoleate, a polyethylene glycol, and a propylene glycol.In an aspect of this embodiment, a semi-solid formulation comprisesabout 15% to about 55% by weight of an ibuprofen, about 7% to about 20%by weight of a mixture of mono-, di-, and triglycerides and PEG fattyacid esters, about 20% to about 50% by weight of a glycerylmonolinoleate, about 7% to about 20% of polyethylene glycol, and about1% to about 8% of propylene glycol. In another aspect of thisembodiment, a semi-solid formulation comprises about 20% to about 50% byweight of an ibuprofen, about 8% to about 18% by weight of a mixture ofmono-, di-, and triglycerides and PEG fatty acid esters, about 25% toabout 45% by weight of a glyceryl monolinoleate, about 8% to about 18%of polyethylene glycol, and about 2% to about 6% of propylene glycol. Inanother aspect of this embodiment, a semi-solid formulation comprisesabout 20% to about 50% by weight of an ibuprofen, about 10% to about 16%by weight of a mixture of mono-, di-, and triglycerides and PEG fattyacid esters, about 25% to about 45% by weight of a glycerylmonolinoleate, about 10% to about 16% of polyethylene glycol, and about2% to about 6% of propylene glycol. In yet another aspect of thisembodiment, a semi-solid formulation comprises about 20% to about 50% byweight of an ibuprofen, about 11% to about 15% by weight of a mixture ofmono-, di-, and triglycerides and PEG fatty acid esters, about 30% toabout 40% by weight of a glyceryl monolinoleate, and about 11% to about15% of polyethylene glycol, and about 3% to about 5% of propyleneglycol. In still another aspect of this embodiment, a semi-solidformulation comprises about 25% to about 44% by weight of an ibuprofen,about 12% to about 14% by weight of a mixture of mono-, di-, andtriglycerides and PEG fatty acid esters, about 32% to about 39% byweight of a glyceryl monolinoleate, about 12% to about 14% ofpolyethylene glycol, and about 4% of propylene glycol. In other aspectsof this embodiment, a polyethylene glycol is, e.g., a PEG 100, a PEG200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, or a PEG 700.

In another embodiment, a semi-solid formulation comprises a therapeuticcompound, a hard fat, a partially-hydrogenated fat, a polyethyleneglycol, and a propylene glycol. In an aspect of this embodiment, asemi-solid formulation comprises about 10% to about 35% by weight of afree acid of a therapeutic compound, about 1% to about 30% by weight ofa salt of a therapeutic compound, about 7% to about 20% by weight ofhard fat, about 20% to about 50% by weight of partially-hydrogenatedfat, about 7% to about 20% of polyethylene glycol, and about 1% to about8% of propylene glycol. In another aspect of this embodiment, asemi-solid formulation comprises about 15% to about 30% by weight of afree acid of a therapeutic compound, about 1% to about 25% by weight ofa salt of a therapeutic compound, about 10% to about 16% by weight ofhard fat, about 25% to about 45% by weight of partially-hydrogenatedfat, about 10% to about 16% of polyethylene glycol, and about 2% toabout 6% of propylene glycol. In yet another aspect of this embodiment,a semi-solid formulation comprises about 15% to about 30% by weight of afree acid of a therapeutic compound, about 1% to about 25% by weight ofa salt of a therapeutic compound, about 11% to about 15% by weight ofhard fat, about 30% to about 40% by weight of partially-hydrogenatedfat, about 11% to about 15% of polyethylene glycol, and about 3% toabout 5% of propylene glycol. In still another aspect of thisembodiment, a semi-solid formulation comprises about 20% to about 24% byweight of a free acid of a therapeutic compound, about 5% to about 20%by weight of a salt of a therapeutic compound, about 12% to about 14% byweight of hard fat, about 32% to about 39% by weight ofpartially-hydrogenated fat, about 12% to about 14% of polyethyleneglycol, and about 4% of propylene glycol. In other aspects of thisembodiment, a polyethylene glycol is, e.g., a PEG 100, a PEG 200, a PEG300, a PEG 400, a PEG 500, a PEG 600, or a PEG 700.

In another embodiment, a semi-solid formulation comprises a therapeuticcompound, a mixture of mono-, di-, and triglycerides and PEG fatty acidesters, a glyceryl monolinoleate, a polyethylene glycol, and a propyleneglycol. In an aspect of this embodiment, a semi-solid formulationcomprises about 10% to about 35% by weight of a free acid of atherapeutic compound, about 1% to about 30% by weight of a salt of atherapeutic compound, about 7% to about 20% by weight of a mixture ofmono-, di-, and triglycerides and PEG fatty acid esters, about 20% toabout 50% by weight of a glyceryl monolinoleate, about 7% to about 20%of polyethylene glycol, and about 1% to about 8% of propylene glycol. Inanother aspect of this embodiment, a semi-solid formulation comprisesabout 15% to about 30% by weight of a free acid of a therapeuticcompound, about 1% to about 25% by weight of a salt of a therapeuticcompound, about 10% to about 16% by weight of a mixture of mono-, di-,and triglycerides and PEG fatty acid esters, about 25% to about 45% byweight of a glyceryl monolinoleate, about 10% to about 16% ofpolyethylene glycol, and about 2% to about 6% of propylene glycol. Inyet another aspect of this embodiment, a semi-solid formulationcomprises about 15% to about 30% by weight of a free acid of atherapeutic compound, about 1% to about 25% by weight of a salt of atherapeutic compound, about 11% to about 15% by weight of a mixture ofmono-, di-, and triglycerides and PEG fatty acid esters, about 30% toabout 40% by weight of a glyceryl monolinoleate, and about 11% to about15% of polyethylene glycol, and about 3% to about 5% of propyleneglycol. In still another aspect of this embodiment, a semi-solidformulation comprises about 20% to about 24% by weight of a free acid ofa therapeutic compound, about 5% to about 20% by weight of a salt of atherapeutic compound, about 12% to about 14% by weight of a mixture ofmono-, di-, and triglycerides and PEG fatty acid esters, about 32% toabout 39% by weight of a glyceryl monolinoleate, about 12% to about 14%of polyethylene glycol, and about 4% of propylene glycol. In otheraspects of this embodiment, a polyethylene glycol is, e.g., a PEG 100, aPEG 200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, or a PEG 700.

In another embodiment, a semi-solid formulation comprises an ibuprofen,a mixture of mono-, di-, and triglycerides and PEG fatty acid esters, aglyceryl monolinoleate, a polyethylene glycol, and a propylene glycol.In an aspect of this embodiment, a semi-solid formulation comprisesabout 10% to about 35% by weight of a free acid of an ibuprofen, about1% to about 30% by weight of a salt of an ibuprofen, about 7% to about20% by weight of a mixture of mono-, di-, and triglycerides and PEGfatty acid esters, about 20% to about 50% by weight of a glycerylmonolinoleate, about 7% to about 20% of polyethylene glycol, and about1% to about 8% of propylene glycol. In another aspect of thisembodiment, a semi-solid formulation comprises about 15% to about 30% byweight of a free acid of an ibuprofen, about 1% to about 25% by weightof a salt of an ibuprofen, about 10% to about 16% by weight of a mixtureof mono-, di-, and triglycerides and PEG fatty acid esters, about 25% toabout 45% by weight of a glyceryl monolinoleate, about 10% to about 16%of polyethylene glycol, and about 2% to about 6% of propylene glycol. Inyet another aspect of this embodiment, a semi-solid formulationcomprises about 15% to about 30% by weight of a free acid of anibuprofen, about 1% to about 25% by weight of a salt of an ibuprofen,about 11% to about 15% by weight of a mixture of mono-, di-, andtriglycerides and PEG fatty acid esters, about 30% to about 40% byweight of a glyceryl monolinoleate, and about 11% to about 15% ofpolyethylene glycol, and about 3% to about 5% of propylene glycol. Instill another aspect of this embodiment, a semi-solid formulationcomprises about 20% to about 24% by weight of a free acid of anibuprofen, about 5% to about 20% by weight of a salt of an ibuprofen,about 12% to about 14% by weight of a mixture of mono-, di-, andtriglycerides and PEG fatty acid esters, about 32% to about 39% byweight of a glyceryl monolinoleate, about 12% to about 14% ofpolyethylene glycol, and about 4% of propylene glycol. In other aspectsof this embodiment, a polyethylene glycol is, e.g., a PEG 100, a PEG200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, or a PEG 700.

A solid or semi-solid formulation disclosed herein takes advantage ofthe different melting point temperatures of the various adjuvants likefatty acids. Formation of a solid or semi-solid dosage form can be bymodifying the respective concentrations of the fatty acids comprising apharmaceutical composition disclosed herein. For example, linolenic acidhas a melting point temperature (T_(m)) of about −11° C., linoleic acidhas a T_(m) of about −5° C., oleic acid has a T_(m) of about 16° C.,palmitic acid has a T_(m) of about 61-62° C., and Stearic acid has aT_(m) of about 67-72° C. Increasing the proportion(s) of palmitic,stearic or oleic acid would increase the overall melting temperature ofa composition, while, conversely, increasing the proportion(s) oflinoleic and linolenic acid would decrease the melting temperature of acomposition. Thus, by controlling the types and amounts of the adjuvantcomponents added, a pharmaceutical composition disclosed herein can bemade that is substantially solid or semi-solid at room temperature, butmelts when it is ingested, and reaches body temperature. The resultingmelted composition readily forms micelles which are absorbed by theintestine, assembled into chylomicrons, and ultimately absorbed bymacrophages. The solid dosage form may be a powder, granule, tablet,capsule or suppository.

In an embodiment, a pharmaceutical composition disclosed herein is solidat room temperature. In aspects of this embodiment, a pharmaceuticalcomposition disclosed herein may be formulated to be a solid at atemperature of, e.g., about 35° C. or lower, about 33° C. or lower,about 31° C. or lower, about 29° C. or lower, about 27° C. or lower,about 25° C. or lower, about 23° C. or lower, about 21° C. or lower,about 19° C. or lower, about 17° C. or lower, about 15° C. or lower,about 12° C. or lower, about 10° C. or lower, about 8° C. or lower,about 6° C. or lower, about 4° C. or lower, or about 0° C. or lower.

In other aspects of this embodiment, a pharmaceutical compositiondisclosed has a melting point temperature of, e.g., 5° C. or higher, 10°C. or higher, 15° C. or higher, 22° C. or higher, 23° C. or higher, 24°C. or higher, 25° C. or higher, 26° C. or higher, 27° C. or higher, 28°C. or higher, 29° C. or higher, 30° C. or higher, 31° C. or higher, 32°C. or higher, 33° C. or higher, 34° C. or higher, or 35° C. or higher.In other aspects of this embodiment, a pharmaceutical compositiondisclosed has a melting point temperature in the range of, e.g., about5° C. to about 24° C., about 10° C. to about 24° C. about 22° C. toabout 24° C., about 23° C. to about 25° C., about 24° C. to about 26°C., about 25° C. to about 27° C., about 26° C. to about 28° C., about27° C. to about 29° C., about 28° C. to about 30° C., about 29° C. toabout 31° C., about 30° C. to about 32° C., about 31° C. to about 33°C., about 32° C. to about 34° C., or about 33° C. to about 35° C. Inother aspects of this embodiment, a pharmaceutical composition disclosedhas a melting point temperature in the range of, e.g., about 22° C. toabout 26° C., about 24° C. to about 28° C., about 26° C. to about 30°C., about 28° C. to about 32° C., or about 30° C. to about 34° C.

Aspects of the present specification disclose, in part, a method oftreating an individual with a severe pain condition. In one embodiment,the method comprises the step of administering to an individual in needthereof a pharmaceutical composition disclosed herein, whereinadministration reduces a symptom associated with the severe pain,thereby treating the individual.

Aspects of the present specification disclose, in part, treating anindividual suffering from a severe pain condition. As used herein, theterm “treating,” refers to reducing or eliminating in an individual aclinical symptom of a severe pain condition; or delaying or preventingin an individual the onset of a clinical symptom of a severe paincondition. For example, the term “treating” can mean reducing a symptomof a condition characterized by a severe pain condition by, e.g., atleast 20%, at least 25%, at least 30%, at least 35%, at least 40%, atleast 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90% atleast 95%, or at least 100%. The actual symptoms associated with asevere pain condition are well known and can be determined by a personof ordinary skill in the art by taking into account factors, including,without limitation, the location of the severe pain condition, the causeof the severe pain condition, the severity of the severe pain condition,and/or the tissue or organ affected by the severe pain condition. Thoseof skill in the art will know the appropriate symptoms or indicatorsassociated with a specific type of severe pain condition and will knowhow to determine if an individual is a candidate for treatment asdisclosed herein.

Pain may be measured using one or more pain thresholds. Pain thresholdsare measured by gradually increasing the intensity of a stimulus such aselectric current or heat applied to the body. The pain perceptionthreshold is the point at which the stimulus begins to hurt, and thepain tolerance threshold is reached when the individual acts to stop thepain.

Pain may be measured using one or more pain scale questionnaires.Although a self-reported questionnaire by an individual suffering from asevere pain condition tend to be the most reliable measure of pain,reports from health care professionals may also be used. A number ofpain measurement scales have been developed including, withoutlimitation, Alder Hey Triage Pain Score, Behavioral Pain Scale (BPS),Brief Pain Inventory (BPI), Checklist of Nonverbal Pain Indicators(CNPI), Critical-Care Pain Observation Tool (CPOT), COMFORT scale,Dallas Pain Questionnaire, Descriptor differential scale (DDS),Disease-Specific Pain Scale (DSPI), Dolorimeter Pain Index (DPI), FacesPain Scale-Revised (FPS-R), Face Legs Activity Cry Consolability scale,Lequesne algofunctional index, Original index, McGill Pain Questionnaire(MPQ), Multidimensional Pain Inventory (MPI), Neck Pain and DisabilityScale-NPAD, Numerical 11 point box (BS-11), Numeric Rating Scale(NRS-11), Pediatric Pain Questionnaire (PPQ), Roland-Morris Back PainQuestionnaire, Visual analog scale (VAS), and Wong-Baker FACES PainRating Scale. As one example, a NRS-11 scale is an 11-point scale forpatient self-reporting that ranks the pain being experienced on a scaleof 0 to 10, with 0 being no pain at all, 1-3 being mild pain thatinterferes little with activities of daily life, 4-6 being moderate painthat interferes significantly with activities of daily life, and 7-10being severe pain that completely interferes with activities of dailylife. Quality can be established by having the individual complete theMcGill Pain Questionnaire indicating which words best describe theirpain.

Severe pain condition symptoms include, without limitation, a coldness,a numbness, an itching, a paresthesias, an electric shock sensation, aburning sensation, an ice-burn sensation, dysesthesia, allodynia,hyperalgesia, hyperpathia, a somatic pain sensation, and a visceral painsensation. The actual symptoms associated with a severe pain conditionare well known and can be determined by a person of ordinary skill inthe art by taking into account factors, including, without limitation,the location of the severe pain, the cause of the severe pain, theseverity of the severe pain, the tissue or organ affected, and theassociated disorder.

A pharmaceutical composition disclosed herein are useful to treat severepain. Pain is any unpleasant sensory and/or emotional experienceassociated with actual or potential tissue damage, or described in termsof such damage. Pain may occur in varying degrees of severity and isusually a consequence of an injury, a disease, or an emotional disorder,although the underlying cause may or may not be apparent to a healthcareprovider. A severe pain is one where the severity of the pain responsesignificantly interferes or prevents an individual from performing oneor more activities of daily life. An activity of daily life (ADL) is anactivity an individual normally does such as feeding, bathing, dressing,grooming, work, homemaking, and leisure. ADLs may be categorized basedon whether the activity is a basic, an instrumental, or an occupationalone. Basic ADLs (BADLs) comprise self-care tasks, including, e.g.,personal hygiene and grooming, dressing and undressing, self feeding,functional transfers (getting into and out of bed or wheelchair, gettingonto or off toilet, etc.), bowel and bladder management, and ambulation(walking with or without use of an assistive device (walker, cane, orcrutches) or using a wheelchair). Instrumental ADLs (IADLs) are notnecessary for fundamental functioning, but let an individual liveindependently in a community. IADLs include, e.g., performing housework,taking medications as prescribed, managing money, shopping for groceriesor clothing, using communication devices, using technology, usingtransportation within the community. Occupational ADLs (OADLs) aregenerally optional in nature and may be delegated to others. OADLsinclude, e.g., caring of others (including selecting and supervisingcaregivers), caring of pets, child rearing, using of communicationdevices, community mobility, financial management, health management andmaintenance, meal preparation and cleanup, and safety procedures andemergency responses.

As used herein, the term “severe pain” comprises any acute, subacute,chronic nociceptive, pathological pain, or psychological pain. Inaspects of this embodiment, a severe pain is not an inflammatory pain ora pain whose primary origin is due to an inflammatory response.

A severe pain condition may be classified according to duration andpattern of occurrence, such as, e.g., acute pain, subacute pain, andchronic pain. Acute pain is an organic pain state that is typicallytransitory and of sudden onset, lasting only until the noxious stimulusis removed and/or the underlying damage or pathology has healed. Chronicpain is an organic pain state that is persistent and extends beyond theexpected period of healing and may be present continuously orintermediately. Subacute pain is an organic pain state that refers to apain that is somewhere in between acute pain and chronic pain. Althoughsomewhat arbitrary, the distinction between acute, subacute, and chronicpain may be defined based on the interval of time from onset. Thus, anacute pain is one that lasts less then one month, a subacute pain is onethat lasts from one to six months, and a chronic pain is one that lastssix months or more.

A severe pain condition may also be classified as 1) a nociceptive pain;2) a pathological pain; and 3) an inflammatory pain.

In one embodiment, a severe pain condition comprises a nociceptive pain.Nociceptive pain is a severe pain condition where an organic pain stateis caused by a noxious insult or injury of peripheral nerve fibers thatrespond only to stimuli approaching or exceeding harmful intensity(nociceptors), and is commonly described as an aching pain. This type ofpain is associated with damage to non-neural tissue, such as skin,muscles, visceral organs, joints, tendons, or bones, and is representedby a normally functioning somatosensory nervous system. Nociceptive painmay be classified according to the mode of noxious stimulation, such as,e.g., thermal pain, mechanical pain, and chemical pain, or according tothe location of the pain, such as, e.g., somatic pain or visceral pain.

In one embodiment, a severe pain condition comprises a somatic pain.Somatic pain is a nociceptive pain that originates from ligaments,tendons, bones, blood vessels, and even nerves themselves. It isdetected with somatic nociceptors. The scarcity of pain receptors inthese areas produces a dull, poorly-localized pain of longer durationthan cutaneous pain. Non-limiting examples of somatic pain include 1)excessive muscle tension can be caused, for example, by a sprain or astrain; 2) repetitive motion disorders can result from overuse of thehands, wrists, elbows, shoulders, neck, back, hips, knees, feet, legs,or ankles; 3) muscle disorders causing somatic pain include, forexample, a polymyositis, a dermatomyositis, a lupus, a fibromyalgia, apolymyalgia rheumatica, and a rhabdomyolysis; 4) myalgia including,e.g., muscle pain caused by overuse, over-stretching, viral infection,metabolic myopathy, a nutritional deficiency, or chronic fatiguesyndrome; 5) infections including, e.g., an abscess, a trichinosis, aninfluenza, a Lyme disease, a malaria, a Rocky Mountain spotted fever,Avian influenza, the common cold, community-acquired pneumonia,meningitis, monkeypox, Severe Acute Respiratory Syndrome, toxic shocksyndrome, trichinosis, typhoid fever, and upper respiratory tractinfection; and 6) drugs including, e.g., cocaine, a statin for loweringcholesterol (such as atorvastatin, simvastatin, and lovastatin), and anACE inhibitor for lowering blood pressure (such as enalapril andcaptopril). Somatic pain may be classified as a superficial somatic painor a deep somatic pain. Superficial somatic pain is initiated byactivation of nociceptors in the skin or other superficial tissue, andis sharp, well-defined and clearly located. Examples of injuries thatproduce superficial somatic pain include minor wounds and minor (firstdegree) burns. Deep somatic pain is initiated by stimulation ofnociceptors in ligaments, tendons, bones, blood vessels, fasciae andmuscles, and is dull, aching, poorly localized pain. Examples includesprains and broken bones.

In one embodiment, a severe pain condition comprises a visceral pain.Visceral pain is a nociceptive pain that is initiated by stimulation ofnociceptors in the body's organs and internal cavities typically causedby stretching or ischemia. Visceral pain is a diffuse, poorly localizedpain and may be described as aching pain, sickening pain, dull pain,squeezing pain, and/or deep pain, and it may be accompanied by nauseaand vomiting. Visceral pain is extremely difficult to localize, andseveral injuries to visceral tissue may exhibit “referred” pain, wherethe sensation is localized to an area completely unrelated to the siteof injury. The even greater scarcity of nociceptors in these areasproduces pain that is usually more aching and of a longer duration thansomatic pain. Non-limiting examples of somatic pain include 1)functional visceral pain including, e.g., an irritable bowel syndromeand a chronic functional abdominal pain (CFAP), a functionalconstipation and a functional dyspepsia, a non-cardiac chest pain (NCCP)and a chronic abdominal pain; 2) chronic gastrointestinal inflammationincluding, e.g., a gastritis, an inflammatory bowel disease, like, e.g.,a Crohn's disease, an ulcerative colitis, a microscopic colitis, adiverticulitis and a gastroenteritis; an interstitial cystitis; anintestinal ischemia; a cholecystitis; an appendicitis; agastroesophageal reflux; an ulcer, a nephrolithiasis, an urinary tractinfection, a pancreatitis and a hernia; 3) autoimmune pain including,e.g., a sarcoidosis and a vasculitis; 4) organic visceral painincluding, e.g., pain resulting from a traumatic, inflammatory ordegenerative lesion of the gut or produced by a tumor impinging onsensory innervation; and 5) treatment-induced visceral pain including,e.g., a pain attendant to chemotherapy therapy or a pain attendant toradiation therapy.

In one embodiment, a severe pain condition comprises a pathologicalpain. Damage A pathological pain is a severe pain condition where anorganic pain state caused by disease or damage to any part of thenervous system or by caused by an abnormal functioning of the nervoussystem. This type of pain is associated with damage to neural tissue andan abnormally functioning somatosensory nervous system, rather thanstimulation of pain receptors. Non-limiting examples of a pathologicalpain include neuropathic pain and dysfunctional pain.

In one embodiment, a severe pain condition comprises a neuropathic pain.Damage Neuropathic pain is a pathological pain where an organic painstate is caused by damage or disease of the somatosensory nervoussystem, resulting in abnormal sensory firing from the peripheral nervoussystem, central nervous systems, or both. Neuropathic pain may involvespontaneous or evoked pain, and may have continuous and/or episodic(paroxysmal) components. Neuropathic pain may be associated withdysesthesia (abnormal pain responses), such as, e.g., allodynia (apainful response to a stimulus that normally is not painful),hyperalgesia (an accentuated response to a painful stimulus that usuallycauses only a mild discomfort), and hyperpathia (where a shortdiscomfort becomes a prolonged severe pain). Painful sensations can bedescribed as a coldness, numbness, itching, paresthesias (tingling or“pins and needles” sensation), an electric shock, and a burning orice-burn pain. Non-limiting examples of a neuropathic pain includecentral neuropathic pain, peripheral neuropathic pain, anddeafferentation pain.

In one embodiment, a severe pain condition comprises a centralneuropathic pain. Damage or disease affecting nerves of the centralnervous system is referred to as a central neuropathic pain. Typically,the damage or disease occurs as cerebral lesions, predominantly thalamicbut may involve suprathalamic and infrathalamic regions. Generally, theonset of central neuropathic pain is usually delayed after theoccurrence of the initial episode that results in damage to the centralnervous system; onset of pain may occur during the phase of recoveryfrom neurologic deficits. Central neuropathic pain may be present inpost-stroke conditions including, e.g., thalamic infarction, brainsteminfarction, or subarachnoid hemorrhage, cerebral venous thrombosis,cerebral tumors compressing the thalamus or brainstem, cerebralabscesses compressing the thalamus or brainstem, traumatic brain injury,post-surgical pain following brain or spine surgery, complicationsfollowing brain surgery including thalamotomy for movement disorders,multiple sclerosis, and Parkinson disease, spinal cord injury,complications following spinal surgery including anterolateral cordotomyand commissural myelotomy, ischemic lesions including anterior spinalartery syndrome and Wallenberg syndrome, syringomyelia, radiationmyelopathy, HIV myelopathy.

In one embodiment, a severe pain condition comprises a peripheralneuropathic pain. Damage or disease affecting sensory, motor, and/orautonomic nerves of the peripheral nervous system is referred to as aperipheral neuropathic pain. Peripheral neuropathic pain occurs whenperipheral nerves fail to carry information to and from the brain andspinal cord, resulting in pain, loss of sensation, or inability tocontrol muscles. In some cases, the failure of nerves that control bloodvessels, intestines, and other organs results in abnormal bloodpressure, digestion problems, and loss of other basic body processes.Symptoms also depend on whether the condition affects the whole body orjust one nerve. Risk factors for neuropathy include diabetes, heavyalcohol use, exposure to certain chemicals and drugs, prolonged pressureon a nerve. Some people have a hereditary predisposition for peripheralneuropathy. The four cardinal patterns of peripheral neuropathic painare mononeuropathy, mononeuropathic multiplex, polyneuropathy, andautonomic neuropathy.

In one embodiment, a severe pain condition comprises a mononeuropathic.A mononeuropathy is a peripheral neuropathy involving functional loss orpathological change affecting a single nerve or nerve group.Mononeuropathy is most often caused by damage to a local area resultingfrom injury or trauma, although occasionally systemic disorders maycause isolated nerve damage. The usual causes are direct trauma,prolonged pressure on the nerve, and compression of the nerve byswelling or injury to nearby body structures. The damage includesdestruction of the myelin sheath (covering) of the nerve or of part ofthe nerve cell (the axon). This damage slows or prevents conduction ofimpulses through the nerve. Mononeuropathy may involve any part of thebody. Mononeuropathic pain is associated with, e.g., a sciatic nervedysfunction, a common peroneal nerve dysfunction, a radial nervedysfunction, an ulnar nerve dysfunction, a cranial mononeuropathy VI, acranial mononeuropathy VII, a cranial mononeuropathy III (compressiontype), a cranial mononeuropathy III (diabetic type), an axillary nervedysfunction, a carpal tunnel syndrome, a femoral nerve dysfunction, atibial nerve dysfunction, a Bell's palsy, a thoracic outlet syndrome, acarpal tunnel syndrome or other focal entrapment neuropathy, and a sixth(abducent) nerve palsy

In one embodiment, a severe pain condition comprises a mononeuropathicmultiplex. A mononeuropathic multiplex is a peripheral neuropathyinvolving functional loss or pathological change that sequentially orsimultaneously affects several non-contiguous nerves in an asymmetricmanner. A neuropathic pain based on mononeuropathy multiplex may developover days to years and typically presents with acute or subacute loss ofsensory and motor function of individual nerves. The pattern ofinvolvement is asymmetric; however, as the disease progresses deficit(s)becomes more confluent and symmetrical, making it difficult todifferentiate from polyneuropathy. Mononeuropathic multiplex may alsocause pain characterized as deep, aching pain that is worse at night,and frequently present in the lower back, hip, or leg. Mononeuropathicmultiplex may also cause pain characterized as acute, unilateral, severelimb pain followed by anterior muscle weakness and loss of knee reflex.Mononeuropathic multiplex pain is associated with, e.g., diabetesmellitus, infections, such as, e.g., leprosy, lyme disease, HIV, andtoxicity.

In one embodiment, a severe pain condition comprises a polyneuropathy. Apolyneuropathy is a peripheral neuropathy involving functional loss orpathological change affecting multiple nerves throughout the body in asymmetric manner. A polyneuropathy may be acute and appear withoutwarning, or chronic and develop gradually over a longer period of time.Many polyneuropathies have both motor and sensory involvement, and somealso involve dysfunction of the autonomic nervous system. Thesedisorders are often symmetrical, and usually due to various systematicillnesses and disease processes that affect the peripheral nervoussystem in its entirety. A polyneuropathy frequently affect the feet andhands, causing weakness, loss of sensation, pins-and-needle sensationsor burning pain. Polyneuropathies can be classified in different ways,such as by cause, by speed of progression, or by the parts of the bodyinvolved. Classes of polyneuropathy are also distinguished by which partof the nerve cell is mainly affected: the axon, the myelin sheath, orthe cell body.

In one embodiment, a severe pain condition comprises a distalaxonopathy. Distal axonopathy, or “dying-back neuropathy”, is the resultof some metabolic or toxic derangement of a neuron. They may be causedby metabolic diseases such as diabetes, renal failure, deficiencysyndromes such as malnutrition and alcoholism, or the effects of toxinsor drugs such as chemotherapy. The most common cause of distalaxonopathy is diabetes, and the most common distal axonopathy isdiabetic neuropathy. They can be divided according to the type of axonaffected: large-fiber, small-fiber, or both. The most distal portions ofaxons are usually the first to degenerate, and axonal atrophy advancesslowly towards the nerve's cell body. If the cause is removed,regeneration is possible, though the prognosis depends on the durationand severity of the stimulus. People with distal axonopathies usuallypresent with sensorimotor disturbances that have a symmetrical “stockingand glove” distribution. Deep tendon reflexes and autonomic nervoussystem functions are also lost or diminished in affected areas.

In one embodiment, a severe pain condition comprises a myelinopathy.Myelinopathy, or “demyelinating polyneuropathy”, is due to a loss ofmyelin (or of the Schwann cells that make and contain it). Thisdemyelination leaves the axon intact, but slows down or completelyblocks the conduction of action potentials through the axon of the nervecell. The most common cause is acute inflammatory demyelinatingpolyneuropathy (AIDP, the most common form of Guillain-Barré syndrome),though other causes include chronic inflammatory demyelinatingpolyneuropathy (CIDP), genetic metabolic disorders (e.g.,leukodystrophy), and toxins.

In one embodiment, a severe pain condition comprises a neuronopathy.Neuronopathy is the result of destruction of peripheral nervous systemneurons. They may be caused by motor neuron diseases, sensoryneuronopathies (e.g., Herpes zoster), toxins or autonomic dysfunction.Neurotoxins may cause neuronopathies, such as the chemotherapy agentvincristine. A person with neuronopathy may present in different ways,depending on the cause, the way it affects the nerve cells, and the typeof nerve cell that is most affected.

There are numerous conditions that can cause polyneuropathy. Peripheralneuropathic pain include, without limitation, neuropathies associatedwith systemic disease like diabetic neuropathy, neuropathies associatedwith metabolic conditions like alcoholic neuropathy and burning feetsyndrome, neuropathies associated with viral infections like herpeszoster and HIV, neuropathies associated with nutritional deficiencies,neuropathies associated with toxins, neuropathies associated with tumorcompression, neuropathies associated with remote manifestations ofmalignancies, neuropathies associated with drugs like chemotherapy,neuropathies associated with radiation, neuropathies associated withimmune mediated disorders, and neuropathies associated with physicaltrauma to a nerve trunk. Polyneuropathic pain, includes, withoutlimitation, post-polio syndrome, postmastectomy syndrome, diabeticneuropathy, alcohol neuropathy, amyloid, toxins, AIDS, hypothyroidism,uremia, vitamin deficiencies, chemotherapy-induced pain,2′,3′-didexoycytidine (ddC) treatment, Guillain-Barre syndrome orFabry's disease.

In one embodiment, a severe pain condition comprises an autonomicneuropathy. An autonomic neuropathy is a peripheral neuropathy involvingfunctional loss or pathological change affecting the non-voluntary,non-sensory nervous system (i.e., the autonomic nervous system).Autonomic neuropathy is a form of polyneuropathy which affects mostlythe internal organs such as the bladder, muscles, the cardiovascularsystem, the digestive tract, and the genital organs.

Peripheral neuropathic pain may be present in systemic diseases,metabolic disorders, nutrient disorders, drug-induced disorders,traumatic injury, traumatic and entrapment syndromes, post-surgical painsurgery, complications following surgery, HIV sensory neuropathy,demyelinating polyradiculoneuropathy, postherpetic neuralgia, nerve rootavulsions, cranial neuralgias like trigeminal neuralgia, neuropathiccancer pain, compression of peripheral nerves, nerve plexuses, and nerveroots, paraneoplastic peripheral neuropathy, ganglionopathy,complication of cancer therapies like chemotherapy, radiation, andsurgery, and complex regional pain syndrome like Type 1 and Type 2.

In one embodiment, a severe pain condition comprises a neuralgia. Aneuralgia is a peripheral neuropathic pain that radiates along thecourse of one or more specific nerves usually without any demonstrablepathological change in the nerve structure. The affected nerves areresponsible for sensing touch, temperature and pressure. Simple stimulisuch as eating, talking, washing the face, or any light touch orsensation can trigger an attack (even the sensation of a gentle breeze).The attacks can occur in clusters or as an isolated attack. Generally, aneuralgia causes short episodes of excruciating pain, usually for lessthan two minutes. However, in the atypical forms of neuralgia, the paincan also present as merely aching to severe pain and last for extendedperiods. Symptoms include sharp, stabbing pain or constant, burning painlocated anywhere, usually on or near the surface of the body, in thesame location for each episode; pain along the path of a specific nerve;impaired function of affected body part due to pain, or muscle weaknessdue to concomitant motor nerve damage; increased sensitivity of the skinor numbness of the affected skin area; and any touch or pressure isinterpreted as pain. Movement may also be painful. A neuralgia,includes, without limitation, a trigeminal neuralgia, a glossopharyngealneuralgia, a post-herpetic neuralgia (caused by, e.g., herpesvirus,syphilis and Lyme disease), a carpal tunnel syndrome, a meralgiaparesthetica, a sciatica and an atypical facial pain.

In one embodiment, a severe pain condition comprises a Complex RegionalPain Syndrome (CRPS). A CRPS is a neuropathy resulting fromsympathetically-maintained pain. Although unknown, mechanisms probablyinvolve abnormal sympathetic-somatic nerve connections (ephapses), localinflammatory changes, and changes in the spinal cord. CRPS presents intwo forms. CRPS 1 (reflex sympathetic dystrophy syndrome) is a chronicnerve disorder that occurs most often in the arms or legs after a minoror major injury. CRPS 1 is associated with severe pain; changes in thenails, bone, and skin; and an increased sensitivity to touch in theaffected limb. CRPS 2 (causalgia) is caused by an identified injury tothe nerve and results in a syndrome of sustained burning pain,allodynia, and hyperpathia after a traumatic nerve lesion, oftencombined with vasomotor and sudomotor dysfunction and later trophicchanges.

In one embodiment, a severe pain condition comprises a referred pain.Referred pain arises from pain localized to an area separate from thesite of pain stimulation. Often, referred pain arises when a nerve iscompressed or damaged at or near its origin. In this circumstance, thesensation of pain will generally be felt in the territory that the nerveserves, even though the damage originates elsewhere. A common exampleoccurs in intervertebral disc herniation, in which a nerve root arisingfrom the spinal cord is compressed by adjacent disc material. Althoughpain may arise from the damaged disc itself, pain will also be felt inthe region served by the compressed nerve (for example, the thigh, knee,or foot). Relieving the pressure on the nerve root may ameliorate thereferred pain, provided that permanent nerve damage has not occurred.Myocardial ischaemia (the loss of blood flow to a part of the heartmuscle tissue) is possibly the best known example of referred pain; thesensation can occur in the upper chest as a restricted feeling, or as anache in the left shoulder, arm or even hand.

In one embodiment, a severe pain condition comprises a deafferentationpain. Damage or disease affecting peripheral or central afferent neuralactivity is referred to as a deafferentation pain. Deafferentation painis due to partial or complete loss of the sensory input from a portionof the body, and can be caused by interruption of either peripheralsensory fibres or nerves from the central nervous system. The mechanismunderlying this type of pain is unknown but may involve sensitization ofcentral neurons, with lower activation thresholds and expansion ofreceptive fields. A deafferentation pain syndrome, includes, withoutlimitation, a phantom pain, a brain injury, a spinal cord injury, alumbar radiculopathy, a post-stroke pain, a paraplegia, avulsion of thebrachial plexus or other types of lesions of peripheral nerves, apathology of the central nervous system.

In one embodiment, a severe pain condition comprises a dysfunctionalpain. Dysfunctional pain is a pathological pain where an organic painstate is caused by abnormal function of the somatosensory nervoussystem, but which are not initiated by an identifiable lesion of anypart of the nervous system. Similar to neuropathic pain, dysfunctionalpain is commonly described as a burning pain, a coldness, an electricshock, a “pins and needles” sensation, numbness and itching.

In one embodiment, a severe pain condition comprises a headache. Asevere pain condition may be a headache (medically known as cephalgia)is a condition of mild to severe pain in the head; sometimes neck orupper back pain may also be interpreted as a headache. It may indicatean underlying local or systemic disease or be a disorder in itself. Aheadache includes, without limitation, a muscular/myogenic headache, avascular headache, a traction headache, inflammatory headache, a chronicsinusitis headache, a hormone headache, a rebound headache, an organicheadache, and an ictal headache.

In one embodiment, a severe pain condition comprises a muscular/myogenicheadache.

Muscular/myogenic headaches appear to involve the tightening or tensingof facial and neck muscles; they may radiate to the forehead. Tensionheadache is the most common form of myogenic headache. A tensionheadache is a condition involving pain or discomfort in the head, scalp,or neck, usually associated with muscle tightness in these areas.Tension headaches result from the contraction of neck and scalp muscles.One cause of this muscle contraction is a response to stress, depressionor anxiety. Any activity that causes the head to be held in one positionfor a long time without moving can cause a headache. Such activitiesinclude typing or use of computers, fine work with the hands, and use ofa microscope. Sleeping in a cold room or sleeping with the neck in anabnormal position may also trigger this type of headache. A tension-typeheadache, includes, without limitation, an episodic tension headache anda chronic tension headache.

In one embodiment, a severe pain condition comprises a vascularheadache. The most common type of vascular headache is migraine. Otherkinds of vascular headaches include cluster headaches, which causerepeated episodes of intense pain, and headaches resulting from highblood pressure.

In one embodiment, a severe pain condition comprises a migraineheadache. A migraine is a heterogeneous disorder that generally involvesrecurring headaches. Migraines are different from other headachesbecause they occur with other symptoms, such as, e.g., nausea, vomiting,or sensitivity to light. In most people, a throbbing pain is felt onlyon one side of the head. Clinical features such as type of aurasymptoms, presence of prodromes, or associated symptoms such as vertigo,may be seen in subgroups of patients with different underlyingpathophysiological and genetic mechanisms. A migraine headache,includes, without limitation, a migraine without aura (common migraine),a migraine with aura (classic migraine), a menstrual migraine, amigraine equivalent (acephalic headache), a complicated migraine, anabdominal migraine and a mixed tension migraine.

In one embodiment, a severe pain condition comprises a cluster headache.Cluster headaches affect one side of the head (unilateral) and may beassociated with tearing of the eyes and nasal congestion. They occurs inclusters, happening repeatedly every day at the same time for severalweeks and then remitting.

In one embodiment, a severe pain condition comprises a sinusitisheadache. Sinusitis is inflammation, either bacterial, fungal, viral,allergic or autoimmune, of the paranasal sinuses. Chronic sinusitis isone of the most common complications of the common cold. Symptomsinclude: Nasal congestion; facial pain; headache; fever; generalmalaise; thick green or yellow discharge; feeling of facial ‘fullness’worsening on bending over. In a small number of cases, chronic maxillarysinusitis can also be brought on by the spreading of bacteria from adental infection. Chronic hyperplastic eosinophilic sinusitis is anoninfective form of chronic sinusitis.

In one embodiment, a severe pain condition comprises a tractionheadache. Traction and inflammatory headaches are usually symptoms ofother disorders, ranging from stroke to sinus infection.

In one embodiment, a severe pain condition comprises a rebound headache.Rebound headaches, also known as medication overuse headaches, occurwhen medication is taken too frequently to relieve headache. Reboundheadaches frequently occur daily and can be very painful.

In one embodiment, a severe pain condition comprises a ictal headache.Ictal headaches are headaches associated with seizure activity.

In one embodiment, a severe pain condition comprises a psychogenic pain.Psychogenic pain, also called psychalgia or somatoform pain, is paincaused, increased, or prolonged by mental, emotional, or behavioralfactors. Headache, back pain, and stomach pain are sometimes diagnosedas psychogenic. Sufferers are often stigmatized, because both medicalprofessionals and the general public tend to think that pain from apsychological source is not “real”. However, specialists consider thatit is no less actual or hurtful than pain from any other source.Individuals with long term pain frequently display psychologicaldisturbance.

In one embodiment, a severe pain condition comprises an inflammatorypain. An inflammatory pain is a severe pain condition where an organicpain state is caused by the release of mediators at a site of tissueinflammation which activate and sensitize the nociceptive pain pathway.This type of pain is associated with any tissue damage caused by achronic inflammatory response. Inflammatory pain may be associate withan arthritic disorder, an autoimmune disease, a connective tissuedisorder, an injury, an infection, and a neuritis.

In one embodiment, a severe pain condition does not comprise aninflammatory pain.

In one embodiment, a severe pain condition is not caused by aninflammatory response.

A pharmaceutical composition disclosed herein is administered to anindividual. An individual is typically a human being. Typically, anyindividual who is a candidate for a conventional severe pain treatmentis a candidate for a severe pain treatment disclosed herein.Pre-operative evaluation typically includes routine history and physicalexamination in addition to thorough informed consent disclosing allrelevant risks and benefits of the procedure.

A pharmaceutical composition disclosed herein may comprise a therapeuticcompound in a therapeutically effective amount. As used herein, the term“effective amount” is synonymous with “therapeutically effectiveamount”, “effective dose”, or “therapeutically effective dose” and whenused in reference to treating a severe pain condition refers to theminimum dose of a therapeutic compound disclosed herein necessary toachieve the desired therapeutic effect and includes a dose sufficient toreduce a symptom associated with a severe pain condition. Theeffectiveness of a therapeutic compound disclosed herein in treating asevere pain condition can be determined by observing an improvement inan individual based upon one or more clinical symptoms, and/orphysiological indicators associated with the condition. An improvementin a severe pain condition also can be indicated by a reduced need for aconcurrent therapy.

The appropriate effective amount of a therapeutic compound disclosedherein to be administered to an individual for a particular severe paincondition can be determined by a person of ordinary skill in the art bytaking into account factors, including, without limitation, the type ofthe severe pain condition, the location of the severe pain condition,the cause of the severe pain condition, the severity of the severe paincondition, the degree of relief desired, the duration of relief desired,the particular therapeutic compound used, the rate of excretion of thetherapeutic compound used, the pharmacodynamics of the therapeuticcompound used, the nature of the other compounds to be included in thecomposition, the particular formulation, the particular route ofadministration, the particular characteristics, history and risk factorsof the patient, such as, e.g., age, weight, general health and the like,or any combination thereof. Additionally, where repeated administrationof a therapeutic compound is used, an effective amount of a therapeuticcompound will further depend upon factors, including, withoutlimitation, the frequency of administration, the half-life of thetherapeutic compound, or any combination thereof. In is known by aperson of ordinary skill in the art that an effective amount of atherapeutic compound disclosed herein can be extrapolated from in vitroassays and in vivo administration studies using animal models prior toadministration to humans.

In aspects of this embodiment, a therapeutically effective amount of atherapeutic compound disclosed herein reduces a symptom associated witha severe pain condition by, e.g., at least 10%, at least 15%, at least20%, at least 25%, at least 30%, at least 35%, at least 40%, at least45%, at least 50%, at least 55%, at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least95% or at least 100%. In other aspects of this embodiment, atherapeutically effective amount of a therapeutic compound disclosedherein reduces a symptom associated with a severe pain condition by,e.g., at most 10%, at most 15%, at most 20%, at most 25%, at most 30%,at most 35%, at most 40%, at most 45%, at most 50%, at most 55%, at most60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, atmost 90%, at most 95% or at most 100%. In yet other aspects of thisembodiment, a therapeutically effective amount of a therapeutic compounddisclosed herein reduces a symptom associated with a severe paincondition by, e.g., about 10% to about 100%, about 10% to about 90%,about 10% to about 80%, about 10% to about 70%, about 10% to about 60%,about 10% to about 50%, about 10% to about 40%, about 20% to about 100%,about 20% to about 90%, about 20% to about 80%, about 20% to about 20%,about 20% to about 60%, about 20% to about 50%, about 20% to about 40%,about 30% to about 100%, about 30% to about 90%, about 30% to about 80%,about 30% to about 70%, about 30% to about 60%, or about 30% to about50%.

In yet other aspects of this embodiment, a therapeutically effectiveamount of a therapeutic compound disclosed herein generally is in therange of about 0.001 mg/kg/day to about 100 mg/kg/day. In aspects ofthis embodiment, an effective amount of a therapeutic compound disclosedherein may be, e.g., at least 0.001 mg/kg/day, at least 0.01 mg/kg/day,at least 0.1 mg/kg/day, at least 1.0 mg/kg/day, at least 5.0 mg/kg/day,at least 10 mg/kg/day, at least 15 mg/kg/day, at least 20 mg/kg/day, atleast 25 mg/kg/day, at least 30 mg/kg/day, at least 35 mg/kg/day, atleast 40 mg/kg/day, at least 45 mg/kg/day, or at least 50 mg/kg/day. Inother aspects of this embodiment, an effective amount of a therapeuticcompound disclosed herein may be in the range of, e.g., about 0.001mg/kg/day to about 10 mg/kg/day, about 0.001 mg/kg/day to about 15mg/kg/day, about 0.001 mg/kg/day to about 20 mg/kg/day, about 0.001mg/kg/day to about 25 mg/kg/day, about 0.001 mg/kg/day to about 30mg/kg/day, about 0.001 mg/kg/day to about 35 mg/kg/day, about 0.001mg/kg/day to about 40 mg/kg/day, about 0.001 mg/kg/day to about 45mg/kg/day, about 0.001 mg/kg/day to about 50 mg/kg/day, about 0.001mg/kg/day to about 75 mg/kg/day, or about 0.001 mg/kg/day to about 100mg/kg/day. In yet other aspects of this embodiment, an effective amountof a therapeutic compound disclosed herein may be in the range of, e.g.,about 0.01 mg/kg/day to about 10 mg/kg/day, about 0.01 mg/kg/day toabout 15 mg/kg/day, about 0.01 mg/kg/day to about 20 mg/kg/day, about0.01 mg/kg/day to about 25 mg/kg/day, about 0.01 mg/kg/day to about 30mg/kg/day, about 0.01 mg/kg/day to about 35 mg/kg/day, about 0.01mg/kg/day to about 40 mg/kg/day, about 0.01 mg/kg/day to about 45mg/kg/day, about 0.01 mg/kg/day to about 50 mg/kg/day, about 0.01mg/kg/day to about 75 mg/kg/day, or about 0.01 mg/kg/day to about 100mg/kg/day. In still other aspects of this embodiment, an effectiveamount of a therapeutic compound disclosed herein may be in the rangeof, e.g., about 0.1 mg/kg/day to about 10 mg/kg/day, about 0.1 mg/kg/dayto about 15 mg/kg/day, about 0.1 mg/kg/day to about 20 mg/kg/day, about0.1 mg/kg/day to about 25 mg/kg/day, about 0.1 mg/kg/day to about 30mg/kg/day, about 0.1 mg/kg/day to about 35 mg/kg/day, about 0.1mg/kg/day to about 40 mg/kg/day, about 0.1 mg/kg/day to about 45mg/kg/day, about 0.1 mg/kg/day to about 50 mg/kg/day, about 0.1mg/kg/day to about 75 mg/kg/day, or about 0.1 mg/kg/day to about 100mg/kg/day.

In other aspects of this embodiment, an effective amount of atherapeutic compound disclosed herein may be in the range of, e.g.,about 1 mg/kg/day to about 10 mg/kg/day, about 1 mg/kg/day to about 15mg/kg/day, about 1 mg/kg/day to about 20 mg/kg/day, about 1 mg/kg/day toabout 25 mg/kg/day, about 1 mg/kg/day to about 30 mg/kg/day, about 1mg/kg/day to about 35 mg/kg/day, about 1 mg/kg/day to about 40mg/kg/day, about 1 mg/kg/day to about 45 mg/kg/day, about 1 mg/kg/day toabout 50 mg/kg/day, about 1 mg/kg/day to about 75 mg/kg/day, or about 1mg/kg/day to about 100 mg/kg/day. In yet other aspects of thisembodiment, an effective amount of a therapeutic compound disclosedherein may be in the range of, e.g., about 5 mg/kg/day to about 10mg/kg/day, about 5 mg/kg/day to about 15 mg/kg/day, about 5 mg/kg/day toabout 20 mg/kg/day, about 5 mg/kg/day to about 25 mg/kg/day, about 5mg/kg/day to about 30 mg/kg/day, about 5 mg/kg/day to about 35mg/kg/day, about 5 mg/kg/day to about 40 mg/kg/day, about 5 mg/kg/day toabout 45 mg/kg/day, about 5 mg/kg/day to about 50 mg/kg/day, about 5mg/kg/day to about 75 mg/kg/day, or about 5 mg/kg/day to about 100mg/kg/day.

Dosing can be single dosage or cumulative (serial dosing), and can bereadily determined by one skilled in the art. For instance, treatment ofa severe pain condition may comprise a one-time administration of aneffective dose of a pharmaceutical composition disclosed herein.Alternatively, treatment of a severe pain condition may comprisemultiple administrations of an effective dose of a pharmaceuticalcomposition carried out over a range of time periods, such as, e.g.,once daily, twice daily, trice daily, once every few days, or onceweekly. The timing of administration can vary from individual toindividual, depending upon such factors as the severity of anindividual's symptoms. For example, an effective dose of apharmaceutical composition disclosed herein can be administered to anindividual once daily for an indefinite period of time, or until theindividual no longer requires therapy. A person of ordinary skill in theart will recognize that the condition of the individual can be monitoredthroughout the course of treatment and that the effective amount of apharmaceutical composition disclosed herein that is administered can beadjusted accordingly.

Various routes of administration can be useful for administering atherapeutic compound disclosed herein, according to a method of treatinga severe pain condition disclosed herein. A pharmaceutical compositionmay be administered to an individual by any of a variety of meansdepending, e.g., on the type of the severe pain condition to be treated,the location of the severe pain condition to be treated, the specifictherapeutic compound or composition used, or other compound to beincluded in the composition, and the history, risk factors and symptomsof the individual. As such, topical, enteral or parenteral routes ofadministration may be suitable for of treating a severe pain conditiondisclosed herein and such routes include both local and systemicdelivery of a therapeutic compound or composition disclosed herein.Compositions comprising either a single therapeutic compound disclosedherein, or two or more therapeutic compounds disclosed herein areintended for inhaled, topical, intranasal, sublingual, injection,infusion, instillation, rectal and/or vaginal use may be preparedaccording to any method known to the art for the manufacture ofpharmaceutical compositions.

In one embodiment, upon administration to an individual, apharmaceutical composition comprising a therapeutic compound disclosedherein results in a bio-distribution of the therapeutic compounddifferent than a bio-distribution of the therapeutic compound includedin the same pharmaceutical composition, except without an adjuvantdisclosed herein.

In another embodiment, upon administration to an individual, atherapeutic compound of the pharmaceutical composition disclosed hereinis delivered to a macrophage. Macrophages are one of the key cell typesbelieved to be involved in the control of the inflammation response. Theresultant high level of a therapeutic compound having anti-pain activitypresent in the macrophages results in a clinically effective treatmentof a severe pain condition. In an aspect of this embodiment, uponadministration to an individual, a therapeutically effective amount of atherapeutic compound of the pharmaceutical composition disclosed hereinis preferentially delivered to a macrophage. In other aspect of thisembodiment, upon administration to an individual, a therapeutic compoundof the pharmaceutical composition disclosed herein is substantiallydelivered to a macrophage. In yet other aspect of this embodiment, uponadministration to an individual, the amount of a therapeutic compound ofthe pharmaceutical composition disclosed herein delivered to amacrophage is, e.g., at least 5%, at least 10%, at least 15%, at least20%, at least 25%, at least 30%, at least 35%, at least 40%, at least45%, at least 50%, at least 55%, at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least95%, or at least 100% of the total amount of the therapeutic compoundcontained in the administered pharmaceutical composition. In still otheraspects of this embodiment, upon administration to an individual, theamount of a therapeutic compound of the pharmaceutical compositiondisclosed herein delivered to a macrophage is in a range of, e.g., about5% to about 100%, about 10% to about 100%, about 15% to about 100%,about 20% to about 100%, about 25% to about 100%, about 30% to about100%, about 35% to about 100%, about 40% to about 100%, about 45% toabout 100%, about 50% to about 100%, about 5% to about 90%, about 10% toabout 90%, about 15% to about 90%, about 20% to about 90%, about 25% toabout 90%, about 30% to about 90%, about 35% to about 90%, about 40% toabout 90%, about 45% to about 90%, about 50% to about 90%, about 5% toabout 80%, about 10% to about 80%, about 15% to about 80%, about 20% toabout 80%, about 25% to about 80%, about 30% to about 80%, about 35% toabout 80%, about 40% to about 80%, about 45% to about 80%, about 50% toabout 80%, about 5% to about 70%, about 10% to about 70%, about 15% toabout 70%, about 20% to about 70%, about 25% to about 70%, about 30% toabout 70%, about 35% to about 70%, about 40% to about 70%, about 45% toabout 70%, or about 50% to about 70% of the total amount of thetherapeutic compound contained in the administered pharmaceuticalcomposition.

In another embodiment, upon administration to an individual, atherapeutic compound of the pharmaceutical composition disclosed hereinis delivered to a dentritic cell. Dendritic cells are one of the keycell types believed to coordinate the interplay between innate andadaptive immunity. The resultant high level of a therapeutic compoundhaving anti-pain activity present in the dentritic cells results in aclinically effective treatment of a severe pain condition. In an aspectof this embodiment, upon administration to an individual, atherapeutically effective amount of a therapeutic compound of thepharmaceutical composition disclosed herein is preferentially deliveredto a dentritic cell. In other aspect of this embodiment, uponadministration to an individual, a therapeutic compound of thepharmaceutical composition disclosed herein is substantially deliveredto a dentritic cell. In yet other aspect of this embodiment, uponadministration to an individual, the amount of a therapeutic compound ofthe pharmaceutical composition disclosed herein delivered to a dentriticcell is, e.g., at least 5%, at least 10%, at least 15%, at least 20%, atleast 25%, at least 30%, at least 35%, at least 40%, at least 45%, atleast 50%, at least 55%, at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 85%, at least 90%, at least 95%, or atleast 100% of the total amount of the therapeutic compound contained inthe administered pharmaceutical composition. In still other aspects ofthis embodiment, upon administration to an individual, the amount of atherapeutic compound of the pharmaceutical composition disclosed hereindelivered to a dentritic cell is in a range of, e.g., about 5% to about100%, about 10% to about 100%, about 15% to about 100%, about 20% toabout 100%, about 25% to about 100%, about 30% to about 100%, about 35%to about 100%, about 40% to about 100%, about 45% to about 100%, about50% to about 100%, about 5% to about 90%, about 10% to about 90%, about15% to about 90%, about 20% to about 90%, about 25% to about 90%, about30% to about 90%, about 35% to about 90%, about 40% to about 90%, about45% to about 90%, about 50% to about 90%, about 5% to about 80%, about10% to about 80%, about 15% to about 80%, about 20% to about 80%, about25% to about 80%, about 30% to about 80%, about 35% to about 80%, about40% to about 80%, about 45% to about 80%, about 50% to about 80%, about5% to about 70%, about 10% to about 70%, about 15% to about 70%, about20% to about 70%, about 25% to about 70%, about 30% to about 70%, about35% to about 70%, about 40% to about 70%, about 45% to about 70%, orabout 50% to about 70% of the total amount of the therapeutic compoundcontained in the administered pharmaceutical composition.

In another embodiment, upon administration to an individual, apharmaceutical composition disclosed herein reduces gastric irritation.In an aspect of this embodiment, a pharmaceutical composition disclosedherein substantially reduces gastric irritation. In yet anotherembodiment, upon administration to an individual, a pharmaceuticalcomposition disclosed herein reduces gastric irritation when compared tothe same pharmaceutical composition disclosed herein, except without thepharmaceutically-acceptable adjuvant. In an aspect of this embodiment, apharmaceutical composition disclosed herein substantially reducesgastric irritation when compared to the same pharmaceutical compositiondisclosed herein, except without the pharmaceutically-acceptableadjuvant. In other aspects of this embodiment, a pharmaceuticalcomposition disclosed herein reduces gastric irritation by, e.g., atleast 5%, at least 10%, at least 15%, at least 20%, at least 25%, atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, or at least 100%.In yet other aspects of this embodiment, a pharmaceutical compositiondisclosed herein reduces gastric irritation in a range of, e.g., about5% to about 100%, about 10% to about 100%, about 15% to about 100%,about 20% to about 100%, about 25% to about 100%, about 30% to about100%, about 35% to about 100%, about 40% to about 100%, about 45% toabout 100%, about 50% to about 100%, about 5% to about 90%, about 10% toabout 90%, about 15% to about 90%, about 20% to about 90%, about 25% toabout 90%, about 30% to about 90%, about 35% to about 90%, about 40% toabout 90%, about 45% to about 90%, about 50% to about 90%, about 5% toabout 80%, about 10% to about 80%, about 15% to about 80%, about 20% toabout 80%, about 25% to about 80%, about 30% to about 80%, about 35% toabout 80%, about 40% to about 80%, about 45% to about 80%, about 50% toabout 80%, about 5% to about 70%, about 10% to about 70%, about 15% toabout 70%, about 20% to about 70%, about 25% to about 70%, about 30% toabout 70%, about 35% to about 70%, about 40% to about 70%, about 45% toabout 70%, or about 50% to about 70%.

In another embodiment, upon administration to an individual, apharmaceutical composition disclosed herein reduces intestinalirritation. In an aspect of this embodiment, a pharmaceuticalcomposition disclosed herein substantially reduces intestinalirritation. In yet another embodiment, upon administration to anindividual, a pharmaceutical composition disclosed herein reducesintestinal irritation when compared to the same pharmaceuticalcomposition disclosed herein, except without thepharmaceutically-acceptable adjuvant. In an aspect of this embodiment, apharmaceutical composition disclosed herein substantially reducesintestinal irritation when compared to the same pharmaceuticalcomposition disclosed herein, except without thepharmaceutically-acceptable adjuvant. In other aspects of thisembodiment, a pharmaceutical composition disclosed herein reducesintestinal irritation by, e.g., at least 5%, at least 10%, at least 20%,at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, or at least 100% when compared to the samepharmaceutical composition disclosed herein, except without thepharmaceutically-acceptable adjuvant. In yet other aspects of thisembodiment, a pharmaceutical composition disclosed herein reducesintestinal irritation by, e.g., about 5% to about 100%, about 10% toabout 100%, about 15% to about 100%, about 20% to about 100%, about 25%to about 100%, about 30% to about 100%, about 35% to about 100%, about40% to about 100%, about 45% to about 100%, about 50% to about 100%,about 5% to about 90%, about 10% to about 90%, about 15% to about 90%,about 20% to about 90%, about 25% to about 90%, about 30% to about 90%,about 35% to about 90%, about 40% to about 90%, about 45% to about 90%,about 50% to about 90%, about 5% to about 80%, about 10% to about 80%,about 15% to about 80%, about 20% to about 80%, about 25% to about 80%,about 30% to about 80%, about 35% to about 80%, about 40% to about 80%,about 45% to about 80%, about 50% to about 80%, about 5% to about 70%,about 10% to about 70%, about 15% to about 70%, about 20% to about 70%,about 25% to about 70%, about 30% to about 70%, about 35% to about 70%,about 40% to about 70%, about 45% to about 70%, or about 50% to about70% when compared to the same pharmaceutical composition disclosedherein, except without the pharmaceutically-acceptable adjuvant.

A pharmaceutical composition disclosed herein can also be administeredto an individual in combination with other therapeutic compounds toincrease the overall therapeutic effect of the treatment. The use ofmultiple compounds to treat an indication can increase the beneficialeffects while reducing the presence of side effects.

Aspects of the present invention can also be described as follows:

-   1. A pharmaceutical composition comprising: a) a therapeutic    compound, wherein the therapeutic compound has an anti-pain    activity; and b) a pharmaceutically-acceptable adjuvant.-   2. The pharmaceutical composition according to embodiment 1, wherein    the composition further comprises a pharmaceutically-acceptable    solvent.-   3. A pharmaceutical composition comprising: a) a therapeutic    compound, wherein the therapeutic compound has an anti-pain    activity; b) a pharmaceutically-acceptable solvent; and c) a    pharmaceutically-acceptable adjuvant.-   4. A pharmaceutical composition comprising: a) a therapeutic    compound, wherein the therapeutic compound has an anti-pain    activity; b) a pharmaceutically-acceptable solvent; and c) a    pharmaceutically-acceptable adjuvant, wherein the ratio of the    pharmaceutically-acceptable solvent to pharmaceutically-acceptable    adjuvant is in a range from about 0:1 to about 1:25.-   5. The pharmaceutical composition according to embodiment 2 or 3,    wherein the ratio of the pharmaceutically-acceptable solvent to    pharmaceutically-acceptable adjuvant is in a range from about 0:1 to    about 1:25.-   6. The pharmaceutical composition according to embodiments 1-5,    wherein the anti-pain activity reduces a severe pain response.-   7. The pharmaceutical composition according to embodiment 6, wherein    the anti-pain activity reduces a severe pain response by at least    10%.-   8. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a nociceptive pain response.-   9. The pharmaceutical composition according to embodiment 8, wherein    the anti-pain activity reduces a nociceptive pain response by at    least 10%.-   10. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a pain response mediated by a    nociceptive receptor.-   11. The pharmaceutical composition according to embodiment 10,    wherein the anti-pain activity reduces a pain response mediated by a    nociceptive receptor by at least 10%.-   12. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a somatic pain response.-   13. The pharmaceutical composition according to embodiment 12,    wherein the anti-pain activity reduces a somatic pain response by at    least 10%.-   14. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a visceral pain response.-   15. The pharmaceutical composition according to embodiment 14,    wherein the anti-pain activity reduces a visceral pain response by    at least 10%.-   16. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a pathological pain response.-   17. The pharmaceutical composition according to embodiment 16,    wherein the anti-pain activity reduces a pathological pain response    by at least 10%.-   18. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a neuropathic pain response.-   19. The pharmaceutical composition according to embodiment 18,    wherein the anti-pain activity reduces a neuropathic pain response    by at least 10%.-   20. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a central neuropathic pain    response.-   21. The pharmaceutical composition according to embodiment 20,    wherein the anti-pain activity reduces a central neuropathic pain    response by at least 10%.-   22. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a peripheral neuropathic pain    response.-   23. The pharmaceutical composition according to embodiment 22,    wherein the anti-pain activity reduces a peripheral neuropathic pain    response by at least 10%.-   24. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a mononeuropathic pain    response.-   25. The pharmaceutical composition according to embodiment 24,    wherein the anti-pain activity reduces a mononeuropathic pain    response by at least 10%.-   26. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a mononeuropathic multiplex    pain response.-   27. The pharmaceutical composition according to embodiment 26,    wherein the anti-pain activity reduces a mononeuropathic multiplex    pain response by at least 10%.-   28. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a polyneuropathic pain    response.-   29. The pharmaceutical composition according to embodiment 28,    wherein the anti-pain activity reduces a polyneuropathic pain    response by at least 10%.-   30. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces an autonomic neuropathic pain    response.-   31. The pharmaceutical composition according to embodiment 30,    wherein the anti-pain activity reduces an autonomic neuropathic pain    response by at least 10%.-   32. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a neuralgia pain response.-   33. The pharmaceutical composition according to embodiment 32,    wherein the anti-pain activity reduces a neuralgia pain response by    at least 10%.-   34. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a complex regional pain    syndrome pain response.-   35. The pharmaceutical composition according to embodiment 34,    wherein the anti-pain activity reduces a complex regional pain    syndrome pain response by at least 10%.-   36. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a referred pain response.-   37. The pharmaceutical composition according to embodiment 36,    wherein the anti-pain activity reduces a referred pain response by    at least 10%.-   38. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a deafferentation pain    response.-   39. The pharmaceutical composition according to embodiment 38,    wherein the anti-pain activity reduces a deafferentation pain    response by at least 10%.-   40. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a dysfunctional pain    response.-   41. The pharmaceutical composition according to embodiment 38,    wherein the anti-pain activity reduces a dysfunctional pain response    by at least 10%.-   42. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a headache pain response.-   43. The pharmaceutical composition according to embodiment 42,    wherein the anti-pain activity reduces a headache pain response by    at least 10%.-   44. The pharmaceutical composition according to embodiments 1-7,    wherein the anti-pain activity reduces a migraine pain response.-   45. The pharmaceutical composition according to embodiment 44,    wherein the anti-pain activity reduces a migraine pain response by    at least 10%.-   46. The pharmaceutical composition according to embodiments 1-45,    wherein the therapeutic compound has a log P value indicating that    the compound is soluble in an organic solvent.-   47. The pharmaceutical composition according to embodiments 1-46,    wherein the therapeutic compound has a log P value of more than 1.0.-   48. The pharmaceutical composition according to embodiments 1-46,    wherein the therapeutic compound has a log P value of more than 2.0.-   49. The pharmaceutical composition according to embodiments 1-48,    wherein the therapeutic compound has a polar surface area that is    hydrophobic.-   50. The pharmaceutical composition according to embodiments 1-49,    wherein the therapeutic compound has a polar surface area that is    less than 8.0 nm².-   51. The pharmaceutical composition according to embodiments 1-49,    wherein the therapeutic compound has a polar surface area that is    less than 6.0 nm².-   52. The pharmaceutical composition according to embodiments 1-51,    wherein the therapeutic compound comprises a non-steroidal anti-pain    drug (NSAID).-   53. The pharmaceutical composition according to embodiment 52,    wherein the NSAID comprises a salicylate derivative NSAID, a p-amino    phenol derivative NSAID, a propionic acid derivative NSAID, an    acetic acid derivative NSAID, an enolic acid derivative NSAID, a    fenamic acid derivative NSAID, a non-selective cyclo-oxygenase (COX)    inhibitor, a selective cyclooxygenase 1 (COX 1) inhibitor, a    selective cyclooxygenase 2 (COX 2) inhibitor or a combination    thereof.-   54. The pharmaceutical composition according to embodiments 1-53,    wherein the therapeutic compound comprises a PPARγ agonist.-   55. The pharmaceutical composition according to embodiment 54,    wherein the PPARγ agonist comprises Monascin, Irbesartan,    Telmisartan, mycophenolic acid, Resveratrol,    Delta(9)-tetrahydrocannabinol, a cannabidiol, Curcumin, Cilostazol,    Benzbromarone, 6-shogaol, glycyrrhetinic acid, a thiazolidinedione,    a NSAID, a fibrate, or a combination thereof.-   56. The pharmaceutical composition according to embodiments 1-55,    wherein the therapeutic compound comprises a nuclear receptor    binding agent.-   57. The pharmaceutical composition according to embodiment 56,    wherein the nuclear receptor binding agent comprises a Retinoic Acid    Receptor (RAR) binding agent, a Retinoid X Receptor (RXR) binding    agent, a Liver X Receptor (LXR) binding agent, a Vitamin D binding    agent, or a combination thereof.-   58. The pharmaceutical composition according to embodiments 1-57,    wherein the therapeutic compound comprises an anti-hyperlipidemic    agent.-   59. The pharmaceutical composition according to embodiment 58,    wherein the anti-hyperlipidemic agent comprises a fibrate, a statin,    a tocotrienol, a niacin, a bile acid sequestrants (resin), a    cholesterol absorption inhibitor, a pancreatic lipase inhibitor, a    sympathomimetic amine, or a combination thereof.-   60. The pharmaceutical composition according to embodiment 59,    wherein the fibrate comprises Bezafibrate, Ciprofibrate, Clofibrate,    Gemfibrozil, Fenofibrate, or a combination thereof.-   61. The pharmaceutical composition according to embodiment 59,    wherein the statin comprises Atorvastatin, Fluvastatin, Lovastatin,    Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin, or a    combination thereof.-   62. The pharmaceutical composition according to embodiment 59,    wherein the niacin comprises acipimox, niacin, nicotinamide, vitamin    B3, or a combination thereof.-   63. The pharmaceutical composition according to embodiment 59,    wherein the bile acid sequestrant comprises Cholestyramine,    Colesevelam, Colestipol, or a combination thereof.-   64. The pharmaceutical composition according to embodiment 59,    wherein the cholesterol absorption inhibitor comprises Ezetimibe, a    phytosterol, a sterol, a stanol, or a combination thereof.-   65. The pharmaceutical composition according to embodiment 59,    wherein the fat absorption inhibitor comprises Orlistat-   66. The pharmaceutical composition according to embodiment 59,    wherein the sympathomimetic amine comprises Clenbuterol, Salbutamol,    ephedrine, pseudoephedrine, methamphetamine, amphetamine,    phenylephrine, isoproterenol, dobutamine, methylphenidate,    lisdexamfetamine, cathine, cathinone, methcathinone, cocaine,    benzylpiperazine (BZP), methylenedioxypyrovalerone (MDPV),    4-methylaminorex, pemoline, phenmetrazine, propylhexedrine, or a    combination thereof.-   67. The pharmaceutical composition according to embodiments 1-66,    wherein the therapeutic compound comprises an ester of a therapeutic    compound.-   68. The pharmaceutical composition according to embodiments 1-67,    wherein the therapeutic compound comprises an ester of a therapeutic    compound according to embodiments 52-66.-   69. The pharmaceutical composition according to embodiments 1-68,    wherein the pharmaceutically-acceptable solvent is less than about    20% (v/v).-   70. The pharmaceutical composition according to embodiments 1-69,    wherein the pharmaceutically-acceptable solvent comprises a    pharmaceutically-acceptable polar aprotic solvent, a    pharmaceutically-acceptable polar protic solvent, a    pharmaceutically-acceptable non-polar solvent, or a combination    thereof.-   71. The pharmaceutical composition according to embodiments 1-70,    wherein the pharmaceutically-acceptable solvent comprises a    pharmaceutically-acceptable alcohol.-   72. The pharmaceutical composition according to embodiment 71,    wherein the pharmaceutically-acceptable alcohol comprises an acyclic    alcohol, a monohydric alcohol, a polyhydric alcohol, an unsaturated    aliphatic alcohol, an alicyclic alcohol, or a combination thereof.-   73. The pharmaceutical composition according to embodiment 71,    wherein the pharmaceutically-acceptable alcohol comprises a C₁-20    alcohol.-   74. The pharmaceutical composition according to embodiment 71,    wherein the pharmaceutically-acceptable alcohol comprises methanol,    ethanol, propanol, butanol, pentanol, 1-hexadecanol, or a    combination thereof. 75. The pharmaceutical composition according to    embodiments 1-74, wherein the pharmaceutically-acceptable solvent    comprises a pharmaceutically-acceptable ester of    pharmaceutically-acceptable alcohol and an acid.-   76. The pharmaceutical composition according to embodiment 75,    wherein the pharmaceutically-acceptable ester comprises methyl    acetate, methyl buterate, methyl formate, ethyl acetate, ethyl    buterate, ethyl formate, propyl acetate, propyl buterate, propyl    formate, butyl acetate, butyl buterate, butyl formate, isobutyl    acetate, isobutyl buterate, isobutyl formate, pentyl acetate, pentyl    buterate, pentyl formate, and 1-hexadecyl acetate, 1-hexadecyl    buterate, and 1-hexadecyl formate, or a combination thereof.-   77. The pharmaceutical composition according to embodiments 1-76,    wherein the pharmaceutically-acceptable solvent comprises a    pharmaceutically-acceptable glycol ether, a    pharmaceutically-acceptable diol, a pharmaceutically-acceptable    propylene glycol, a pharmaceutically-acceptable dipropylene glycol,    a pharmaceutically-acceptable polypropylene glycol (PPG) polymer, a    pharmaceutically-acceptable polyethylene glycol (PEG) polymer, or    any combination thereof.-   78. The pharmaceutical composition according to embodiment 77,    wherein the pharmaceutically-acceptable glycol ether comprises    diethylene glycol monomethyl ether (2-(2-methoxyethoxy)ethanol),    diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol),    diethylene glycol monopropyl ether (2-(2-propoxyethoxy)ethanol),    diethylene glycol monoisopropyl ether    (2-(2-isopropoxyethoxy)ethanol), diethylene glycol mono-n-butyl    ether (2-(2-butoxyethoxy)ethanol), or any combination thereof.-   79. The pharmaceutical composition according to embodiment 77,    wherein the pharmaceutically-acceptable polypropylene glycol (PPG)    polymer or the pharmaceutically-acceptable polyethylene glycol (PEG)    polymer is less than about 2,000 g/mol.-   80. The pharmaceutical composition according to embodiment 77,    wherein the pharmaceutically-acceptable polypropylene glycol (PPG)    polymer or the pharmaceutically-acceptable polyethylene glycol (PEG)    polymer is more than about 2,000 g/mol.-   81. The pharmaceutical composition according to embodiments 1-51,    wherein the pharmaceutically-acceptable solvent comprises a    pharmaceutically-acceptable glyceride.-   82. The pharmaceutical composition according to embodiment 81,    wherein the pharmaceutically-acceptable glyceride comprises a    monoglyceride, a diglyceride, a triglyceride, an acetylated    monoglyceride, an acetylated diglyceride, an acetylated    triglyceride, or a combination thereof.-   83. The pharmaceutical composition according to embodiments 1-82,    wherein the pharmaceutically-acceptable solvent is a liquid at    20° C. or wherein the pharmaceutically-acceptable solvent is a solid    at 20° C.-   84. The pharmaceutical composition according to embodiment 83,    wherein the pharmaceutically-acceptable solid solvent comprises    menthol.-   85. The pharmaceutical composition according to embodiments 1-84,    wherein the adjuvant is at least 80% (v/v).-   86. The pharmaceutical composition according to embodiments 1-85,    wherein the pharmaceutically-acceptable adjuvant is a liquid at 20°    C.-   87. The pharmaceutical composition according to embodiments 1-86,    wherein the pharmaceutically-acceptable adjuvant is a solid at 20°    C.-   88. The pharmaceutical composition according to embodiments 1-87,    wherein the pharmaceutically-acceptable adjuvant comprises a    pharmaceutically-acceptable lipid.-   89. The pharmaceutical composition according to embodiment 88,    wherein the pharmaceutically-acceptable lipid comprises a saturated    fatty acid, an unsaturated fatty acid, or a combination thereof.-   90. The pharmaceutical composition according to embodiment 88 or 89,    wherein the pharmaceutically-acceptable lipid comprises two or more    saturated or unsaturated fatty acids.-   91. The pharmaceutical composition according to embodiment 90,    wherein the two or more saturated or unsaturated fatty acids    includes palmitic acid, stearic acid, oleic acid, linoleic acid,    linolenic acid, or a combination thereof.-   92. The pharmaceutical composition according to embodiments 89-91,    wherein the unsaturated fatty acid has a melting point temperature    of 20° C. or below or wherein the unsaturated fatty acid is a solid    at 20° C.-   93. The pharmaceutical composition according to embodiments 89-91,    wherein the unsaturated fatty acid comprises an omega fatty acid.-   94. The pharmaceutical composition according to embodiment 88,    wherein the pharmaceutically-acceptable lipid comprises a    pharmaceutically-acceptable oil.-   95. The pharmaceutical composition according to embodiment 94,    wherein the pharmaceutically-acceptable oil comprises almond oil,    arachis oil, avocado oil, canola oil, castor oil, coconut oil, corn    oil, cottonseed oil, grape seed oil, hazelnut oil, hemp oil, linseed    oil, olive oil, palm oil, peanut oil, rapeseed oil, rice bran oil,    safflower oil, sesame oil, soybean oil, soya oil, sunflower oil,    theobroma oil, walnut oil, wheat germ oil, or a combination thereof.-   96. The pharmaceutical composition according to embodiment 88,    wherein the pharmaceutically-acceptable lipid comprises a    pharmaceutically-acceptable glycerolipid, a    pharmaceutically-acceptable glycol fatty acid ester, a    pharmaceutically-acceptable polyether fatty acid ester, a mixture of    pharmaceutically-acceptable lipids, or any combination thereof.-   97. The pharmaceutical composition according to embodiments 1-96,    wherein the pharmaceutical composition further comprises a    pharmaceutically-acceptable stabilizing agent.-   98. The pharmaceutical composition according to embodiment 97,    wherein the pharmaceutically-acceptable stabilizing agent comprises    water, a sacrificial acid comprising a fatty acid component and    acetic acid, ethyl acetate, a sodium acetate/acetic acid, a    monoglyceride, an acetylated monoglyceride, a diglyceride, an    acetylated diglyceride, a fatty acid, a fatty acid salt, or a    combination thereof.-   99. The pharmaceutical composition according to embodiment 97,    wherein the pharmaceutically-acceptable stabilizing agent comprises    a pharmaceutically-acceptable emulsifying agent.-   100. The pharmaceutical composition according to embodiment 99,    wherein the pharmaceutically-acceptable emulsifying agent comprises    a surfactant, a polysaccharide, a lectin, a phospholipid, or a    combination thereof.-   101. The pharmaceutical composition according to embodiments 1-100,    wherein the pharmaceutical composition does not comprise a    pharmaceutically-acceptable emulsifying agent.-   102. A method of preparing a pharmaceutical composition, the method    comprising the step of contacting a therapeutic compound with a    pharmaceutically-acceptable adjuvant under conditions which allow    the formation of the pharmaceutical composition.-   103. A method of preparing a pharmaceutical composition, the method    comprising the steps: a) contacting a pharmaceutically-acceptable    solvent with a therapeutic compound under conditions which allow the    therapeutic compound to dissolve in the pharmaceutically-acceptable    solvent, thereby forming a solution, wherein the therapeutic    compound has anti-pain activity, and b) contacting the solution    formed in step (a) with a pharmaceutically-acceptable adjuvant under    conditions which allow the formation of the pharmaceutical    composition.-   104. A method of preparing a pharmaceutical composition, the method    comprising the steps: a) contacting a pharmaceutically-acceptable    solvent with a therapeutic compound under conditions which allow the    therapeutic compound to dissolve in the pharmaceutically-acceptable    solvent, thereby forming a solution, wherein the therapeutic    compound has anti-pain activity, and b) contacting the solution    formed in step (a) with a pharmaceutically-acceptable adjuvant under    conditions which allow the formation of the pharmaceutical    composition, wherein the ratio of the pharmaceutically-acceptable    solvent to pharmaceutically-acceptable adjuvant is in a range from    about 0:1 to about 1:25.-   105. The method according to embodiments 102-104, wherein the    therapeutic compound has a log P value indicating that the compound    is soluble in an organic solvent.-   106. The method according to embodiment 102-105, wherein the    therapeutic compound has a log P value of more than 1.0.-   107. The method according to embodiment 102-105, wherein the    therapeutic compound has a log P value of more than 2.0.-   108. The method according to embodiments 102-107, wherein the    therapeutic compound has a polar surface area that is hydrophobic.-   109. The method according to embodiments 102-108, wherein the    therapeutic compound has a polar surface area that is less than 8.0    nm².-   110. The method according to embodiments 102-108, wherein the    therapeutic compound has a polar surface area that is less than 6.0    nm².-   111. The method according to embodiments 102-110, wherein the    therapeutic compound comprises a non-steroidal anti-pain drug    (NSAID).-   112. The method according to embodiment 111, wherein the NSAID    comprises a salicylate derivative NSAID, a p-amino phenol derivative    NSAID, a propionic acid derivative NSAID, an acetic acid derivative    NSAID, an enolic acid derivative NSAID, a fenamic acid derivative    NSAID, a non-selective cyclo-oxygenase (COX) inhibitor, a selective    cyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2    (COX 2) inhibitor, or a combination thereof.-   113. The method according to embodiments 102-112, wherein the    therapeutic compound comprises a PPARγ agonist.-   114. The method according to embodiment 113, wherein the PPARγ    agonist comprises Monascin, Irbesartan, Telmisartan, mycophenolic    acid, Resveratrol, Delta(9)-tetrahydrocannabinol, a cannabidiol,    Curcumin, Cilostazol, Benzbromarone, 6-shogaol, glycyrrhetinic acid,    a thiazolidinedione, a NSAID, a fibrate, or a combination thereof.-   115. The method according to embodiments 102-114, wherein the    therapeutic compound comprises a nuclear receptor binding agent.-   116. The method according to embodiment 115, wherein the nuclear    receptor binding agent comprises a Retinoic Acid Receptor (RAR)    binding agent, a Retinoid X Receptor (RXR) binding agent, a Liver X    Receptor (LXR) binding agent, a Vitamin D binding agent, or a    combination thereof.-   117. The method according to embodiments 102-116, wherein the    therapeutic compound comprises an anti-hyperlipidemic agent.-   118. The method according to embodiment 117, wherein the    anti-hyperlipidemic agent comprises a fibrate, a statin, a    tocotrienol, a niacin, a bile acid sequestrants (resin), a    cholesterol absorption inhibitor, a pancreatic lipase inhibitor, a    sympathomimetic amine, or a combination thereof.-   119. The method according to embodiment 118, wherein the fibrate    comprises Bezafibrate, Ciprofibrate, Clofibrate, Gemfibrozil,    Fenofibrate, or a combination thereof.-   120. The method according to embodiment 118, wherein the statin    comprises Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin,    Pravastatin, Rosuvastatin, Simvastatin, or a combination thereof.-   121. The method according to embodiment 118, wherein the niacin    comprises acipimox, niacin, nicotinamide, vitamin B3, or a    combination thereof.-   122. The method according to embodiment 118, wherein the bile acid    sequestrant comprises Cholestyramine, Colesevelam, Colestipol, or a    combination thereof.-   123. The method according to embodiment 118, wherein the cholesterol    absorption inhibitor comprises Ezetimibe, a phytosterol, a sterol, a    stanol, or a combination thereof.-   124. The method according to embodiment 118, wherein the fat    absorption inhibitor comprises Orlistat-   125. The method according to embodiment 118, wherein the    sympathomimetic amine comprises Clenbuterol, Salbutamol, ephedrine,    pseudoephedrine, methamphetamine, amphetamine, phenylephrine,    isoproterenol, dobutamine, methylphenidate, lisdexamfetamine,    cathine, cathinone, methcathinone, cocaine, benzylpiperazine (BZP),    methylenedioxypyrovalerone (MDPV), 4-methylaminorex, pemoline,    phenmetrazine, propylhexedrine, or a combination thereof.-   126. The method according to embodiments 102-125, wherein the    therapeutic compound comprises an ester of a therapeutic compound.-   127. The method according to embodiments 102-126, wherein the    therapeutic compound comprises an ester of a therapeutic compound    according to embodiments 111-126.-   128. The method according to embodiments 103-127, wherein the    pharmaceutically-acceptable solvent is less than about 20% (v/v).-   129. The method according to embodiments 103-128, wherein the    pharmaceutically-acceptable solvent comprises a    pharmaceutically-acceptable polar aprotic solvent, a    pharmaceutically-acceptable polar protic solvent, a    pharmaceutically-acceptable non-polar solvent, or a combination    thereof.-   130. The method according to embodiments 103-129, wherein the    pharmaceutically-acceptable solvent comprises a    pharmaceutically-acceptable alcohol.-   131. The method according to embodiment 130, wherein the    pharmaceutically-acceptable alcohol comprises an acyclic alcohol, a    monohydric alcohol, a polyhydric alcohol, an unsaturated aliphatic    alcohol, an alicyclic alcohol, or a combination thereof.-   132. The method according to embodiment 130, wherein the    pharmaceutically-acceptable alcohol comprises a C₁₋₂₀ alcohol.-   133. The method according to embodiment 130, wherein the    pharmaceutically-acceptable alcohol comprises methanol, ethanol,    propanol, butanol, pentanol, 1-hexadecanol, or a combination    thereof.-   134. The method according to embodiment 130, wherein the    pharmaceutically-acceptable solvent comprises a    pharmaceutically-acceptable ester of pharmaceutically-acceptable    alcohol and an acid.-   135. The method according to embodiment 134, wherein the    pharmaceutically-acceptable ester comprises methyl acetate, methyl    buterate, methyl formate, ethyl acetate, ethyl buterate, ethyl    formate, propyl acetate, propyl buterate, propyl formate, butyl    acetate, butyl buterate, butyl formate, isobutyl acetate, isobutyl    buterate, isobutyl formate, pentyl acetate, pentyl buterate, pentyl    formate, and 1-hexadecyl acetate, 1-hexadecyl buterate, and    1-hexadecyl formate, or a combination thereof.-   136. The method according to embodiments 103-135, wherein the    pharmaceutically-acceptable solvent is a pharmaceutically-acceptable    polyethylene glycol (PEG) polymer.-   137. The method according to embodiment 136, wherein the    pharmaceutically-acceptable polyethylene glycol (PEG) polymer is    less than about 2,000 g/mol.-   138. The method according to embodiment 136, wherein the    pharmaceutically-acceptable polyethylene glycol (PEG) polymer is    more than about 2,000 g/mol.-   139. The method according to embodiments 103-138, wherein the    pharmaceutically-acceptable solvent comprises a    pharmaceutically-acceptable glyceride.-   140. The method according to embodiments 139, wherein the    pharmaceutically-acceptable glyceride is a monoglyceride, a    diglyceride, a triglyceride, an acetylated monoglyceride, an    acetylated diglyceride, an acetylated triglyceride, or a combination    thereof.-   141. The method according to embodiments 103-140, wherein the    pharmaceutically-acceptable solvent is a liquid at 20° C.-   142. The method according to embodiments 103-141, wherein the    pharmaceutically-acceptable solvent is a solid at 20° C.-   143. The method according to embodiment 142, wherein the    pharmaceutically-acceptable solid solvent is menthol.-   144. The method according to embodiments 102-143, wherein the    pharmaceutically-acceptable adjuvant is at least 80% (v/v).-   145. The method according to embodiments 102-144, wherein the    pharmaceutically-acceptable adjuvant is a liquid at 20° C.-   146. The method according to embodiments 102-144, wherein the    pharmaceutically-acceptable adjuvant is a solid at 20° C.-   147. The method according to embodiments 102-146, wherein the    pharmaceutically-acceptable adjuvant comprises a    pharmaceutically-acceptable lipid.-   148. The method according to embodiment 147, wherein the    pharmaceutically-acceptable lipid comprises a    pharmaceutically-acceptable saturated fatty acid, an unsaturated    fatty acid, or a combination thereof.-   149. The method according to embodiment 147 or 148, wherein the    pharmaceutically-acceptable lipid comprises two or more    pharmaceutically-acceptable saturated or unsaturated fatty acids.-   150. The method according to embodiments 149, wherein the two or    more pharmaceutically-acceptable saturated or unsaturated fatty    acids include palmitic acid, stearic acid, oleic acid, linoleic    acid, linolenic acid, or a combination thereof.-   151. The method according to embodiments 148-150, wherein the    pharmaceutically-acceptable unsaturated fatty acid has a melting    point temperature of 20° C. or below.-   152. The method according to embodiments 148-150, wherein the    pharmaceutically-acceptable unsaturated fatty acid is a solid at 20°    C.-   153. The method according to embodiments 148-152, wherein the    pharmaceutically-acceptable unsaturated fatty acid comprises an    omega fatty acid.-   154. The method according to embodiments 147-153, wherein the    pharmaceutically-acceptable lipid comprises a    pharmaceutically-acceptable oil.-   155. The method according to embodiment 154, wherein the    pharmaceutically-acceptable oil comprises almond oil, arachis oil,    avocado oil, canola oil, castor oil, coconut oil, corn oil,    cottonseed oil, grape seed oil, hazelnut oil, hemp oil, linseed oil,    olive oil, palm oil, peanut oil, rapeseed oil, rice bran oil,    safflower oil, sesame oil, soybean oil, soya oil, sunflower oil,    walnut oil, wheat germ oil, or a combination thereof.-   156. The method according to embodiments 103 or 105-155, wherein in    step(b) the ratio of the pharmaceutically-acceptable solvent to    pharmaceutically-acceptable adjuvant is in a range from about 0:1 to    about 1:25.-   157. The method according to embodiments 102-156, wherein the    step (a) further comprising contacting a pharmaceutically-acceptable    stabilizing agent with the pharmaceutically-acceptable solvent and    the therapeutic compound.-   158. The method according to embodiment 157, wherein the    pharmaceutically-acceptable stabilizing agent comprises water, a    sacrificial acid comprising a fatty acid component and acetic acid,    ethyl acetate, a sodium acetate/acetic acid, a monoglyceride, an    acetylated monoglyceride, a diglyceride, an acetylated diglyceride,    a fatty acid, a fatty acid salt, or a combination thereof.-   159. The method according to embodiment 157 or 158, wherein the    pharmaceutically-acceptable stabilizing agent comprises a    pharmaceutically-acceptable emulsifying agent.-   160. The method according to embodiment 159, wherein the    pharmaceutically-acceptable emulsifying agent comprises a    surfactant, a polysaccharide, a lectin, a phospholipid, or a    combination thereof.-   161. The method according to embodiments 102-158, wherein the    pharmaceutical composition does not comprise a    pharmaceutically-acceptable emulsifying agent.-   162. The method according to embodiments 103-161, wherein the method    further comprises removing the pharmaceutically-acceptable solvent    from the pharmaceutical composition.-   163. The method according to embodiment 162, wherein at least 5% the    pharmaceutically-acceptable solvent is removed from the    pharmaceutical composition.-   164. The method according to embodiment 162 or 163, wherein at,    removal of solvent from the pharmaceutical composition disclosed    herein is carried out at a temperature of less than 20° C.-   165. The method according to embodiments 102-164, wherein the    pharmaceutical composition made is according to embodiments 1-101.-   166 A method of treating an individual with a severe pain condition,    the method comprising the step of: administering to the individual    in need thereof a pharmaceutical composition according to    embodiments 1-101, wherein administration results in a reduction in    a symptom associated with the severe pain condition, thereby    treating the individual.-   167. Use of a pharmaceutical composition according to embodiments    1-101 in the manufacture of a medicament for the treatment of a    chronic inflammation.-   168. Use of a pharmaceutical composition according to embodiments    1-101 for the treatment of a severe pain condition.-   169. The method according to embodiment 166 or the use according to    embodiment 167 or 168, wherein the severe pain condition is an acute    pain, a subacute pain, or a chronic pain.-   170. The method according to embodiment 166 or the use according to    embodiment 167 or 168, wherein the severe pain condition is a    nociceptive pain.-   171. The method or use according to embodiment 170, wherein the    nociceptive pain is a visceral pain, a deep somatic pain, a    superficial somatic pain, or any combination thereof.-   172. The method according to embodiment 166 or the use according to    embodiment 167 or 168, wherein the severe pain condition is a    pathological pain.-   173. The method or use according to embodiment 172, wherein the    pathological pain is a neuropathic pain, a dysfunctional pain, or    any combination thereof.-   174. The method or use according to embodiment 173, wherein the    neuropathic pain is a central neuropathic pain, a peripheral    neuropathic pain, a deafferentation pain, or any combination    thereof.-   175. The method or use according to embodiment 174, wherein the    peripheral neuropathic pain is a mononeuropathy, a mononeuropathic    multiplex, a polyneuropathy, or an autonomic neuropathy.-   176. The method or use according to embodiment 175, wherein the    polyneuropathy is a distal axonopathy, a myelinopathy, or a    neuronopathy.-   177. The method or use according to embodiment 174, wherein the    peripheral neuropathic pain is a neuralgia or a complex regional    pain syndrome.-   178. The method according to embodiment 166 or the use according to    embodiment 167 or 168, wherein the severe pain condition is a    referred pain.-   179. The method according to embodiment 166 or the use according to    embodiment 167 or 168, wherein the severe pain condition is a    headache.-   180. The method or use according to embodiment 179, wherein the    headache is a muscular/myogenic headache, a vascular headache, a    traction headache, inflammatory headache, a chronic sinusitis    headache, a hormone headache, a rebound headache, an organic    headache, or an ictal headache.-   181. The method according to embodiment 166 or the use according to    embodiment 167 or 168, wherein the severe pain condition is a    migraine.-   182. The method according to embodiments 166 or 169-181 or the use    according to embodiments 167-181, wherein upon administration to an    individual, the pharmaceutical composition comprising the    therapeutic compound according to embodiments 1-101 results in a    bio-distribution of the therapeutic compound different than a    bio-distribution of the therapeutic compound included in the same    pharmaceutical composition, except without the    pharmaceutically-acceptable adjuvant.-   183. The method according to embodiments 166 or 169-182 or the use    according to embodiments 167-182, wherein upon administration to an    individual, the amount of the therapeutic compound of the    pharmaceutical composition according to embodiments 1-101 delivered    to a macrophage is at least 5% of the total amount of the    therapeutic compound contained in the administered pharmaceutical    composition.-   184. The method according to embodiments 166 or 169-183 or the use    according to embodiments 167-183, wherein upon administration to an    individual, the pharmaceutical composition according to embodiments    1-101 reduces intestinal irritation by at least 5% when compared to    the pharmaceutical composition according to embodiments 1-101,    except without the pharmaceutically-acceptable adjuvant.-   185. The method according to embodiments 166 or 169-184 or the use    according to embodiments 167-184, wherein upon administration to an    individual, the pharmaceutical composition according to embodiments    1-101 reduces gastric irritation by at least 5% when compared to the    pharmaceutical composition according to embodiments 1-101, except    without the pharmaceutically-acceptable adjuvant.

EXAMPLES

The following non-limiting examples are provided for illustrativepurposes only in order to facilitate a more complete understanding ofrepresentative embodiments now contemplated. These examples should notbe construed to limit any of the embodiments described in the presentspecification, including those pertaining to the compounds, alcohols,lipids, pharmaceutical compositions, methods of preparing pharmaceuticalcompositions, or methods or uses of treating a severe pain condition.

Example 1 Liquid Formulations of Pharmaceutical Composition

This example illustrates how to make a pharmaceutical composition asdisclosed herein as a liquid formulation.

Initially, 2,400 mg of ibuprofen was contacted directly with 2.0 mL ofrapeseed oil in an attempt to dissolve a therapeutic compound directlyinto an adjuvant at a concentration of 1,200 mg/mL. However, ibuprofenremained insoluble in the oil and did not dissolve to substantiallymeasurable degree. Ibuprofen remained insolubility even if the mixturewas mixed by vortexing for 20 seconds, the contacting was done at 20° C.or 37° C., and/or the mixture was allowed to incubate for 24 hours at20° C. or 37° C. The insolubility of ibuprofen in rapeseed oil wassurprising given that ibuprofen has a log P value of 3.6; such a highlog P value is indicative of a compound that would readily soluble in anadjuvant like oil.

Since, it was not possible to dissolve ibuprofen directly into oil,despite its high log P value, it was next tried to dissolve atherapeutic drug in a solvent to first create a solution comprising thecompound. As a first step, experiments were conducted to the miscibilityof a solvent in an adjuvant like oil in the absence of a therapeuticcompound. In these experiments 0.5 mL ethanol was contacted with tendifferent volumes of rapeseed oil (Table 1). Each mixture was tested at22° C. and at 37° C. in which the ethanol and oil were initially heatedin a water bath before being mixed together. Mixing was attempted byvortex mixing for 20 seconds, and the containers were allowed to settlebefore visual assessment, either immediately, or after 24 hours. Eachmixture was evaluated to determine whether or not the ethanol andrapeseed oil form immiscible layers, or a homogeneous mixture. Theresults are summarized in Table 1. Mixtures comprising solvent:adjuvantratios of 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6 formed immiscible layers ateither 22° C. or at 37° C., either immediately or after 24 hours ofincubation, indicating that the ethanol and oil did not mix well atthese ratios. However, in solvent:adjuvant ratios above 1:7 ahomogeneous mixture was formed under all conditions tested.

TABLE 1 Liquid Formulations without Therapeutic Compound TemperatureComponents 22° C. 37° C. Solvent Adjuvant 24 24 (mL) (mL) RatioImmediate hours Immediate hours 0.5 0.5 1:1 IL IL IL IL 0.5 1.0 1:2 ILIL IL IL 0.5 1.5 1:3 IL IL IL IL 0.5 2.0 1:4 IL IL IL IL 0.5 2.5 1:5 ILIL IL IL 0.5 3.0 1:6 IL IL IL IL 0.5 3.5 1:7 HM HM HM HM 0.5 4.0 1:8 HMHM HM HM 0.5 4.5 1:9 HM HM HM HM 0.5 5.0  1:10 HM HM HM HM IL,Immiscible layers. HM, Homogeneous mixture.

Once the appropriate ratios of alcohol and lipid necessary to form ahomogenous mixture were determined, it was next determined whethercontacting a therapeutic compound first in a solvent before contactingwith an adjuvant would result in the compound dissolving in thesolvents. To conduct these experiments, either 1,000 mg or 1,200 mg ofibuprofen was dissolved into 0.5 mL of ethanol. The resulting alcoholsolution was then contacted with rapeseed oil at two differentsolvent:adjuvant ratios (1:2 and 1:9). Each mixture was tested at 20° C.and at 37° C. in which the ethanol solution and oil were initiallyheated in a water bath before being mixed together. Mixing was attemptedby vortex mixing for 20 seconds, and the containers were allowed tosettle before visual assessment, either immediately, or after 24 hours.Each mixture was evaluated to determine whether or not the ethanolsolution and rapeseed oil form immiscible layers, or a homogeneousmixture. The results are summarized in Table 2. In contrast to thesituation in the absence of a therapeutic compound, when ibuprofen ispresent in the ethanol, it caused the ethanol and oil to form ahomogeneous mixture under all conditions tested in solvent:adjuvantratios above 1:2. This observation was very surprising because, althoughnot wish to be bound by any theory, it appears that a therapeuticcompound may be having some effect on the manner in which an adjuvantand solvent interact with each other, such that a homogeneous mixture isformed in a way that does not occur when the therapeutic compound isabsent. In addition, the results indicate that a therapeutic compoundcan be formulated at clinically useful concentrations.

TABLE 2 Liquid Formulations with Therapeutic Compound TemperatureComponents 22° C. 37° C. Compound Solvent Adjuvant Imme- 24 Imme- 24(mg) (mL) (mL) Ratio diate hours diate hours 500 0.5 1.0 1:2 HM HM HM HM600 0.5 1.0 1:2 HM HM HM HM 500 0.5 4.5 1:9 HM HM HM HM 600 0.5 4.5 1:9HM HM HM HM IL, Immiscible layers. HM, Homogeneous mixture.

Example 2 Liquid Formulations of Pharmaceutical Composition

This example illustrates how to make a pharmaceutical composition asdisclosed herein as a liquid formulation.

To prepare a pharmaceutical composition disclosed herein usinggemfibrozil, the following formulations were examined. In theseexperiments, 600 mg gemfibrozil was contacted with different volumes ofethanol, as the solvent, warmed to 37° C., and the resulting solutionwas then contacted with different volumes of linseed oil, as theadjuvant, warmed to 37° C. (Table 3). Each formulation was evaluated todetermine whether or not the ethanol and linseed oil form immisciblelayers, a clear homogeneous mixture, as well as whether or not thegemfibrozil crystallized out of solution. The results are summarized inTable 3.

Like ibuprofen in Example 1 above, gemfibrozil remained insoluble in theoil alone and did not dissolve to substantially measurable degree. Theformulation comprising 0.2 mL ethanol was unable to completely dissolvegemfibrozil. In addition, although the formulation comprising 0.3 mLethanol was capable of dissolving gemfibrozil, the therapeutic compoundbegan to crystallizing out of solution within 3 hours and completecrystallization occurred within 48 hours. All other formulations testedwere capable of dissolving gemfibrozil and forming a pharmaceuticalcomposition disclosed herein. However, only the formulation comprising0.5 mL ethanol appeared to for a stable pharmaceutical composition inthat gemfibrozil remained completely dissolved after three weeks.

TABLE 3 Liquid Formulations with Therapeutic Compound ComponentsTemperature Compound Solvent Adjuvant 22° C. (mg) (mL) (mL) RatioImmediate 3 weeks 600 0 1.0 — IM N/A 600 0.2 — — IM N/A 600 0.3 0.6 1:2CR CR 600 0.4 0.4 1:1 HM CR 600 0.4 0.8 1:2 HM CR 600 0.5 1.0 1:2 HM HMHM, Clear homogeneous mixture. CR, Crystallization. IM, Immiscible.

Example 3 Liquid Formulations of Pharmaceutical Compositions

This example illustrates how to make a pharmaceutical composition asdisclosed herein as a liquid formulation.

To prepare a liquid pharmaceutical composition disclosed herein usingibuprofen, the following method was performed. About 4 g ibuprofen wascontacted with 3.6 mL of ethyl acetate, as the solvent, and theresulting solution was then contacted with 76.4 mL of rapeseed oil, asthe adjuvant. The resulting pharmaceutical composition had asolvent:adjuvant ratio of about 1:21. This pharmaceutical compositionwas then placed in a round bottom flask and subjected to low pressure ona rotary evaporator. The temperature was kept low and evaporationcontinued to constant weight. The total volume lost was 3.65% of thetotal weight. The resulting liquid no longer retained the characteristicethyl acetate odor/taste, indicating that there was a substantialremoval of ethyl acetate form the pharmaceutical composition.

To prepare a liquid pharmaceutical composition disclosed herein usingibuprofen, the following method was performed. About 2 g ibuprofen wascontacted with 1.2 mL of diethylene glycol monoethyl ether(2-(2-ethoxyethoxy)ethanol), as the solvent, 2.2 mL MAISINE® 35-1(Gattefosse), a glyceryl monolinoleate, and 2.2 mL rapeseed oil, as theadjuvants, and the resulting mixture was then contacted with 0.46 mLisopropanol. The mixture was added to a vessel heated to about 40° C. toabout 50° C. and stirred until all components of the mixture dissolvedand then cooled to about 30° C. The resulting pharmaceutical compositionhad a solvent:adjuvant ratio of about 1:3.67. This pharmaceuticalcomposition was then aliquoted to produce 10 liquid capsules eachcontaining about 200 mg ibuprofen.

Example 4 Solid Formulation of Pharmaceutical Composition

This example illustrates how to make a pharmaceutical composition asdisclosed herein as a solid formulation.

Since certain fatty acids are liquid at room temperature, while othersare solid, an examination of the different fatty acids was undertaken inan effort to evaluate the potential of each fatty acid in themanufacture of a solid formulation. This understanding would enable thedevelopment of a wide array of solid formulation by adjusting therelative ratios of each fatty acid. As an initial experiment, linolenicacid, linoleic acid, palmitic acid and stearic acid were evaluated toassess whether it was possible to prepare a pharmaceutical compositiondisclosed herein that could be formulated using only one of these fattyacids to be a solid or semi-solid at 22° C. (simulating room temperatureconditions), but melt into a liquid at 37° C. (simulating internal bodytemperature conditions after ingestion).

Four different test formulations were prepared and evaluated on theirability to form a solid dose formulation at 22° C. and melt into ahomogeneous solution at 37° C. without forming a suspension (Table 4).Formulation 1 was prepared by dissolving 200 mg of Ibuprofen into 400 mgof menthol, and the resulting solution was then mixed with 200 mg ofstearic acid (T_(m) of about 67-72° C.) and heated at 60° C. for 30minutes to form a homogeneous solution. Formulation 1 solidifiedimmediately upon cooling to 22° C. Formulation 1 remained a solid evenafter incubating at 37° C. overnight. Formulation 2 was prepared bydissolving 200 mg of Ibuprofen into 400 mg of menthol, and the resultingsolution was then mixed with 200 mg of palmitic acid (T_(m) of about61-62° C.) and heated at 60° C. for 30 minutes to form a homogeneoussolution. Formulation 2 solidified about 1 hour after cooling to 22° C.Incubating at 37° C. overnight cause Formulation 2 to completely meltinto a clear homogenous liquid. However, Formulation 2 once againsolidified about 1 hour after cooling to 22° C. Formulation 3 wasprepared by dissolving 200 mg of Ibuprofen into 400 mg of menthol, andthe resulting solution was then mixed with 200 mg of linoleic acid(T_(m) of about −5° C.) and heated at 37° C. for 2 hours to form ahomogeneous solution. Formulation 3 remained a liquid, even aftercooling to 22° C. for 72 hours. Formulation 4 was prepared by dissolving200 mg of Ibuprofen into 400 mg of menthol, and the resulting solutionwas then mixed with 200 mg of linolenic acid (T_(m) of about −11° C.)and heated at 37° C. for 2 hours to form a homogeneous solution.Formulation 4 remained a liquid, even after cooling to 22° C. for 72hours.

TABLE 4 Solid Formulations with Therapeutic Compound TemperatureComponents 22° C. 37° C. Compound Solvent Adjuvant Upon 24 72 (mg) (mg)(mg) Ratio Cooling hours hours 200 400 200 2:1 Solid Solid — (stearicacid) 200 400 200 2:1 Solid Liquid — (palmitic acid) 200 400 200 2:1Liquid Liquid Liquid (linoleic acid) 200 400 200 2:1 Liquid LiquidLiquid (linolenic acid)

Based on these data, a solid dosage form of a pharmaceutical compositiondisclosed herein can be made. For example, a pharmaceutical compositionwill be formulated to be solid or semi-solid at 22° C., but melt into aproper clear solution (and not a suspension) at 37° C. (Table 5).

TABLE 5 Solid Formulations of Pharmaceutical Compositions Compound 600mg Ibuprofen Solvent 500 mg Methanol Adjuvant 2000 mg Palmitic acid 2000mg Stearic acid 250 mg Linolenic acid 250 mg Linoleic acid Ratio 1:9Volume 5 mL Concentration 120 mg/mL

To prepare a solid pharmaceutical composition disclosed herein usingibuprofen, the following method was performed. About 15 g ibuprofen wascontacted with about 9.0 mL of diethylene glycol monoethyl ether(2-(2-ethoxyethoxy)ethanol), as the solvent, about 33 g GELUCIRE® 39/01(Gattefosse), a waxy solid having a melting point of between 37° C. to41° C. and comprising a mixture of saturated C₁₀-C₁₈ triglycerides, asthe adjuvant, and about 3.6 mL isopropanol. The mixture was added to avessel heated to about 40° C. to about 50° C. and stirred until allcomponents of the mixture dissolved, cooled to about 30° C., and thenaliquoted by poring into molds and cooled to room temperature. Theresulting pharmaceutical composition had a solvent:adjuvant ratio ofabout 1:3.67. This pharmaceutical composition produced 75 solid tabletseach containing about 200 mg ibuprofen.

To prepare a solid pharmaceutical composition disclosed herein usingibuprofen, the following method was performed. About 20 g ibuprofen wascontacted with about 12.0 mL of diethylene glycol monoethyl ether(2-(2-ethoxyethoxy)ethanol), as the solvent, about 16 g GELUCIRE® 43/01(Gattefosse), a waxy solid having a melting point of between 41° C. to45° C. and comprising a mixture of saturated C₁₀-C₁₈ triglycerides, andabout 16 g MAISINE® 35-1 (Gattefosse), a glyceryl monolinoleate, as theadjuvant, and about 3.6 mL isopropanol. The mixture was added to avessel heated to about 40° C. to about 50° C. and stirred until allcomponents of the mixture dissolved, cooled to about 30° C., and thenaliquoted by poring into molds and cooled to room temperature. Theresulting pharmaceutical composition had a solvent:adjuvant ratio ofabout 1:2.67. This pharmaceutical composition produced 100 solid tabletseach containing about 200 mg ibuprofen.

To prepare a solid pharmaceutical composition disclosed herein usingibuprofen, the following method was performed. About 80 g ibuprofen,about 152 g GELUCIRE® 43/01 (Gattefosse), a waxy solid having a meltingpoint of between 41° C. to 45° C. and comprising a mixture of saturatedC₁₀-C₁₈ triglycerides, and about 72 mL MAISINE® 35-1 (Gattefosse), aglyceryl monolinoleate, and about 32 mL PEG 400 were added to a vesselheated to about 50° C. to about 60° C. and stirred until all componentsof the mixture dissolved. The heated mixture is cooled to about 40° C.,and then aliquoted by poring into molds and cooled to room temperature.This pharmaceutical composition produced 400 solid tablets eachcontaining about 200 mg ibuprofen.

To prepare a solid pharmaceutical composition disclosed herein usingibuprofen, the following method was performed. About 1.1 g ibuprofensodium salt, about 1.9 g GELUCIRE® 43/01 (Gattefosse), a waxy solidhaving a melting point of between 41° C. to 45° C. and comprising amixture of saturated C₁₀-C₁₈ triglycerides, and about 0.9 mL MAISINE®35-1 (Gattefosse), a glyceryl monolinoleate, about 0.4 mL PEG 400, andabout 0.3 mL propylene glycol were added to a vessel heated to about 50°C. to about 60° C. and stirred until all components of the mixturedissolved. The heated mixture is cooled to about 40° C., and thenaliquoted by poring into molds and cooled to room temperature. Thispharmaceutical composition produced 5 solid tablets each containingabout 200 mg ibuprofen.

To prepare a solid pharmaceutical composition disclosed herein usingibuprofen, the following method was performed. About 5 g ibuprofen freeacid, about 5 g ibuprofen sodium salt, about 3 g GELUCIRE® 43/01(Gattefosse), a waxy solid having a melting point of between 41° C. to45° C. and comprising a mixture of saturated C₁₀-C₁₈ triglycerides, andabout 8 mL MAISINE® 35-1 (Gattefosse), a glyceryl monolinoleate, about 3mL PEG 400, and about 1 mL propylene glycol were added to a vesselheated to about 50° C. to about 60° C. and stirred until all componentsof the mixture dissolved. The heated mixture is cooled to about 40° C.,and then aliquoted by poring into molds and cooled to room temperature.This pharmaceutical composition produced 50 solid tablets eachcontaining about 200 mg ibuprofen.

Example 5 Semi-Solid Formulation of Pharmaceutical Composition

This example illustrates how to make a pharmaceutical composition asdisclosed herein as a semi-solid formulation useful for topicaladministration.

To prepare a semi-solid pharmaceutical composition disclosed hereinusing ibuprofen, the following method was performed. About 1 g ibuprofenfree acid, about 0.2 g ibuprofen sodium salt, about 0.6 g GELUCIRE®43/01 (Gattefosse), a waxy solid having a melting point of between 41°C. to 45° C. and comprising a mixture of saturated C₁₀-C₁₈triglycerides, and about 1.6 mL MAISINE® 35-1 (Gattefosse), a glycerylmonolinoleate, about 0.6 mL PEG 400, and about 0.15 mL propylene glycolwere added to a vessel heated to about 50° C. to about 60° C. andstirred until all components of the mixture dissolved. The heatedmixture is cooled to room temperature and aliquoted into an appropriatecontainer. This pharmaceutical composition produced a semisolid ointmenthaving a concentration of ibuprofen that is about 400 mg/mL.

To prepare a semi-solid pharmaceutical composition disclosed hereinusing ibuprofen, the following method was performed. About 5 g ibuprofenfree acid, about 5 g ibuprofen sodium salt, about 3 g GELUCIRE® 43/01(Gattefosse), a waxy solid having a melting point of between 41° C. to45° C. and comprising a mixture of saturated C₁₀-C₁₈ triglycerides, andabout 8 mL MAISINE® 35-1 (Gattefosse), a glyceryl monolinoleate, about 3mL PEG 400, and about 1 mL propylene glycol were added to a vesselheated to about 50° C. to about 60° C. and stirred until all componentsof the mixture dissolved. The heated mixture is cooled to roomtemperature and aliquoted into an appropriate container. Thispharmaceutical composition produced a semisolid ointment having aconcentration of ibuprofen that is about 650 mg/mL.

Example 6 Animal Model for Intestinal Erosion

To assess whether a pharmaceutical composition disclosed herein reducedgastric irritation, experiments were conducted using an intestinalerosion murine model.

Sprague-Dawley rats were divided into seven experimental groupscontaining five animals each. After fasting overnight, the animals werechallenged with one with one of seven different treatments. Group A wasa control in which each mouse was orally administered 1%methylcellulose/0.5% polysorbate 80 vehicle only. Group B was a controlin which each mouse was orally administered solvent/adjuvant vehicleonly (gavage of 10% ethanol and 90% linseed oil). Group C was a controlin which each mouse was orally administered 150 mg/kg aspirin. Group Dwas a control in which each mouse was orally administered 100 mg/kgibuprofen suspended in 1% methylcellulose/0.5% polysorbate 80. Group Ewas the experimental group in which each mouse was administered apharmaceutical composition disclosed herein (BC1054-100) comprising 100mg/kg of ibuprofen, 10% ethanol, and 90% linseed oil. Group F was acontrol in which each mouse was orally administered 100 mg/kg ibuprofensuspended in 1% methylcellulose/0.5% polysorbate 80. Group G was theexperimental group in which each mouse was administered a pharmaceuticalcomposition disclosed herein (BC1054-200) comprising 200 mg/kg ofibuprofen, 10% ethanol, and 90% linseed oil. Animals were sacrificed 4hours after treatment and the stomachs were examined for degree ofhemorrhage and severity of mucosal erosive lesions. Gastric irritationwas scored as follows: 0, no lesions; 1, hyperemia; 2, one or two slightlesions; 3, more than two slight lesions or severe lesions; and 4, verysevere lesions. A score of 50% or more relative to Group C(aspirin-treated control group), which was set to 100%, was considered apositive score for gastric irritation.

Results are shown in Table 6. Group D (100 mg/kg of ibuprofen-treatedcontrol group) and Group F (200 mg/kg of ibuprofen-treated controlgroup) produced gastric lesions that were 75% and 95%, respectively,severe as those induced by Group C (aspirin-treated control group).However, Group E (BC1054-100-treated experimental group) and Group G(BC1054-200-treated experimental group) produced gastric lesions thatwere 20% and 40%, respectively, as severe as those associated with GroupC (aspirin-treated control group). These results demonstrate that that apharmaceutical composition disclosed herein reduced the extent to whicha therapeutic compound may cause mucosal lesions and cause gastricirritation.

TABLE 6 Results from Intestinal Erosion Assay Mean Group UlcerationScore % Aspirin Erosion A 0  0 B 0  0 C 4 (100)  D 3  75¹ E 0.8 20 F 3.8 95¹ G 1.6 40 ¹Positive score for gastric erosion.

Example 7 Case Studies for the Treatment of Severe Pain

A 51 year old male experienced severe dental pain due to the exposure ofa nerve after a tooth filling disintegrated. The pain was perceived tobe too severe to be controlled by ibuprofen or diclofenac, but thepatient was reluctant to use codeine (30 mg) with paracetamol (500 mg)which was available to him. Prior to the patient coming into to see thedentist for remedial dental work, he took 7 day course of apharmaceutical composition disclosed herein (BC1054) comprising 20 mg/kgof ibuprofen, 10% ethanol, and 90% rapeseed oil (800 mg b.id), whicheffectively controlled the pain. Relief of pain occurred within 30minutes of taking each dose and lasted for approximately 12 hours beforeredosing. The pain control was so good that he was no longer aware ofpain in the affected tooth.

A 50 year old male was diagnosed with a maison neuve fracture in theankle after a sport injury. The patient was initially administered 30 mgcodeine with 500 mg paracetamol bid, along with 10 mg diclofenac tid for8 months to control his severe pain. After experiencing unacceptableside effects he ceased opiate paracetamol and diclofenac therapy andcommenced a 5 day course of a pharmaceutical composition disclosedherein (BC1054) comprising 20 mg/kg of ibuprofen, 10% ethanol, and 90%rapeseed oil (600 mg bid). After 2 days reported a significantimprovement in his pain, and then after 3 days he reported that the painwas completely controlled. After a 2 month follow the patient is stillfree of severe pain and he has since resumed an active sporting life.

Example 8 Treatment of a Severe Pain Condition

A 62 year old female complains of severe lower back pain after lifting aheavy box the day before. A physician determines that the lower pain isdue to an acute pain. The woman is treated by oral administration apharmaceutical composition comprising ibuprofen as disclosed hereintaken twice daily. Alternatively, the woman is treated by oraladministration a pharmaceutical composition comprising aspirin asdisclosed herein taken thrice daily. Alternatively, the woman is treatedby oral administration a pharmaceutical composition comprising naproxenas disclosed herein taken twice daily. The woman's condition ismonitored and after about 3 days of treatment the woman indicates thereis reduced pain. At one and three week check-ups, the woman indicatesthat she continues to have reduced pain. This reduction in acute painsymptoms indicates successful treatment with the pharmaceuticalcomposition disclosed herein. In a similar manner, any of thetherapeutic compounds such as, e.g., a salicylate derivative NSAID, ap-amino phenol derivative NSAID, a propionic acid derivative NSAID, anacetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamicacid derivative NSAID, a non-selective cyclo-oxygenase (COX) inhibitor,a selective cyclooxygenase 1 (COX 1) inhibitor, a selectivecyclooxygenase 2 (COX 2) inhibitor, or a fibrate, will be formulatedinto a pharmaceutical composition and administered to the patient asdescribed above.

A 22 year old male complains of severe pain in his right shoulder thatoccurred while he was lifting weighs in the gym one month ago. Aphysician determines that the severe pain is a subacute pain. The man istreated by oral administration a pharmaceutical composition comprisingibuprofen as disclosed herein taken twice daily. Alternatively, the manis treated by oral administration a pharmaceutical compositioncomprising aspirin as disclosed herein taken thrice daily.Alternatively, the man is treated by oral administration apharmaceutical composition comprising naproxen as disclosed herein takentwice daily. The man's condition is monitored and after about 3 days oftreatment the man indicates there is improvement in his ability to movehis arm without pain in his shoulder. At one week and one and threemonth check-ups, the man indicates that he continues to have improvedshoulder mobility and no pain. This reduction in subacute pain symptomsindicates successful treatment with the pharmaceutical compositiondisclosed herein. In a similar manner, any of the therapeutic compoundssuch as, e.g., a salicylate derivative NSAID, a p-amino phenolderivative NSAID, a propionic acid derivative NSAID, an acetic acidderivative NSAID, an enolic acid derivative NSAID, a fenamic acidderivative NSAID, a non-selective cyclo-oxygenase (COX) inhibitor, aselective cyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase2 (COX 2) inhibitor, or a fibrate, will be formulated into apharmaceutical composition and administered to the patient as describedabove.

A 67 year old male complains of severe pain in his ankle from a fall hetook two months before. A physician determines that the pain is achronic pain. The man is treated by oral administration a pharmaceuticalcomposition comprising ibuprofen as disclosed herein taken twice daily.Alternatively, the man is treated by oral administration apharmaceutical composition comprising aspirin as disclosed herein takenthrice daily. Alternatively, the man is treated by oral administration apharmaceutical composition comprising naproxen as disclosed herein takentwice daily. The man's condition is monitored and after about 3 days oftreatment the man indicates there is reduced pain in his ankle andmobility in his ankle is better. At one and three month check-ups, theman indicates that he continues to have improved ankle mobility and nopain. This reduction in chronic pain symptoms indicates successfultreatment with the pharmaceutical composition disclosed herein. In asimilar manner, any of the therapeutic compounds such as, e.g., asalicylate derivative NSAID, a p-amino phenol derivative NSAID, apropionic acid derivative NSAID, an acetic acid derivative NSAID, anenolic acid derivative NSAID, a fenamic acid derivative NSAID, anon-selective cyclo-oxygenase (COX) inhibitor, a selectivecyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2 (COX 2)inhibitor, or a fibrate, will be formulated into a pharmaceuticalcomposition and administered to the patient as described above.

A 73 year old female complains of severe pain after burning her forearmon a hot oven. A physician determines that the pain is due tosuperficial somatic noceceptive pain. The woman is treated by oraladministration a pharmaceutical composition comprising ibuprofen asdisclosed herein taken twice daily. Alternatively, the woman is treatedby oral administration a pharmaceutical composition comprising aspirinas disclosed herein taken thrice daily. Alternatively, the woman istreated by oral administration a pharmaceutical composition comprisingnaproxen as disclosed herein taken twice daily. The woman's condition ismonitored and after about 3 days of treatment the woman indicates thatshe no longer feels pain in her forearm. At one and three weekcheck-ups, the woman indicates that she still feels no pain. Thisreduction in superficial somatic noceceptive pain symptoms indicatessuccessful treatment with the pharmaceutical composition disclosedherein. A similar type of oral administration of a pharmaceuticalcomposition disclosed herein will be used to treat a patient sufferingfrom severe pain associated with any other deep somatic noceceptivepain, including, without limitation, an excessive muscle tension, arepetitive motion disorder, a muscle disorder, a myalgia, an infection,and a drug-induced pain. In a similar manner, any of the therapeuticcompounds such as, e.g., a salicylate derivative NSAID, a p-amino phenolderivative NSAID, a propionic acid derivative NSAID, an acetic acidderivative NSAID, an enolic acid derivative NSAID, a fenamic acidderivative NSAID, a non-selective cyclo-oxygenase (COX) inhibitor, aselective cyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase2 (COX 2) inhibitor, or a fibrate, will be formulated into apharmaceutical composition and administered to the patient as describedabove.

A 37 year old male complains of severe pain due to a lower leg bonefracture while skiing. A physician determines that the pain is due todeep somatic noceceptive pain. The man is treated by oral administrationa pharmaceutical composition comprising ibuprofen as disclosed hereintaken twice daily. Alternatively, the man is treated by oraladministration a pharmaceutical composition comprising aspirin asdisclosed herein taken thrice daily. Alternatively, the man is treatedby oral administration a pharmaceutical composition comprising naproxenas disclosed herein taken twice daily. The man's condition is monitoredand after about 3 days of treatment the man indicates there is reducedpain in his leg. At one and two month check-ups, the man indicates thathe continues to have reduced pain. This reduction in deep somaticnoceceptive pain symptoms indicates successful treatment with thepharmaceutical composition disclosed herein. A similar type of oraladministration of a pharmaceutical composition disclosed herein will beused to treat a patient suffering from severe pain associated with anyother deep somatic noceceptive pain, including, without limitation, anexcessive muscle tension, a repetitive motion disorder, a muscledisorder, a myalgia, an infection, and a drug-induced pain. In a similarmanner, any of the therapeutic compounds such as, e.g., a salicylatederivative NSAID, a p-amino phenol derivative NSAID, a propionic acidderivative NSAID, an acetic acid derivative NSAID, an enolic acidderivative NSAID, a fenamic acid derivative NSAID, a non-selectivecyclo-oxygenase (COX) inhibitor, a selective cyclooxygenase 1 (COX 1)inhibitor, a selective cyclooxygenase 2 (COX 2) inhibitor, or a fibrate,will be formulated into a pharmaceutical composition and administered tothe patient as described above.

A 33 year old female complains of chronic abdominal pain. A physiciandetermines that the pain is due to deep visceral noceceptive pain. Thewoman is treated by oral administration a pharmaceutical compositioncomprising ibuprofen as disclosed herein taken twice daily.Alternatively, the woman is treated by oral administration apharmaceutical composition comprising aspirin as disclosed herein takenthrice daily. Alternatively, the woman is treated by oral administrationa pharmaceutical composition comprising naproxen as disclosed hereintaken twice daily. The woman's condition is monitored and after about 3days of treatment the woman indicates that there is a reduction inabdominal pain. At one and three month check-ups, the woman indicatesthat she continues to have reduced abdominal pain. This reduction indeep visceral noceceptive pain symptoms indicates successful treatmentwith the pharmaceutical composition disclosed herein. A similar type oforal administration of a pharmaceutical composition disclosed hereinwill be used to treat a patient suffering from severe pain associatedwith any other deep visceral noceceptive pain, including, withoutlimitation, a functional visceral pain, a chronic gastrointestinalinflammation, an autoimmune pain, an organic visceral pain, and atreatment-induced visceral pain. In a similar manner, any of thetherapeutic compounds such as, e.g., a salicylate derivative NSAID, ap-amino phenol derivative NSAID, a propionic acid derivative NSAID, anacetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamicacid derivative NSAID, a non-selective cyclo-oxygenase (COX) inhibitor,a selective cyclooxygenase 1 (COX 1) inhibitor, a selectivecyclooxygenase 2 (COX 2) inhibitor, or a fibrate, will be formulatedinto a pharmaceutical composition and administered to the patient asdescribed above.

A 66 year old male complains of severe pain after suffering a stroke. Aphysician determines that the pain is due to central neuropathic pain.The man is treated by oral administration a pharmaceutical compositioncomprising ibuprofen as disclosed herein taken twice daily.Alternatively, the man is treated by oral administration apharmaceutical composition comprising aspirin as disclosed herein takenthrice daily. Alternatively, the man is treated by oral administration apharmaceutical composition comprising naproxen as disclosed herein takentwice daily. The man's condition is monitored and after about 3 days oftreatment the man indicates that there is a reduction in abdominal pain.At one and three month check-ups, the man indicates that he continues tohave reduced pain. This reduction in central neuropathic pain symptomsindicates successful treatment with the pharmaceutical compositiondisclosed herein. A similar type of oral administration of apharmaceutical composition disclosed herein will be used to treat apatient suffering from severe pain associated with any other centralneuropathic or dysfunctional pain, including, without limitation,cerebral venous thrombosis, cerebral tumors or abscesses compressing abrain portion, traumatic brain or spinal cord injury, complicationsfollowing brain or spinal surgery, multiple sclerosis, and Parkinsondisease, ischemic lesions, syringomyelia, radiation myelopathy, and HIVmyelopathy. In a similar manner, any of the therapeutic compounds suchas, e.g., a salicylate derivative NSAID, a p-amino phenol derivativeNSAID, a propionic acid derivative NSAID, an acetic acid derivativeNSAID, an enolic acid derivative NSAID, a fenamic acid derivative NSAID,a non-selective cyclo-oxygenase (COX) inhibitor, a selectivecyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2 (COX 2)inhibitor, or a fibrate, will be formulated into a pharmaceuticalcomposition and administered to the patient as described above.

A 58 year old male, who is a diabetic, complains of severe pain. Aphysician determines that the pain is due to peripheral neuropathic painfrom diabetic neuropathy. The man is treated by oral administration apharmaceutical composition comprising ibuprofen as disclosed hereintaken twice daily. Alternatively, the man is treated by oraladministration a pharmaceutical composition comprising aspirin asdisclosed herein taken thrice daily. Alternatively, the man is treatedby oral administration a pharmaceutical composition comprising naproxenas disclosed herein taken twice daily. The man's condition is monitoredand after about 3 days of treatment the man indicates there is reductionin the pain. At one and three month check-ups, the man indicates that hestill experiences reduced pain. This reduction in a peripheralneuropathic pain indicates successful treatment with the pharmaceuticalcomposition disclosed herein. A similar type of oral administration of apharmaceutical composition disclosed herein will be used to treat apatient suffering from severe pain associated with any other peripheralneuropathic or dysfunctional pain, including, without limitation,systemic diseases, metabolic disorders, nutrient disorders, drug-induceddisorders, traumatic and entrapment syndromes, complications followingsurgery, distal axonopathy, HIV sensory neuropathy, demyelinatingpolyradiculoneuropathy, postherpetic neuralgia, nerve root avulsions,cranial neuralgias like trigeminal neuralgia, neuropathic cancer pain,compression of peripheral nerves, nerve plexuses, and nerve roots,paraneoplastic peripheral neuropathy, ganglionopathy, complication ofcancer therapies like chemotherapy, radiation, and surgery, and complexregional pain syndrome like Type 1 and Type 2. In a similar manner, anyof the therapeutic compounds such as, e.g., a salicylate derivativeNSAID, a p-amino phenol derivative NSAID, a propionic acid derivativeNSAID, an acetic acid derivative NSAID, an enolic acid derivative NSAID,a fenamic acid derivative NSAID, a non-selective cyclo-oxygenase (COX)inhibitor, a selective cyclooxygenase 1 (COX 1) inhibitor, a selectivecyclooxygenase 2 (COX 2) inhibitor, or a fibrate, will be formulatedinto a pharmaceutical composition and administered to the patient asdescribed above.

A 59 year old female complains of severe pain by even the faintestamount of pressure is applied to her forearm. A physician determinesthat the pain is due to allodynia. The woman is treated by topicaladministration a pharmaceutical composition comprising ibuprofen asdisclosed herein taken twice daily. Alternatively, the woman is treatedby topical administration a pharmaceutical composition comprisingaspirin as disclosed herein taken thrice daily. Alternatively, the womanis treated by topical administration a pharmaceutical compositioncomprising naproxen as disclosed herein taken twice daily. The woman'scondition is monitored and after about 3 days of treatment the womanindicates there is reduced pain. At one and three month check-ups, thewoman indicates that she continues to have reduced pain. This reductionin allodynia symptoms indicates successful treatment with thepharmaceutical composition disclosed herein. A similar type of topicaladministration of a pharmaceutical composition disclosed herein will beused to treat a patient suffering from severe pain associated with anydysesthesia, such as, e.g., hyperalgesia or hyperpathia. In a similarmanner, any of the therapeutic compounds such as, e.g., a salicylatederivative NSAID, a p-amino phenol derivative NSAID, a propionic acidderivative NSAID, an acetic acid derivative NSAID, an enolic acidderivative NSAID, a fenamic acid derivative NSAID, a non-selectivecyclo-oxygenase (COX) inhibitor, a selective cyclooxygenase 1 (COX 1)inhibitor, a selective cyclooxygenase 2 (COX 2) inhibitor, or a fibrate,will be formulated into a pharmaceutical composition and administered tothe patient as described above.

A 47 year old female complains of severe pain down her left leg when sheleans over to do the dishes. A physician determines that the leg pain isdue to a sciatic nerve dysfunction. The woman is treated by oraladministration a pharmaceutical composition comprising ibuprofen asdisclosed herein taken twice daily. Alternatively, the woman is treatedby oral administration a pharmaceutical composition comprising aspirinas disclosed herein taken thrice daily. Alternatively, the woman istreated by oral administration a pharmaceutical composition comprisingnaproxen as disclosed herein taken twice daily. The woman's condition ismonitored and after about 3 days of treatment the woman indicates thereis reduced pain. At one and three month check-ups, the woman indicatesthat she continues to have reduced pain in her leg. This reduction insciatic nerve dysfunction symptoms indicates successful treatment withthe pharmaceutical composition disclosed herein. A similar type oftopical administration of a pharmaceutical composition disclosed hereinwill be used to treat a patient suffering from severe pain associatedwith any mononeuropathy, such as, e.g., a common peroneal nervedysfunction, a radial nerve dysfunction, an ulnar nerve dysfunction, acranial mononeuropathy VI, a cranial mononeuropathy VII, a cranialmononeuropathy III (compression type), a cranial mononeuropathy III(diabetic type), an axillary nerve dysfunction, a carpal tunnelsyndrome, a femoral nerve dysfunction, a tibial nerve dysfunction, aBell's palsy, a thoracic outlet syndrome, a carpal tunnel syndrome orother focal entrapment neuropathy, and a sixth (abducent) nerve palsy.In a similar manner, any of the therapeutic compounds such as, e.g., asalicylate derivative NSAID, a p-amino phenol derivative NSAID, apropionic acid derivative NSAID, an acetic acid derivative NSAID, anenolic acid derivative NSAID, a fenamic acid derivative NSAID, anon-selective cyclo-oxygenase (COX) inhibitor, a selectivecyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2 (COX 2)inhibitor, or a fibrate, will be formulated into a pharmaceuticalcomposition and administered to the patient as described above.

A 22 year old male complains of severe pain in his right leg that beganafter a hike in the woods. A physician determines that the severe painis sue to a Lyme disease. The man is treated by intravenous injectionadministration of a pharmaceutical composition comprising ibuprofen asdisclosed herein taken twice daily. Alternatively, the man is treated byintravenous injection administration of a pharmaceutical compositioncomprising aspirin as disclosed herein taken thrice daily.Alternatively, the man is treated by intravenous injectionadministration of a pharmaceutical composition comprising naproxen asdisclosed herein taken twice daily. The man's condition is monitored andafter about 3 days of treatment the man indicates there is reduced pain.At one week and one and three month check-ups, the man indicates that hecontinues to no pain. This reduction in Lyme disease symptoms indicatessuccessful treatment with the pharmaceutical composition disclosedherein. A similar type of intravenous injection administration of apharmaceutical composition disclosed herein will be used to treat apatient suffering from severe pain associated with any mononeuropathicmultiplex, such as, e.g., systemic diseases, metabolic disorders,nutrient disorders, drug-induced disorders, traumatic and entrapmentsyndromes, toxicity, and infections. In a similar manner, any of thetherapeutic compounds such as, e.g., a salicylate derivative NSAID, ap-amino phenol derivative NSAID, a propionic acid derivative NSAID, anacetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamicacid derivative NSAID, a non-selective cyclo-oxygenase (COX) inhibitor,a selective cyclooxygenase 1 (COX 1) inhibitor, a selectivecyclooxygenase 2 (COX 2) inhibitor, or a fibrate, will be formulatedinto a pharmaceutical composition and administered to the patient asdescribed above.

A 67 year old male, a chronic alcoholic, complains of severe pain. Aphysician determines that the pain is a polyneuropathy. The man istreated by oral administration a pharmaceutical composition comprisingibuprofen as disclosed herein taken twice daily. Alternatively, the manis treated by oral administration a pharmaceutical compositioncomprising aspirin as disclosed herein taken thrice daily.Alternatively, the man is treated by oral administration apharmaceutical composition comprising naproxen as disclosed herein takentwice daily. The man's condition is monitored and after about 3 days oftreatment the man indicates there is reduced pain. At one and threemonth check-ups, the man indicates that he continues to have no pain.This reduction in polyneuropathic pain symptoms indicates successfultreatment with the pharmaceutical composition disclosed herein. Asimilar type of oral administration of a pharmaceutical compositiondisclosed herein will be used to treat a patient suffering from severepain associated with any other polyneuropathy, including, withoutlimitation, acute inflammatory demyelinating polyneuropathy, chronicinflammatory demyelinating polyneuropathy, and a genetic metabolicdisorder. In a similar manner, any of the therapeutic compounds such as,e.g., a salicylate derivative NSAID, a p-amino phenol derivative NSAID,a propionic acid derivative NSAID, an acetic acid derivative NSAID, anenolic acid derivative NSAID, a fenamic acid derivative NSAID, anon-selective cyclo-oxygenase (COX) inhibitor, a selectivecyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2 (COX 2)inhibitor, or a fibrate, will be formulated into a pharmaceuticalcomposition and administered to the patient as described above.

A 73 year old female complains of severe pain in her bladder. Aphysician determines that the pain is due to an autonomic neuropathy.The woman is treated by instillation administration of a pharmaceuticalcomposition comprising ibuprofen as disclosed herein taken twice daily.Alternatively, the woman is treated by oral administration of apharmaceutical composition comprising aspirin as disclosed herein takenthrice daily. Alternatively, the woman is treated by oral administrationof a pharmaceutical composition comprising naproxen as disclosed hereintaken twice daily. The woman's condition is monitored and after about 3days of treatment the woman indicates that she no longer feels pain inher bladder. At one and three month check-ups, the woman indicates thatshe still feels no pain. This reduction in autonomic neuropathy symptomsindicates successful treatment with the pharmaceutical compositiondisclosed herein. A similar type of oral administration of apharmaceutical composition disclosed herein will be used to treat apatient suffering from severe pain associated with any other autonomicneuropathy affecting any other internal organ. In a similar manner, anyof the therapeutic compounds such as, e.g., a salicylate derivativeNSAID, a p-amino phenol derivative NSAID, a propionic acid derivativeNSAID, an acetic acid derivative NSAID, an enolic acid derivative NSAID,a fenamic acid derivative NSAID, a non-selective cyclo-oxygenase (COX)inhibitor, a selective cyclooxygenase 1 (COX 1) inhibitor, a selectivecyclooxygenase 2 (COX 2) inhibitor, or a fibrate, will be formulatedinto a pharmaceutical composition and administered to the patient asdescribed above.

A 42 year old male complains of severe pain whenever any pressure isapplied to his left side of his face. A physician determines that thepain is due to a trigeminal neuralgia. The man is treated by topicaladministration of a pharmaceutical composition comprising ibuprofen asdisclosed herein taken twice daily. Alternatively, the man is treated bytopical administration a pharmaceutical composition comprising aspirinas disclosed herein taken thrice daily. Alternatively, the man istreated by topical administration a pharmaceutical compositioncomprising naproxen as disclosed herein taken twice daily. The man'scondition is monitored and after about 3 days of treatment the manindicates there is reduced pain in his face. At one and two monthcheck-ups, the man indicates that he continues to have reduced pain.This reduction in trigeminal neuralgia pain symptoms indicatessuccessful treatment with the pharmaceutical composition disclosedherein. A similar type of topical administration of a pharmaceuticalcomposition disclosed herein will be used to treat a patient sufferingfrom severe pain associated with any other neuralgia, including, withoutlimitation, a glossopharyngeal neuralgia, a post-herpetic neuralgia, acarpal tunnel syndrome, a meralgia paresthetica, a sciatica and anatypical facial pain. In a similar manner, any of the therapeuticcompounds such as, e.g., a salicylate derivative NSAID, a p-amino phenolderivative NSAID, a propionic acid derivative NSAID, an acetic acidderivative NSAID, an enolic acid derivative NSAID, a fenamic acidderivative NSAID, a non-selective cyclo-oxygenase (COX) inhibitor, aselective cyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase2 (COX 2) inhibitor, or a fibrate, will be formulated into apharmaceutical composition and administered to the patient as describedabove.

A 54 year old female complains of pain in her left shoulder aftersuffering a heart-attack. A physician determines that the pain is due toreferred pain from a myocardial ischaemia. The woman is treated by oraladministration a pharmaceutical composition comprising ibuprofen asdisclosed herein taken twice daily. Alternatively, the woman is treatedby oral administration a pharmaceutical composition comprising aspirinas disclosed herein taken thrice daily. Alternatively, the woman istreated by oral administration a pharmaceutical composition comprisingnaproxen as disclosed herein taken twice daily. The woman's condition ismonitored and after about 3 days of treatment the woman indicates thatthere is a reduction in shoulder pain. At one and three month check-ups,the woman indicates that she continues to have reduced shoulder pain.This reduction in referred pain symptoms indicates successful treatmentwith the pharmaceutical composition disclosed herein. A similar type oforal administration of a pharmaceutical composition disclosed hereinwill be used to treat a patient suffering from severe pain associatedwith any other referred pain, including, without limitation, anintervertebral disc herniation. In a similar manner, any of thetherapeutic compounds such as, e.g., a salicylate derivative NSAID, ap-amino phenol derivative NSAID, a propionic acid derivative NSAID, anacetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamicacid derivative NSAID, a non-selective cyclo-oxygenase (COX) inhibitor,a selective cyclooxygenase 1 (COX 1) inhibitor, a selectivecyclooxygenase 2 (COX 2) inhibitor, or a fibrate, will be formulatedinto a pharmaceutical composition and administered to the patient asdescribed above.

A 26 year old male complains of severe pain in the location where isamputated arm once was. A physician determines that the pain is due tophantom pain. The man is treated by oral administration a pharmaceuticalcomposition comprising ibuprofen as disclosed herein taken twice daily.Alternatively, the man is treated by oral administration apharmaceutical composition comprising aspirin as disclosed herein takenthrice daily. Alternatively, the man is treated by oral administration apharmaceutical composition comprising naproxen as disclosed herein takentwice daily. The man's condition is monitored and after about 3 days oftreatment the man indicates that there is a reduction in pain. At oneand three month check-ups, the man indicates that he continues to havereduced pain. This reduction in phantom pain symptoms indicatessuccessful treatment with the pharmaceutical composition disclosedherein. A similar type of oral administration of a pharmaceuticalcomposition disclosed herein will be used to treat a patient sufferingfrom severe pain associated with any other deafferentation painsyndrome, including, without limitation, a brain injury, a spinal cordinjury, a lumbar radiculopathy, a post-stroke pain, a paraplegia,avulsion of the brachial plexus or other types of lesions of peripheralnerves, a pathology of the central nervous system. In a similar manner,any of the therapeutic compounds such as, e.g., a salicylate derivativeNSAID, a p-amino phenol derivative NSAID, a propionic acid derivativeNSAID, an acetic acid derivative NSAID, an enolic acid derivative NSAID,a fenamic acid derivative NSAID, a non-selective cyclo-oxygenase (COX)inhibitor, a selective cyclooxygenase 1 (COX 1) inhibitor, a selectivecyclooxygenase 2 (COX 2) inhibitor, or a fibrate, will be formulatedinto a pharmaceutical composition and administered to the patient asdescribed above.

A 58 year old male complains of a headache. The man is treated by oraladministration of a pharmaceutical composition comprising ibuprofen asdisclosed herein taken twice daily. Alternatively, the man is treated byoral administration of a pharmaceutical composition comprising aspirinas disclosed herein taken thrice daily. Alternatively, the man istreated by oral administration of a pharmaceutical compositioncomprising naproxen as disclosed herein taken twice daily. The man'scondition is monitored and after about 3 hours the headache pain isgone. This elimination in headache pain indicates successful treatmentwith the pharmaceutical composition disclosed herein. A similar type oforal administration of a pharmaceutical composition disclosed hereinwill be used to treat a patient suffering from severe pain associatedwith any other headache pain, including, without limitation, amuscular/myogenic headache, a vascular headache, a traction headache,inflammatory headache, a chronic sinusitis headache, a hormone headache,a rebound headache, an organic headache, and an ictal headache. In asimilar manner, any of the therapeutic compounds such as, e.g., asalicylate derivative NSAID, a p-amino phenol derivative NSAID, apropionic acid derivative NSAID, an acetic acid derivative NSAID, anenolic acid derivative NSAID, a fenamic acid derivative NSAID, anon-selective cyclo-oxygenase (COX) inhibitor, a selectivecyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2 (COX 2)inhibitor, or a fibrate, will be formulated into a pharmaceuticalcomposition and administered to the patient as described above.

A 59 year old female complains of severe headache pain. A physiciandetermines that the pain is due to migraine. The woman is treated byoral administration of a pharmaceutical composition comprising ibuprofenas disclosed herein taken twice daily. Alternatively, the woman istreated by topical administration of a pharmaceutical compositioncomprising aspirin as disclosed herein taken thrice daily.Alternatively, the woman is treated by topical administration of apharmaceutical composition comprising naproxen as disclosed herein takentwice daily. The woman's condition is monitored and after about 3 daysof treatment the woman indicates there is no migraine pain reoccurrence.At one and three month check-ups, the woman indicates that she continuesto have reduced frequency and intensity of migraine headache pain. Thisreduction in migraine symptoms indicates successful treatment with thepharmaceutical composition disclosed herein. A similar type of oraladministration of a pharmaceutical composition disclosed herein will beused to treat a patient suffering from severe pain associated with anyother migraine headache pain, including, without limitation, a migrainewithout aura (common migraine), a migraine with aura (classic migraine),a menstrual migraine, a migraine equivalent (acephalic headache), acomplicated migraine, an abdominal migraine and a mixed tensionmigraine. In a similar manner, any of the therapeutic compounds such as,e.g., a salicylate derivative NSAID, a p-amino phenol derivative NSAID,a propionic acid derivative NSAID, an acetic acid derivative NSAID, anenolic acid derivative NSAID, a fenamic acid derivative NSAID, anon-selective cyclo-oxygenase (COX) inhibitor, a selectivecyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2 (COX 2)inhibitor, or a fibrate, will be formulated into a pharmaceuticalcomposition and administered to the patient as described above.

In closing, it is to be understood that although aspects of the presentspecification are highlighted by referring to specific embodiments, oneskilled in the art will readily appreciate that these disclosedembodiments are only illustrative of the principles of the subjectmatter disclosed herein. Therefore, it should be understood that thedisclosed subject matter is in no way limited to a particularmethodology, protocol, and/or reagent, etc., described herein. As such,various modifications or changes to or alternative configurations of thedisclosed subject matter can be made in accordance with the teachingsherein without departing from the spirit of the present specification.Lastly, the terminology used herein is for the purpose of describingparticular embodiments only, and is not intended to limit the scope ofthe present invention, which is defined solely by the claims.Accordingly, the present invention is not limited to that precisely asshown and described.

Certain embodiments of the present invention are described herein,including the best mode known to the inventors for carrying out theinvention. Of course, variations on these described embodiments willbecome apparent to those of ordinary skill in the art upon reading theforegoing description. The inventor expects skilled artisans to employsuch variations as appropriate, and the inventors intend for the presentinvention to be practiced otherwise than specifically described herein.Accordingly, this invention includes all modifications and equivalentsof the subject matter recited in the claims appended hereto as permittedby applicable law. Moreover, any combination of the above-describedembodiments in all possible variations thereof is encompassed by theinvention unless otherwise indicated herein or otherwise clearlycontradicted by context.

Groupings of alternative embodiments, elements, or steps of the presentinvention are not to be construed as limitations. Each group member maybe referred to and claimed individually or in any combination with othergroup members disclosed herein. It is anticipated that one or moremembers of a group may be included in, or deleted from, a group forreasons of convenience and/or patentability. When any such inclusion ordeletion occurs, the specification is deemed to contain the group asmodified thus fulfilling the written description of all Markush groupsused in the appended claims.

Unless otherwise indicated, all numbers expressing a characteristic,item, quantity, parameter, property, term, and so forth used in thepresent specification and claims are to be understood as being modifiedin all instances by the term “about.” As used herein, the term “about”means that the characteristic, item, quantity, parameter, property, orterm so qualified encompasses a range of plus or minus ten percent aboveand below the value of the stated characteristic, item, quantity,parameter, property, or term. Accordingly, unless indicated to thecontrary, the numerical parameters set forth in the specification andattached claims are approximations that may vary. At the very least, andnot as an attempt to limit the application of the doctrine ofequivalents to the scope of the claims, each numerical indication shouldat least be construed in light of the number of reported significantdigits and by applying ordinary rounding techniques. Notwithstandingthat the numerical ranges and values setting forth the broad scope ofthe invention are approximations, the numerical ranges and values setforth in the specific examples are reported as precisely as possible.Any numerical range or value, however, inherently contains certainerrors necessarily resulting from the standard deviation found in theirrespective testing measurements. Recitation of numerical ranges ofvalues herein is merely intended to serve as a shorthand method ofreferring individually to each separate numerical value falling withinthe range. Unless otherwise indicated herein, each individual value of anumerical range is incorporated into the present specification as if itwere individually recited herein.

The terms “a,” “an,” “the” and similar referents used in the context ofdescribing the present invention (especially in the context of thefollowing claims) are to be construed to cover both the singular and theplural, unless otherwise indicated herein or clearly contradicted bycontext. All methods described herein can be performed in any suitableorder unless otherwise indicated herein or otherwise clearlycontradicted by context. The use of any and all examples, or exemplarylanguage (e.g., “such as”) provided herein is intended merely to betterilluminate the present invention and does not pose a limitation on thescope of the invention otherwise claimed. No language in the presentspecification should be construed as indicating any non-claimed elementessential to the practice of the invention.

Specific embodiments disclosed herein may be further limited in theclaims using consisting of or consisting essentially of language. Whenused in the claims, whether as filed or added per amendment, thetransition term “consisting of” excludes any element, step, oringredient not specified in the claims. The transition term “consistingessentially of” limits the scope of a claim to the specified materialsor steps and those that do not materially affect the basic and novelcharacteristic(s). Embodiments of the present invention so claimed areinherently or expressly described and enabled herein.

All patents, patent publications, and other publications referenced andidentified in the present specification are individually and expresslyincorporated herein by reference in their entirety for the purpose ofdescribing and disclosing, for example, the compositions andmethodologies described in such publications that might be used inconnection with the present invention. These publications are providedsolely for their disclosure prior to the filing date of the presentapplication. Nothing in this regard should be construed as an admissionthat the inventors are not entitled to antedate such disclosure byvirtue of prior invention or for any other reason. All statements as tothe date or representation as to the contents of these documents isbased on the information available to the applicants and does notconstitute any admission as to the correctness of the dates or contentsof these documents.

The invention claimed is:
 1. A method of treating an individual with aninflammatory pain, the method comprising the step of: administering tothe individual in need thereof a pharmaceutical composition, wherein thepharmaceutical composition comprises: a) a propionic acid derivativenon-steroidal anti-pain drug (NSAID), or a pharmaceutically acceptablesalt, solvate, or solvate of a salt thereof, in an amount of about 15%to about 30% of the total weight of the composition; and b) apharmaceutically-acceptable lipid in an amount of at least 50% of thetotal weight of the composition, the pharmaceutically-acceptable lipidcomprising a pharmaceutically-acceptable fat including a triglyceride,the pharmaceutically-acceptable fat in an amount of at least 30% of thetotal weight of the composition, and a pharmaceutically-acceptablepartially hydrolyzed glycerolipid including a mixture of mono-, di-, andtriglycerides in an amount of at least 20% of the total weight of thecomposition; and wherein the pharmaceutical composition is formulated tobe a solid at a temperature of about 15° C. or lower and have a meltingpoint temperature of about 25° C. or higher.
 2. The method according toclaim 1, wherein the inflammatory pain is an acute pain, a subacutepain, a chronic pain, or any combination thereof.
 3. The methodaccording to claim 1, wherein the inflammatory pain is a nociceptivepain, a pathological pain, a referred pain, a headache, or anycombination thereof.
 4. The method according to claim 3, wherein thenociceptive pain is a visceral pain, a deep somatic pain, a superficialsomatic pain, or any combination thereof.
 5. The method according toclaim 3, wherein the pathological pain is a neuropathic pain, adysfunctional pain, or any combination thereof.
 6. The method accordingto claim 5, wherein the neuropathic pain is a central neuropathic pain,a peripheral neuropathic pain, a deafferentation pain, or anycombination thereof.
 7. The method or use according to claim 6, whereinthe peripheral neuropathic pain is a mononeuropathy, a mononeuropathicmultiplex, a polyneuropathy, or an autonomic neuropathy.
 8. The methodor use according to claim 7, wherein the polyneuropathy is a distalaxonopathy, a myelinopathy, or a neuronopathy.
 9. The method or useaccording to claim 6, wherein the peripheral neuropathic pain is aneuralgia or a complex regional pain syndrome.
 10. The method or useaccording to claim 3, wherein the headache is a muscular/myogenicheadache, a vascular headache, a migraine, a traction headache,inflammatory headache, a chronic sinusitis headache, a hormone headache,a rebound headache, an organic headache, or an ictal headache.
 11. Themethod according to claim 1, wherein the propionic acid derivative NSAIDis alminoprofen, benoxaprofen, dexketoprofen, fenoprofen, flurbiprofen,ibuprofen, indoprofen, ketoprofen, loxoprofen, naproxen, oxaprozin,pranoprofen, or suprofen, or a pharmaceutically acceptable salt,solvate, or solvate of a salt thereof.
 12. The method according to claim1, wherein the propionic acid derivative NSAID, or a pharmaceuticallyacceptable salt, solvate, or solvate of a salt thereof, is in an amountof about 20% to about 30% of the total weight of the composition. 13.The method according to claim 1, wherein the pharmaceutically-acceptablelipid is in an amount of at least 60% of the total weight of thecomposition.
 14. The method according to claim 13, wherein thepharmaceutically-acceptable lipid is in an amount of at least 70% of thetotal weight of the composition.
 15. The method according to claim 14,wherein the pharmaceutically-acceptable lipid is in an amount of atleast 75% of the total weight of the composition.
 16. The methodaccording to claim 1, wherein the pharmaceutically-acceptable fat is inan amount of at least 35% of the total weight of the composition. 17.The method according to claim 1, wherein the pharmaceutically-acceptableglyceride mixture is in an amount of at least 25% of the total weight ofthe composition.
 18. The method according to claim 1, wherein thepharmaceutically-acceptable monoglyceride is a glyceryl monolinoleate.19. The method according to claim 1, wherein thepharmaceutically-acceptable liquid PEG polymer comprises a PEG 100, aPEG 200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, a PEG 700, a PEG800, a PEG 900, a PEG 1000, or a combination thereof.
 20. The methodaccording to claim 19, wherein the pharmaceutical composition furthercomprises a pharmaceutically-acceptable liquid PEG polymer is in anamount of about 8% to about 12% of the total weight of the composition.